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Abstract
During the pre-mRNA splicing process introns are removed and exons 
joined together in the resulting mature mRNA, which is then exported to the 
cytoplasm and translated into proteins. Several motifs in the nucleotide sequences 
near the exon-intron boundaries are required for proper exon definition including 
the 3’ and 5’ splice site consensus sequences (3’SS and 5’SS), which recruit basic 
splicing factors. In addition, auxiliary splicing regulatory elements, located in the 
upstream or downstream region of an exon, further influence exon recognition 
through the recruitment of additional binding proteins.
This study shows that intronic UG repeat elements in proximity of the 5’SS of 
an exon can function as splicing regulatory elements, generally enhancing the 
inclusion of the upstream exon in the final mRNA through the recruitment of UG 
repeats-binding proteins. In particular, the strength of the 5’SS consensus 
sequence affects this UG repeats-mediated splicing regulation. Furthermore, this 
study reveals that the UG repeats-binding protein TDP-43 acts as splicing 
modulator either activating of inhibiting the splicing events in different minigene 
systems. In fact, in presence of a disease-causing mutation at the 5’ end of the 
BRCA1 exon 12 TDP-43 enhances exon inclusion, acting as splicing enhancer. 
Alternatively, overexpression of TDP-43 can exert an inhibitory effect on splicing 
by promoting exon skipping in two newly identified TDP-43 target exons (RXRG 
exon 7 and ETF1 exon 7).
In conclusion, this study provides positive proof of concept that UG repeats 
located in the downstream region of poorly defined exons help 5’SS definition. 
Additionally, the study characterizes the role of TDP-43 in various splicing systems 
presenting the UG repeat-binding sites, with the practical application of evaluating 
a putative splicing-affecting pathological mutation.
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Introduction
Elements required for exon recognition
Expression of protein-coding genes in mammals is a multi-step process, 
beginning with transcription of pre-mRNAs by the RNAPII enzyme (RNA 
polymerase II) in the nucleus. The pre-mRNAs undergo several processing steps, 
including splicing, that are physically and functionally coupled to one another [1-5]. 
During pre-mRNA splicing introns are removed and exons joined together in the 
resulting mature mRNA. Several motifs in the nucleotide sequences near the 
exon/intron boundaries are required for proper exon definition, including 3’ and 5’ 
splice site consensus sequences (3’SS and 5’SS) and auxiliary splicing regulatory 
elements.
The 5’ splice site consensus sequences
Mammalian 5’SSs comprises nine partially conserved nucleotides at the 
exon/intron joint: MAG/GURAGU (M is Adenine or Cytosine and R is Adenine or 
Guanine), which nearly correspond to a Watson and Crick base pairing to the U1 
snRNA 5’ end (Figure 1). For each 5’SS, the homology to UlsnRNA is used to 
defined the 5’SS strength, which can be measured with different bioinformatic 
tools in terms of consensus values (CV). Optimal 5’SSs presenting perfect 
homology to U1 snRNA (CV=1=100%) are rare in human genes [6] and the 
average CV of authentic splice sites generally spans from 77 to 89% (0.77-0.89) 
[7].
The 3 ’ splice site consensus sequences
The 3’SSs are defined by three separate sequences: the branch site, the
1
polypyrimidine tract and the nearly invariant AG dinucleotide at the 3’ end of the 
intron (Figure 1). The branch site comprises seven poorly conserved nucleotides: 
YNYURAC (where Y is a pyrimidine and N is any nucleotide), which recruit U2 
snRNA. The invariant adenosine (A) residue within the sequence, which is usually 
located 18-40 bases from the 3’ end [8, 9], represents the branch point forming the 
RNA branch in the lariat structure. The pyrimidine-rich region helps the recognition 
of the 3’ end through the recruitment of U2AF (U2 auxiliary factors). In general, the 
extent of the polypyrimidine tract defines the strength of the 3’SSs: long 
polypyrimidine tracts insure high affinity binding sites for spliceosomal components 
and promote efficient exon recognition [10]. Generally, the first AG dinucleotide 
downstream to the branch site and the polypyrimidine tract are the most 
commonly used as 3’ end.
Exonic/intronic splicing enhancers/silencers
Auxiliary splicing regulatory elements, known as exonic or intronic splicing 
enhancers/silencers (ESE/ISE and ESS/ISS), further influence exons recognition. 
These c/'s-acting regulatory sequences generally recruit auxiliary proteins involved 
in splicing regulation referred to as trans-acting factors (i.e. SR proteins - 
serine/arginine-rich proteins; hnRNP proteins - heterogeneous nuclear 
ribonucleoproteins; other splicing factors). The combinatory effect of all the c/s­
and trans-elements located in proximity or within an exon affects the spliceosome 
assembly, ultimately promoting or inhibiting exon inclusion in the final mRNA 
(reviewed in [11]).
2
5’SS branch site 3’SS< I-------------- '-----1 I-------------- 1
MAGIGURAGU------- 7^— YN YU RAY-------(Y)n—  NAG[G_
polypyrimidine
region
Figure 1: Elements required for proper exon definition. The 3’ splice site 
consensus sequence (defined by the branch site, the polypyrimidine region 
and the nearly invariant AG dinucleotide) together with the 5’ splice site 
consensus sequence ensures proper exon recognition. In addition, auxiliary 
splicing regulatory elements (not illustrated in this figure) further help exon 
definition.
This dissertation focuses on a potential c/'s-regulatory element, the dinucleotides 
TG repeats, and a specific trans-acting factor, TDP-43 (TAR DNA-binding protein 
43kDa).
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Repeats, repeats, repeats
A puzzling observation in the early days of molecular biology was that 
genome size does not always correlate well with organism complexity. For 
example, human genome is 200 times larger than yeast genome, but 200 times as 
small as that of amoeba. This mystery has been largely solved with the recognition 
that genomes can contain a large quantity of repetitive sequences, far in excess of 
that devoted to protein-coding genes [12, 13]. Although extremely abundant in 
prokaryotes and eukaryotes, repeats were initially believed to have no biological 
function and therefore labeled as junk of selfish DNA [14, 15]. Conversely, it is 
now recognized that they actually represent an extraordinary trove of information 
about biological processes. In fact, repeats are markers of crucial evolutionary 
events and provide a tool for medical and population genetic studies. Additionally, 
certain repeats have been linked with several aspects of gene expression such as 
transcription, mRNA processing and translation.
Repeated DNA sequences account for at least 50 % of the human genome 
and broadly fall into five classes: 1) transposable elements, often referred to as 
interspersed repeats; 2) retropseudogenes; 3) segmental duplication; 4) blocks of 
repeated sequences, such as at centromeres and telomeres and 5) tandem 
repeats [13, 16]. Among them, the class of tandem repeats and its subclass of 
dinucleotide TG repeats in particular is thoroughly reviewed in the next pages.
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Tandem repeats
Characteristics
Tandem repeats (TRs) are short DNA repeated sequences located right 
next to the other (in tandem), generally thought to arise by slippage during DNA 
replication. Although some are conserved over considerable evolutionary 
distances implying an advantageous effect of some kind, TRs are extremely 
unstable [17].
Their classification is based on characteristic such as unit length, repeat 
unit number and repeat purity (Figure 2).
The “unit length” represents the number of repeated nucleotides within a unit. 
When the unit length ranges from 1 to 9 nucleotides, the TRs are called 
microsatellites (or short tandem repeats). Among them are for example 
mononucleotide repeats (unit length equal to 1), dinucleotide repeats (unit length 
equal to 2) and trinucleotide repeats (unit length equal to 3). Alternatively, when 
the unit length is greater than 10 nucleotides TRs are defined as minisatellites.
The “repeat unit number” (or repeat length) represents the number of times a 
single unit is repeated within a TR and it is also the most important factor defining 
TRs instability. In general, the higher the repeat unit number, the more unstable 
the TR. The variability in repeat unit number is defined as length polymorphism, a 
feature largely used for human genetic studies. In fact, addition or deletion of 
entire units is a frequent event that provides useful markers and is also capable of 
inducing different phenotypes.
Finally, the “repeat purity” discerns between perfect repeats, where a unit is 
uninterruptedly repeated, and imperfect repeats, which instead have accumulated 
mutations within their units (Figure 2).
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Unit Length
G G G G 
LJ
unit
TG TG TG TG
y i
unit
CTG CTG CTG CTG
unit
unit length = 1 nt 
unit length = 2 nt 
unit length = 3 nt
Microsatellites: unit length = 1 to 9 nt
Example: CCTG CCTG CCTG CCTG CCTG CCTG
Minisatellites: unit length greater than 10 nt
Example: GTACACTTTACC GTACACTTTACC GTACACTTTACC
Repeat Length
TG TG TG TG TG TG
CTG CTG CTG
repeat length = 6 
repeat length = 3
Repeat Purity
Perfect repeat Purity
Example: TGTGTGTGTGTGTGTGTGTGTG 10o%
(NTRK1 intron 4)
Imperfect repeat
Example 1: TGTGTGTCTGTGTGTATGTG 90%
(MYL intron 5)
Example 2: TGTTGGGGTGGTGTGTGTG 74%
(EPHX1 intron 6)
Figure 2: Tandem repeats characteristics. TRs are classified based on their 
unit length, repeat unit number and repeat purity.
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Interestingly, TRs comprise about 3% of the human genome and are almost 
as abundant as coding sequences, which account for less than 5% of it [13, 18]. 
The greatest single contribution is coming from the dinucleotide repeats (0.5%), 
followed by tetranucleotides (unit length equal to 4) and pentanucleotides (unit 
length equal to 5).
Localization
TRs have been shown to localize both in coding and non-coding regions 
where they exert disparate biological functions. Polymorphisms of the repeated 
regions have great impact on their functionality in both locations.
The presence of TRs in the coding sequence results in a stretch of amino 
acid residues (i.e. trinucleotide CAG repeats encode for polyglutamine stretch; 
dinucleotide TG repeats encode for alternating cysteine and valine stretches). 
Within the coding sequence, repeat length variations result in the production of an 
altered protein. This event can either functionally improve the protein and 
positively affect phenotypes, or alternatively result in a non-functional protein 
trigging disease pathogenesis.
On the other hand, TRs localized in non-coding regulatory elements such 
as promoter regions, 573’UTRs and introns, modulate gene expression by 
functioning as protein binding sites or by affecting DNA and RNA secondary 
structures. Consequently, in a variety of different ways, TRs are implicated in 
transcription activation, mRNA stability, constitutive and alternative splicing, 
translation and represent also signals for mRNA export [17, 19-23]. Consequently, 
alteration of the repeat unit number can interfere with all these TRs functions by:
i) disrupting or strengthening binding sites for regulatory proteins [24-26];
ii) changing the spacing between different regulatory sites [27];
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iii) influencing chromatin structure and therefore the accessibility of transcription 
factors and regulatory proteins ultimately interfering with nucleosome formation 
[28];
iv) affecting DNA secondary structure leading to the formation of Z-DNA [29], 
trapping RNAPII on the transcript and influencing transcription intitation and 
elongation [30];
v) affecting RNA secondary structure leading to the formation of Z-RNA or 
extremely stable hairpins that influence both pre-mRNA processing and translation 
[31,32].
Therefore, as for TRs in coding sequences, perturbation of the TRs length 
in non-coding regions can have an ultimate beneficial effect or alternatively result 
in a defective phenotype, or can also be neutral.
Positive effects: TRs relevance in evolution and environmental adaptation
Several examples of how TRs instability can advantageously affect 
phenotypes are reported in literature and also reviewed in reference number 17 
[17]. In two prokaryotic pathogenic bacteria causing gonorrhea and influenza 
respectively, variations of TRs located in coding regions lead to the production of 
differential proteins. Alternatively, variations of TRs located in the promoter region 
modulate gene expression. In this way TRs rapidly mediate the switch between 
different phenotypes, essential for the organism to evade the host defense system 
[33, 34].
Also, in eukaryotic microbes TRs located within coding regions are 
responsible for environmental adaptation. For example, TRs length variability 
within the adhesin gene was proved to modulate cell adherence to the substrate or 
the host tissue, both in benign yeast Saccaromyces cerevisiae and in the 
pathogenic fungus Candida albicans respectively [35, 36]. Furthermore, expanded
TRs leading to longer polyglutamine (poly-Q) stretches were found to correlate 
with circadian clocks control in fungi, fly and birds [37-40].
In higher vertebrates, unstable TRs confer evolutional flexibility to body 
shape and organs [41] as proved for example in Canis familiaris (dog). TRs length 
polymorphism, in fact, was found to correlate with the midface length and 
dorsoventral nose bend in different dog breeds [42]. Interestingly, mutations in the 
TRs of the corresponding human gene were reported to result in craniofacial 
malformations [17].
Negative effect: TRs relevance in human pathologies
In some contexts, TRs high instability can ultimately result in a defective 
phenotype. Among the class of TRs, expansions observed in the subclass of 
trinucleotide repeats are by far the most common cause of human diseases [17]. 
In particular, expanded trinucleotide CAG repeats located within coding regions 
cause poly-Q diseases. These neurodegenerative disorders include Huntington’s 
disease (HD), spinobulbar muscular atrophy (SBMA) [43] and spinocerebellar 
ataxias (SCAs: from SCA1 to SCA17) [44]. The triplet codon CAG corresponds to 
the amino acid glutamine (Q). Therefore, CAG expansions result in altered protein 
products carrying long poly-Q tracts. The poly-Q stretches confer self-aggregating 
properties to the protein ultimately leading to the formation of toxic aggregates in 
patient’s cell.
Trinucleotide expansions in non-coding regions, such as 5’/3’UTRs and 
introns, are responsible for fragile X syndrome, Friedreich ataxia, and myotonic 
dystrophy type 1 and 2 (DM1 and 2). In fragile X syndrome and Friedreich ataxia, 
the most common forms of mental retardation and of ataxia respectively, these 
expansions affect transcription factor binding and chromatin structure, resulting in 
transcriptional silencing of the genes involved. Alternatively, in DM1 and DM2
expansions affect the binding of two RNA processing protein (CELF1 and MNBL), 
resulting in altered splicing of different RNAs [21, 45, 46].
Expansions of polymorphic TRs dinucleotide repeats located in non-coding 
regions have also been linked to several diseases. Interestingly, dinucleotide 
repeats within coding sequences are rare, possibly because they are selected 
against during evolution [17]. Examples of dinucleotide repeats involvement in 
disease onset include: the CA repeats in non-coding region of the interferon- 
gamma gene, in which a polymorphism has been associated with rheumatoid 
arthritis [47]; and the CT repeats in exon 1 of the Norrie-disease gene, which has 
been associated with retinopathy [48]. Most importantly for this study, numerous 
examples of the TG repeats involvement in various diseases were identified by 
thoroughly screening the literature. All these examples are found summarized in 
Table 1 and also described in the next pages. However, although a great number 
of studies associate different dinucleotide repeat polymorphisms with disparate 
diseases, their direct involvement in trigging pathogenesis has not always been 
fully uncovered as for the trinucleotide repeats.
TRs-mediated splicing regulation
As previously mentioned, TRs can significantly affect splicing efficiency and 
splice site choice when located in proximity of splice signals. In particular, various 
TRs (mono-, di-, tri- etc.) affect splicing events by acting as protein-binding sites 
[49].
For example, mononucleotide G repeats regulates 5’ and 3’SSs choice in 
numerous genes through the recruitment of hnRNP H1 [50-53]. Moreover, G-rich 
elements were recently found to redundantly protect 5’SS weakened by single 
nucleotide polymorphisms [54].
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Also, dinucleotide CA repeats located at the 5’SS generally function as 
strong intronic splicing enhancers (ISE) in: eNOS exon 13 [19, 49, 55]; MAPK10 
exon 6; GSTZ1 exon 5; SLC2A2 exon 4; RFXANK exon 5 [49]; and CD45 exon 4 
[56]. The CA repeats were found to determine either constitutive or alternative 
splicing efficiency in a length-dependent manner. They specifically recruit the 
frans-acting factor hnRNP L, which ultimately affects mRNA stability and 
enhances splicing. The CA repeats recruiting hnRNP L were also found to act as 
splicing silencers when located at the 3’SS of TJPI exon 20, repressing exon 
inclusion [57]. In addition, when located at gene promoter regions or in the 5’ and 
3’UTRs the dinucleotide CA repeats affect both mRNA stability and gene 
expression. Examples include: bcl-2 3’UTR [58]; IGF1 promoter region [59]; 
cPLA2 promoter region [60]; HMGA2 promoter region [61]; Cyr61 promoter region 
[62]; and EGFR intron 1 [63]. Further representative examples of TRs-mediated 
splicing regulation include the followings.
Trinucleotide CUG repeats located at the 3’SS regulates the aberrant 
alternative splicing of different pre-mRNAs by affecting the binding of CELF1 and 
MBNL proteins [64, 65].
A tetranucleotide repeats regulates alternative splicing of the alpha2- 
glycine-receptor and many others neurotransmitter receptor subunits through the 
recruitment of Nova-1 [66-68].
A pentanucleotide repeat acts as splicing enhancer of the alternatively 
spliced exon 4 in the calcitonin gene [69].
A hexanucleotide repeat (unit length equal to 6) regulates tissue-specific 
alternative splicing of the fibronectin exon EIIIB [70].
Finally, a six 13-nucleotide repeats (unit length equal to 13) modulate 
Drosophila doublesex exon 4 splicing through the binding of Tra, Tra2 and 9G8 
proteins [71].
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Dinucleotide TG repeats
Global distribution, classification and roles
As previously mentioned, dinucleotide repeats are the most common TRs 
and account for the 0.5% of the entire human genome. Among the dinucleotide 
repeats, TG repeats are the most frequent (50%), followed by AT (35%), GA 
(15%) and the under-represented CG (0.1%) [13]. It has to be noted that when 
screening the genome there are only four possible types of dinucleotide repeats. 
In fact TG=GT=CA=AC, GA=AG=TC=CT, AT=TA, and CG=GC [18].
The TG or CA (TG/CA) repeats are predominantly located in intronic 
regions rather than in exons and are found particularly enriched in some gene 
families. Analysis of six functional classes revealed a correlation between the 
gene function and the TG/CA global distribution [20, 72, 73]. Genes carrying in 
their sequence at least one TG/CA repeat with minimum repeat unit number (or 
repeat length) of six account for: 61% of the cell-communication and signaling 
pathway genes (including receptors, hormones and growth factors and channel 
proteins); 52% of the metabolism genes (including proteasome subunits genes 
and cytochrome p450 superfamily); 52% of the structure and motility genes 
(including collagen gene family); 47% of the cell cycle genes (including cell cycle 
genes, chromosomal structure and DNA repair genes); 45% of the information 
genes (including translation factors, transcription factors, RNA processing and 
repair); and 30% of the immune response genes (including immunoglobulins and 
homeostasis maintainers).
Interestingly, the collagen gene family, belonging to the class of structure and 
motility, has the higher percentage of genes carrying TG/CA repeats (85.6%) [73].
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Based on repeat length and biological properties, TG/CA repeats can be 
categorized in three types: i) type I include short repeats (n= 1 to 11) with low 
propensity to polymorphism; ii) type II include medium length repeats (n= 12 to 
22), which are likely polymorphic and often involved in transcription regulation; and
ii) type III include rare, long (n>22) and highly polymorphic repeats [73].
Dinucleotide UG repeats (in the RNA context TG repeats are referred to as 
UG repeats), just like other TRs, can influence splicing efficiency and splice site 
choice when located in proximity of splicing regulatory sequences (573’SSs). 
However, TG repeats are most frequently localized at gene promoter regions or in 
5’UTRs where they are capable of modulating transcription activation (Table 1). In 
this case, the adoption of unconventional DNA and RNA structures is the most 
accredited mechanism responsible for dinucleotide repeats-mediated transcription 
activation [74]. Interestingly, for each location (573’SSs, introns, 5’/3’UTR, gene 
promoter) the variability of the TG/UG repeats length was found to differentially 
affect their biological function (Table 1).
Dinucleotide repeats form Z-DNA and Z-RNA
DNA is normally found in a right-handed helix with 10.4 base pair per turn 
defined as B-DNA (branched DNA). However, DNA can translate form B to Z-DNA 
(zigzag DNA), a left-handed helix with 12 base pairs per turn.
This alternative, biologically functional and higher energy form is preferentially 
adopted by sequences containing alternating purine-pyrimidine dinucleotide 
repeats (CG, CA, TG) [75, 76]. Z-DNA conformations at the promoter region or 
near the transcription start site can affect transcription either enhancing or 
repressing it.
In fact, chromatin-remodeling proteins unwrap DNA from the nucleosomes 
leaving the DNA negatively supercoiled in Z-conformation. Since nucleosomes
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cannot reform on Z-DNA, the site is kept open allowing transcription factors to 
accumulate and RNAPII transcription initiation to begin [77, 78].
Alternatively, Z-DNA can repress transcription by affecting RNPII 
movements and transcription factor binding. Retarded transcription leads to a 
reduced amount of generated transcripts. Microarray and reporter minigene 
analysis have shown that, in most cases, short TG/CA repeats (repeat length =
12) at the gene promoter downregulate transcription (i.e. TG/CA repeats in 
HSD11B2 gene) [79]. Consistently, the longer is the repeated element at the 
promoter region the lower is the production of transcript (i.e. CA repeats in 
prolactin gene) [20, 73, 80].
It should be noted that Z-DNA, besides acting as cis-elements, can also 
recruit trans-acting factors. In fact, a class of Z-DNA binding proteins was 
identified. Among these proteins, the better characterized is the RNA-editing 
enzyme ADAR1 [78, 81]. ADAR1 (adenosine deaminase, RNA-specific 1) binds 
and stabilizes the Z-DNA preventing its return to the B conformation and therefore 
enhancing transcription [82].
Similarly to DNA, also double stranded RNA can shift from A-RNA to Z- 
RNA. For example, CG repeats adopt Z-RNA conformation, which can also be 
bound by ADAR1 protein [83]. Single stranded UG repeats as well adopt Z-RNA 
conformation, which are bound by CELF1 protein (CUGBP-Elav-like family 
member 1). Specifically it has been suggested that only the left-handed UG Z- 
RNA conformation, but not its right-handed counterpart, can be actually 
accommodated in CELF1 RRM1 and RRM2 pockets (RNA recognition motif 1 and
2). This interaction between CELF1 and the UG in Z-RNA conformation may have 
possible implications in regulating alternative splicing, mRNA stability and 
translation [84].
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Finally, Z-RNA conformation can also affect translation. In fact, it has been 
recently reported that rRNAs form Z-RNA structures involved in target recognition. 
In this case, ADAR1 binds the rRNA Z-structure inhibiting ribosomal complexes 
formation and thus translation [85].
TG repeats polymorphisms
As previously reported, trinucleotide repeats expansions are involved in the 
pathogenesis of various neurological diseases (page 9). In order to uncover a 
similar role for dinucleotide repeats, several genotyping studies have investigated 
the potential link between polymorphic TG repeats and the susceptibility to certain 
pathologies (genetic risk). The numerous studies identified in the literature are 
summarized in Table 1. Indications about the gene involved, the location of the 
polymorphic TG element and the correlated disease are included. The specific 
ethnic group where the polymorphism was validated is also reported. Consistent 
with their predominant distribution, TG repeats analyzed in these studies are 
mostly localized in non-coding regulatory region. All the studies presented in Table 
1 used conventional genotyping methods such as reverse-transcription associated 
with real-time-PCR to evaluate mRNA levels in RNA extracted from blood or tissue 
biopsies. In addition, protein expression levels were also evaluated using 
immunohistochemistry and western blot analysis.
In some notable examples, studies have gone beyond correlating a 
particular TG allele with a phenotype and actually linked polymorphic TG repeats 
with transcription or splicing modulation (in bold in Table 1 and summarized in the 
following paragraphs).
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Table 1. TG repeats polymorphisms and pathologies. Summary of the 
numerous studies investigating the potential link between polymorphic TG repeats 
and the susceptibility to certain pathologies. The asterisk “ * ” indicates the genes 
recently found to be up/d own regulated upon TDP-43 silencing (a TG/UG repeats 
binding protein) in reference 86 [86].
Gene
Symbol
Protein
Name
TG repeats polymorphism  
correlations
Location Ref.
AGT Angiotensinogen Correlation with stroke in pediatric 
patients with sickle cell disease (SCD) 
in African-American and in African- 
Caribbean populations.
intron 4, 
up stream 
region
[87]
APO Apolipoprotein
A-ll
No correlation with plasma 
concentrations of high-density 
lipoproteins (HDLs) and cholesterol 
levels in Irish and French populations. 
UG repeats regulate splicing.
intron 2, 
up 
stream 
region
[88, 89]
BDNF Brain-derived 
neutrophic factor
Correlation with responsiveness to an 
antipsychotic agent in schizophrenic 
patients in Chinese population 
(pharmaco-genetic relationship).
Correlation with schizophrenia in 
Italian, Canadian and French 
populations, but not in Japanese, Irish 
and Spanish populations.
No association with bipolar disorder 
susceptibility.
5'UTR [90]
[91-95]
[96]
Beta-
ENaC
Epithelial sodium 
channel beta 
subunit
Correlation with hypertension in 
Chilean population.
TG repeats regulate gene 
expression.
intron 8 [97]
BRCA1/2
and
RAD51
Breast cancer 
1/2 and RAD51
No correlation with breast cancer 
susceptibility in Polish population.
whole
genes
[98]
BRN3C Brain-specific 
homeobox/POU 
domain protein 
3C
TG repeats regulate gene 
expression.
intron 1 [99]
CD36 CD36 molecule
thrombospondin
receptor
Correlation with cerebral malaria in 
Thai population.
UG repeats regulate alternative 
splicing.
Correlation with cardiovascular risk 
and higher body mass index in 
Korean, American, African-American 
and British-Caucasian populations.
intron 3, 
down 
stream 
region
[100, 101] 
[102-106]
CDH13 H-cadherin
(heart)
Correlation with metastatic cancer: 
loss of TG repeats detected in lung 
and breast cancer.
intron 1 [107, 108]
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CFTR Cystic fibrosis
transmembrane
regulator
Correlation with monosymphomatic 
cystic fibrosis (CF) in Iranian and 
Caucasian populations, where allele 
TG12T7 is the most common.
UG repeats modulate alternative 
splicing.
Possible correlation with lower 
incidence of CF or CF-like diseases in 
Asian/Chinese population; TG11T7 is 
the most common allele in these 
populations.
intron 8, 
up stream 
region
CMA1 Mast cell 
chymase 1
Correlation with atopic asthma and 
IgE levels.
3'UTR
D155976 D155976 No association with schizophrenia in 
Chinese population.
3'UTR
ER alpha Estrogen 
receptor alpha
Correlation with genetic susceptibility 
to breast cancer. Longer TG tracts 
associate with reduced expression of 
progesterone receptor and reduced 
cancer risk in Chinese and Caucasian 
populations.
5'UTR
FGF9 Fibroblast 
growth factor 9
Correlation with gonadal dysgenesis 
(XY female sex reversal).
TG repeats modulate promoter 
activity, mRNA stability and 
translation.
3'UTR
Flt-1 FMS-like 
tyrosine kinase 1
No association with development of 
preeclamsia in Korean population.
3'UTR
FOXP3 forkhead box 
P3/Scurfin
Correlation with type I diabetes in 
Japanese population.
TG repeats modulate promoter 
activity.
No correlation with several 
autoimmune diseases (lupus, 
rheumatoid arthritis, celiac disease, 
Crohn's disease, etc.) in Spanish 
population.
5'UTR
GRIN2A
*
H2
Glutamate 
receptor, 
ionotropic, N- 
methyl D- 
aspartate 2A 
Human H2 
relaxin gene
Correlation with schizophrenia in 
Chinese population.
Possible correlation with transcription 
regulation.
promoter
region
5’UTR
HA Factor 8 for 
hemophilia A
Correlation with hemophilia A in 
Spanish population.
intron 1
hDBH Dopamine beta- 
hydroxylase
No correlation with schizophrenia in 
Spanish population.
[109-111]
[112]
[113]
[114] 
[115-117]
[22 , 118]
[119]
[120-122]
[123]
[124]
[125] 
[126, 127]
[128]
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hERG / 
KCNH2
hGHR
HIF1
alpha
HM0X1
IFNAR1
IL12a/b
MAOB
NEP
NOS1
NTRK1/
TRKa
Human ether-a- 
go-go related 
gene
Growth hormone 
receptor
Hypoxia- 
inducible 
transcription 
factor 1 alpha 
Erne oygenase 1
Interferon alpha 
receptor 1
Interleukin 12a/b
Monoamine 
oxidase A
Neprylisin
Nitric oxide 
synthase 1 
(neuronal)
Neurotrophic 
tyrosine kinase, 
receptor, type 1
Correlation with drug-induced LQTS in promoter 
Chinese and Caucasian populations. region 
TG repeat affect mRNA and protein 
levels resulting in QT interval 
variations.
Correlation with growth disorders in 
Canadian population.
5'UTR
Correlation with non-small cell lung 
cancer patients and increased HIF1 
alpha expression.
Correlation with coronary artery 
disease in diabetics and with 
atherosclerosis after arsenic exposure 
in Taiwanese population.
Correlation with hyperbilirubinemia.
Correlation with lung 
adenocarcinoma, oral squamous 
cancer and gastric adenocarcinoma.
No correlation with malaria 
pathogenicity and severity in general 
Asiatic populations.
Correlation with cerebral ischemic 
stroke.
Correlation with interferon-induced 
depressive symptoms.
Correlation with gastric cancer in H. 
pylori infected individuals in Italian 
population.
Correlation with Parkinson's disease 
in Australian, but not in Chinese 
population.
No correlation with bipolar disorder 
susceptibility in Caucasian population.
intron 13
promoter
region
promoter
region
promoter
region
intron 2
No correlation with sporadic intron 22,
Alzheimer’s disease susceptibility in exon 1 
Japanese population.
Correlation with sporadic Alzheimer’s 
disease when coexisting with 
mutations in the angiotensin- 
converting enzyme in Korean 
population.
Correlation with amount of exhaled 5'UTR
nitric oxide concentrations. TG 
repeats possibly affect gene 
expression, transcription efficiency 
and alternative splicing events.
No correlation with congenital intron 12,
insensitivity to pain with anhidrosis down
(CIPA). Other polymorphisms in this stream
gene are the direct cause of CIPA region
disease.
[129]
[130]
[131]
[132, 133]
[134]
[135]
[136]
[137]
[138]
[139] 
[140, 141]
[142]
[143]
[144]
[145] 
[146, 147]
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p55
*
TNF receptor 1 Correlation with autoinflammatory 
syndromes, such as familiar Iberian 
fever, in Spanish population.
intron 9 
and intron 
25
[148, 149]
PHKA1 Phosphorylase 
kinase, alpha 1; 
muscle specific
Correlation with phosphorilase kinase 
deficiency.
[150]
PSMA6 Human
proteosome core 
particle
Correlation with type II diabetes 
mellitus in Finnish and Latvian 
population.
intron 6 [151-153]
SCN4A Sodium channel, 
voltage-gated, 
type IV, alpha 
subunit
Correlation with paramyotonia 
congenita and hyperkalemic periodic 
paralysis.
[154]
SLC11A1 Solute carrier Correlation with autoimmune disease promoter [155, 156]
* family 11A 
member 1
and infection susceptibility.
TG repeats modulate gene 
expression.
Correlation with tuberculosis 
development.
Correlation with Crohn's disease and 
inflammatory bowel disease.
region
[157]
[158]
SLC12A1 Solute carrier 
family 12
No correlation with essential 
hypertension susceptibility in Kazakhs 
population.
Not
reported
[159, 160]
SLC8A1
*
Solute carrier 
family 8 
member 1
UG repeats modulate alternative 
splicing.
5'UTR [161]
STAT6 Signal
transducer and 
activator of 
transcription 6
Correlation with atopic asthma in 
British population.
TG repeats modulate promoter 
activity.
5'UTR [162-164]
Tau Microtubule- 
associated 
protein tau
Correlation with progressive 
supranuclear palsy (movement 
disorder).
intron 2, 
down 
stream 
region
[165]
TLR2
*
Toll-like 
receptor 2
No correlation with bacterial infection 
susceptibility in Thai population.
Correlation with colorectal cancer in 
Balkan population.
5'UTR [166]
[167]
TNC Tenascin-C Correlation with symptomatic Achilles intron 17, [168, 169]
* gene tendon injury. down
stream
region
VWF Von Willebrand 
factor
TG repeats modulate gene 
expression in response to shear 
stress.
5'UTR [169]
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TG repeats in gene expression
As shown in Table 1, according with their location, polymorphic TG 
dinucleotide repeats are capable of modulating different aspects of gene 
expression including transcription rate at the promoter, exon recognition efficiency 
and also mRNA stability. This TG repeats-mediated regulatory effect involves 
different mechanisms. Generally, if the repeat function as a protein-binding site, 
changes in the repeat length can differentially recruit transcription factors at the 
promoter or splicing factors at the exon-intron junctions. For example, an 
expansion of repeats can lead to the recruitment of a higher level of binding 
proteins (i.e. eNOs intron 13). Differential protein recruitment can also be achieved 
through the formation of alternative length-dependent DNA/RNA structures that 
ultimately mask or emphasize the protein-binding site (i.e. at the promoter of 
SLC11A1).
Alternatively, expansions or contractions of the repeat length can indirectly affect 
gene expression by altering peculiar spacing between other important regulatory 
c/s-elements for transcription activation or for exon recognition.
The next pages report few significant examples of polymorphic TG repeats- 
dependent modulation of gene expression in the context of different cell types.
TG repeats located at the promoter region or 5’UTR
The hERG gene, also called KCNH2, is a voltage activated potassium 
channel involved in a heart condition named drug-induced long-QT syndrome 
(LQTS). The promoter region of this gene carries a polymorphic TG tract ranging 
from 20 to 45 repeats among Caucasian and Chinese populations. Real time 
quantitative RT-PCR analysis on ventricular samples from human subjects 
showed that longer TG repeats correlates with lower hERG mRNA levels. A 
luciferase reporter gene carrying the hERG promoter region with different TG
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repeats length further confirmed this association. Consistent with lower mRNA 
levels, endogenous protein levels were also reduced. Lower levels of hERG 
proteins lead to higher susceptibility to drug-induced LQTS, therefore the TG 
repeats polymorphism might influence the susceptibility to drug-induced LQTS 
[129].
The SLC11A1 gene, also known as NRAMP1 (natural resistance 
associated macrophage protein 1), has multiple effects on macrophage activation 
and plays a role in immune response against infections. At the promoter region, 
SCL11A1 carries a polymorphic TG tract ranging from 4 to 11 repeats. Among the 
nine alleles carrying a variable number of TG repeats identified to date, alleles 2 
and 3 are predominant and exert opposite effects on SLC11A1 expression. Allele 
3 has GT9 repeats and drives high SLC11A1 expression (allele 3: 
T(GT)5AC(GT)5AC(GT)9 ), while allele 2 contains GT10 repeats and drives lower 
expression of SLC11A1 (allele 2: T(GT)5AC(GT)5AC(GT)10 ). Tissue biopsies of 
allele 3 carriers in fact showed higher SCL11A1 mRNA and protein levels 
compared to allele 2 carriers [156-158, 170]. These data indicate that the 
polymorphic TG tract modulates transcription activation in a length dependent 
manner, through the formation of a Z-DNA structure [74].
The promoter region of the VWF gene (Von Willebrand factor) also 
presents a polymorphic TG element (17 to 23). Although variations in the TG tract 
do not affect basal VWF promoter activity, they strongly correlate with increased 
promoter activity upon laminar shear stress. Minigenes carrying longer TG 
elements lead to higher promoter activity and consequent increase of endogenous 
mRNA levels in cell cultures. Therefore TG repeats at the promoter modulates the 
shear stress responsiveness in a length-reliant manner [169].
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The BRN3C gene, involved in adult-onset hearing loss, carries two distant 
polymorphic TG tracts in its 5’UTR. These tracts together with a mononucleotide G 
repeat were shown to co-regulate BRN3C transcription regulation in vitro using 
luciferase reporter constructs. Specifically, TG variability was observed to alter the 
binding site of the trans-acting factor SP1 (stimulating protein 1). The synergic 
effect of longer TG tracts (TG23) and reduced SP1 levels results in lower 
transcriptional activity. Alternatively, shorter TG tracts (TG16) had no effect [99]. 
Similarly, variations in trinucleotide TCC repeat length at the promoter of the EGF 
gene were found to alter gene expression by affecting SP1 binding [26].
The STAT6 gene carries a polymorphic TG repeat variant at its 5’UTR 
ranging from 12 to 17 TG repeats. Luciferase constructs representing different the 
TG lengths detected in patients differentially regulate the promoter activity in vitro. 
In this case, modulation of the transcriptional activity is not proportional to the 
repeat length, since only the specific allele TG13 strongly upregulates gene 
expression [162]. Interestingly, the TG13 allele also specifically associates with 
asthma, increased production of total serum IgE level and consequent 
predisposition to allergic disease in British population [163].
TG repeats located in the intronic sequence:
The beta-ENaC gene carries a polymorphic TG tract (11, 13 or 14 repeats) 
in intron 8. Linked with development of essential hypertension, this epithelial 
channel indirectly modulates blood pressure by regulating sodium and water re­
absorption. Patients with hypertension carry longer TG repeats (TG14). A 
minigene carrying TG14 showed an increased beta-ENaC mRNA expression 
respect to constructs carrying shorter repeats (11 or 13) [97]. Therefore longer TG
repeats are capable of inducing an increase of beta-ENaC mRNA levels
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expression and can be linked with higher susceptibility to hypertension. In this 
case, since the TG repeats are located in intron 8 this effect might be exerted by 
stabilizing the pre-mRNA rather than by affecting promoter activity.
TG repeats located at the 3 ’UTR:
The FGF9 gene is involved in many biological processes including sex 
development at early embryonic stages in humans. The polymorphic TG repeats 
at the 3’UTR of the FGF9 gene range from 13 to 16 repeats, with allele TG15 
being the most common and allele TG14 associating with gonadal dysgenesis. 
This association can be due to the fact that TG14 displays stronger promoter 
activity with respect to TG15 in reporter minigenes. Furthermore, the TG 
microsatellite also forms structural elements at the 3’UTR affecting mRNA 
turnover, and the disease-associated TG14 displays longest mRNA stability [118]. 
Recent mass spectrometry analysis has identified eight trans-acting factors 
binding to the TG15 tract at the 3’UTR of the FGF9 gene, including TDP-43 and 
FUBP3 (FUSE binding protein 3). Silencing and overexpression of the latter was 
shown to differentially regulate FGF9 gene expression at the protein level. 
Therefore, the synergic effect of TG repeats and FUBP3 protein is capable of 
promoting FGF9 mRNA translation [22].
TG repeats enhance retinoic acid-induced gene repression through the 
recruitment of PTB:
Retinoic acid regulates cellular differentiation by modulating gene 
expression and ultimately affects normal embryonic growth and development. In 
genes susceptible to retinoic acid, the presence of TG repeats in regulatory 
sequences (introns, 5’/3’UTRs) was shown to strongly enhance the retinoic acid- 
mediated gene repression. This modulation is granted by TG repeat recruitment of
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the trans-acting factor PTB (polypyrimidine tract-binding protein). In fact, PTB was 
reported to bind both DNA single and double-stranded TG repeats sequences and 
thus modulate retinoic acid-induced repression of gene expression [171]. 
Consistent with this hypothesis, a microarray analysis of retinoic acid-treated 
neural crest cells revealed that 41 out of 43 downregulated genes contain TG 
repeats in either introns or 375’UTRs [171, 172]. Additionally, several genes 
involved in neuronal crest cells differentiation and embryogenesis that also carry 
TG repeats, showed significantly lower expression after PTB overexpression. 
Among them are: Pax7, Otx2, En2 and Snail2 genes. In particular, Snail2 gene 
carries two TG repeats at its 5’UTR and intron 2-3. Minigene systems carrying 
various deletions of these two TG tracts showed that the presence of TG repeats 
is markedly required for retinoic acid-mediated repression of gene expression 
[171].
UG repeats-mediated splicing regulation
As well as others TRs, UG repeats modulate splicing when located in 
proximity of splice signals. Presently, four cases of UG repeats-mediated splicing 
regulation are reported in the literature and reviewed in this section. Besides the 
splicing outcome, consequences at the protein levels and potential implications in 
evolution or disease etiology are highlighted. The synergic effect of trans-acting 
factors binding to the UG elements is also presented when uncovered.
UG repeats at the 3 ’SS of CFTR exon 9: aberrant splicing modulation.
The CFTR gene encodes for a chloride ion channel named cystic fibrosis 
transmembrane regulator (CFTR). This transporter is located in epithelial cell 
membranes where contributes to the formation of the mucus. Mutations in the 
CFTR gene affect the functionality of the channel leading to cystic fibrosis disease.
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At the 3’SS of exon 9 a polymorphic locus contains a variable number of 
dinucleotide TG (ranging from 9 to 13) followed by a T repeat (T5, T7, or T9). 
Although the length of the polymorphic element varies among ethnic groups, 
TG12-T7 is considered the most common allele in general population. The 
increasing number of UG repeats together with the decreasing length of U tracts 
were shown to correlate with exon 9 skipping in a minigene system [173-175]. In 
vivo, skipping of exon 9 results in a non-functional protein causing 
monosymptomatic forms of cystic fibrosis [109, 110, 176, 177].
Two different models based on in silico and in vitro considerations have 
been proposed to explain how changes in the UG repeats length affect exon 9 
splicing outcome and therefore influence disease’s incidence. A first model 
suggests that the UG repeats at the 3’SS form an RNA secondary structure that 
sequesters splicing signals and inhibits proper exon 9 recognition by the splicing 
machinery. In a minigene system, UG tracts correlate with increased exon 9 
skipping in a length-dependent manner and the substitution of the UG tracts with 
another dinucleotide repeat (UA repeats) equally contributes to exon 9 skipping 
[31].
A second model from Baralle’s laboratory suggests that the UG element acts a 
trans-acting factor recruiter, and the recruited protein ultimately modulates the 
splicing outcome. Among the UG binding proteins involved in CFTR exon 9 
processing, TDP-43 is the most studied. A detailed description of TDP-43 
inhibiting exon 9 recognition in a UG repeats-mediated manner is reported later in 
the introduction (see page 48) [178].
Besides TDP-43, the potential role in CFTR exon 9 processing played by 
two CELF family members has also been investigated. Both CELF1 and CELF2 
proteins are known to bind CUG repeats and mediate splicing misregulation in 
muscular dystrophy. Additionally, they display a stronger affinity for UG repeats
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elements [179-181]. In a minigene system, CELF1 (also called CUGBP1, CUG 
binding protein 1) did not seem to affect CFTR exon 9 processing [182]. 
Concerning CELF2 (also called ETR-3, Elav-type RNA-binding protein 3 or 
CUGBP2), two independent studies reported discordant data. In a first study, 
CELF2 enhanced exon 9 inclusion in a minigene system [183]. Alternatively, in a 
second study CELF2 inhibited CFTR exon 9 inclusion both in a minigene system 
and in endogenous CFTR mRNA [182]. In this same study authors suggest that 
structural differences in the minigenes system used can be responsible for the 
discordant results.
UG repeats at the 3 ’SS ofAPOAll exon 3: constitutive splicing regulation
The APOAII gene encodes for the apolipoprotein A-ll, a constitutive 
component of the high density lipoproteins (HDLs) that plays an essential role in 
lipid metabolism. Additionally, the APOAII protein was recently found to be 
essential for embryonic development in zebrafish and a crucial factor for nuclear 
division in mammalian cells [184].
The weak 3’SS ofAPOAll exon 3 present polymorphic UG repeats, ranging 
from 12 to 21 with UG19 being the most frequent repeat. Although this UG repeats 
polymorphism does not affect the APOAII plasma concentrations or the 
cholesterol levels [89], it represents a peculiar c/s-acting element for exon 3 
constitutive processing. In fact, both deletion and replacement of the UG motif 
result in exon 3 skipping [185].
The involvement in APOAII exon 3 processing of the trans-acting factor 
TDP-43 binding the polymorphic UG is illustrated later in the introduction (see 
page 49). No other UG repeats-binding factors have been investigated concerning 
the regulation ofAPOAll exon 3 recognition.
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UG repeats at the 5’SS of CD36 exon 3: an example of the beneficial effect of 
instable polymorphic repeats in humans
The CD36 protein (cluster of differentiation 36) is receptor expressed on the 
surface of various cells types (erythroblasts, macrophages, adipocytes, etc.) that 
associates with numerous functions (i.e. immune response, hemostasis, lipid 
transport, etc.). Interestingly CD36 is also capable of influencing the outcome 
of malaria infection. Malaria is caused by the protozoan parasite Plasmodium 
falciparum, which infects human erythrocytes. The CD36 receptor plays a pivotal 
role in the adherence of parasite-infected erythrocytes to the capillary endothelia. 
This adhesion inhibits the immune response to parasite therefore contributing to 
the pathology of malaria [186].
Genotyping analysis of Thai patients with malaria revealed a polymorphic 
UG element at the 5’SS of CD36 exon 3, ranging from 11 to 16 repeats [101]. Mild 
malaria without cerebral involvement specifically associated with the UG12 repeat 
length, whereas exacerbate cerebral malaria cases associate with longer UG 
tracts (UG>12). It has been proposed that the allele UG12 confers protection 
against disease progression by influencing CD36 alternative splicing. Examination 
of CD36 variants in human blood cells revealed that short UG repeats (UG=11/12) 
associate with full-length CD36 mRNAs. Alternatively, long UG repeats associate 
with alternatively splice CD36 isoforms lacking exons 4 and 5. From a functional 
point of view, this alternative splicing event alters the binding affinity of the 
parasite-infected erythrocytes for CD36. In fact, CD36 exons 5, together with 
exons 3 and 6, encode the ligand-binding domain of the receptor protein [187, 
188]. On the other hand, the expression of full-length CD36 on macrophages plays 
a crucial role in the CD36-dependent phagocytosis of the infected erythrocytes 
[189]. Therefore, the UG12 repeat at the 5’SS of CD36 exon 3 promotes the 
production of a full-length CD36 protein leading to an efficient phagocytosis and
therefore conferring protection from cerebral malaria [101]. This case represents 
an example of the beneficial effect of instable polymorphic repeats in human 
phenotype modulation.
Other disparate polymorphisms in CD36 gene were also found to associate 
with either protection or susceptibility from severe malaria in African population, in 
accordance with the key role played by CD36 gene product in this disease [190, 
191].
Independent studies in Korean, American, African American and British- 
Caucasian populations also linked the polymorphic UG repeats in CD36 gene with 
body mass index and cardiovascular risk (TG=12 leads to higher risk than TG>12) 
[103-106]. Overall, these studies provide further insight of the favorable role of 
polymorphic repeats in phenotype modulation. The involvement of trans-acting 
factors has not been investigated in this case.
UG repeats at the 5’SS of SCL8A1 exon 2: tissue-specific alternative splicing 
modulation
The SCL8A1 (solute carrier family 8, member 1) gene encodes for a 
plasma-membrane reversible transporter of Na+ and Ca2+ ions called NCX1 
(Na+/Ca2+ exchanger 1). In humans SCL8A1 contains 12 exons where an 
unusually long exon 2 encodes for about two-thirds of the entire protein.
Tissue-specific alternative splicing events generate several variants of the 
NCX1 protein in order to fulfill tissue-specific requirements of Ca2+ homeostasis 
[192]. For example, a short isoform resulting from the circularization of exon 2 is 
the most abundant in human heart, whereas full-length transcripts have been 
found in other tissues [193]. The splicing mechanism leading to SCL8A1 exon 2 
circularization is unknown, although it has also been found in other genes (i.e. Sry 
gene and cytochrome P450 gene [194,195]).
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A polymorphic UG tract ranging from 10 to 16 repeats was identified at the 
5’SS of SCL8A1 exon 2. No relationship between the length of the polymorphism 
and cardiac pathologies was detected [161]. However, the UG tract acts as a 
strong intronic splicing enhancer element and can be involved in the regulation of 
SCL8A1 expression.
In a minigene system, a short mRNA product is detected in the construct 
carrying the UG repeats. Alternatively, full-length mRNA is detected when the UG 
element is deleted or substituted with a non-repeated sequence. Based on these 
observations, the UG repeat element is capable of modulating alternative skipping 
of the entire region downstream exon 2, resulting in the production of a short 
transcript (heart specific) [161 ].
The mechanisms through which UG repeats mediate alternative splicing as 
well as potential tissue-specific trans-acting factors involved remain to be 
investigated.
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TDP-43
The protein
Among the different TG/UG repeats-binding proteins (CELF1, CELF2, TDP- 
43, PTB, FUBP3, etc.) this dissertation focuses on TDP-43, a protein presenting 
strong affinity for the TG/UG elements and also involved in numerous 
neuropathologies that present TDP-43 aggregates.
Highly conserved throughout evolution [196] and ubiquitously expressed 
[173], TDP-43 is encoded by the TARDBP gene located in chromosome 1. As a 
member of the heterogeneous nuclear ribonucleoproteins (hnRNPs) family, TDP- 
43 contains two highly conserved RNA recognition motifs (RRM) flanked by an N- 
terminal and a C-terminal domain [178] (Figure 2A).
The N-terminal region contains a nuclear localization signal (NLS), 
consistent with the fact that induced mutations in this region mostly confine TDP- 
43 into the cytoplasm [197].
Among the two RRMs, the RRM1 domain is indispensable for the protein to 
bind single stranded RNAs and DNAs [173, 198]. The RRM2 domain contains the 
predicted nuclear export signal (NES) and plays a role in chromatin organization 
[199] and TDP-43 dimerization [200, 201].
The C-terminal domain mediates protein-protein interactions through a 
glycine (G) rich tail, which was found to recruit other members of the hnRNP 
family such as hnRNP A1, A2/B1, and A3 [202, 203]. Moreover, a 
glutamine/asparagine (Q/N) rich region capable of binding poly-Q aggregates was 
also identified within TDP-43 C-terminal domain [204]. The strong tendency to 
aggregate of these Q/N-rich regions and the discovery of aggregated C-terminal 
fragments in the TDP-43 pathological inclusions suggest a key role for the C- 
terminal domain in aggregates formation.
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Diseases-associated
mutations
Q/N-rich region
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NLS NES 331 369
RRM1 RRM2 G-rich domain
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hnRNP A/B binding domain
C-terminal fragments
□  NLS, nuclear localization signal
□  NES, nuclear export signal
□  RRM1 and 2, RNA-recognition motifs 1 and 2 mutated
n  Glycine-rich domain: hnRNP A/B binding domain (321-366); Q/N rich region (331-369)
Figure 2B: Schematic illustration of TDP-43 domains. The nuclear 
localization and export signals are reported together with the two RNA binding 
motifs. At the C-terminal domain both Q/N-rich region and hnRNP A/B binding 
site are located within the G-rich domain, which is also the region were the 
majority of the disease causing mutations were detected. Finally, the C-terminal 
fragments found in TDP-43 aggregates are also illustrated. Fragments have 
been found to either start at position 208, 219 or 247, whereas the protease 
involved in the cleavage remains presently unknown.
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Localization
In physiological conditions, TDP-43 is ubiquitously distributed in neuronal 
and non-neuronal cells showing a preferential nuclear distribution, with a weak 
cytoplasmatic signal [205-208]. Within the nucleus, TDP-43 normally exhibits a 
fine punctuate pattern on a diffuse nucleoplasmic staining. In situ transcription 
assays demonstrated that TDP-43 is excluded form centromeric and telomeric 
transcriptionally silent heterochromatin but strongly associated with 
transcriptionally active euchromatin domains, where specifically colocalizes with 
perichromatin fibrils (PFs). Enriched in nascent pre-mRNA transcripts and splicing 
factors, PFs domains are considered active sites of pre-mRNA transcription and 
cotranscriptional splicing [209] and microRNAs biogenesis [210]. Nonetheless, 
TDP-43 is absent or rarely detected in transcription-free compartments such as 
Cajal bodies, perichromatin granules (transient storage sites for mRNAs) 
interchromatin granule clusters (storage site for splicing factors) and the nucleolus 
[211]. TDP-43 nuclear localization correlates with its physiological function in 
different aspects of RNA metabolism.
Additionally, although predominantly nuclear, TDP-43 can shuttle between 
cytoplasm and nucleus [206]. In fact, a weak cytoplasmatic signal is detected in 
normal conditions indicating a plausible TDP-43 function also in this cell 
compartment. This is supported by the observation that, beside its pathological 
aggregation in cytoplasm of neurons and glial cells [212], TDP-43 has been found 
to reversibly increase its cytoplasmatic localization in response to neuronal injury 
in motorneuronal cell lines [213, 214]. In addition, within the cytoplasm of neurons, 
TDP-43 reversibly associates with RNA transport granules, processing bodies (P- 
bodies) and stress granules [215-217]. In conclusion, TDP-43 cytoplasmatic 
localization has been linked with a physiological role both in neuronal response to 
injury and in RNA transport.
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Mis-localization and TDP-43 proteinopathies
Accumulation of intracellular misprocessed and misfolded proteins in the 
central nervous system is a feature of many neurological disorders. A newly 
introduced nomenclature defines a group of them as “TDP-43 proteinopathies” 
based on the presence of TDP-43 as the major pathological substrate for 
inclusions formation.
TDP-43 proteinopathies include a variety of neurodegenerative diseases 
with different origin such as amyotrophic lateral sclerosis (ALS) [212, 218], fronto- 
temporal lobar degeneration (FTLD), poly-Q diseases like Huntington’s disease 
(HD) and spinocerebellar ataxias (SCA), myopathies and various forms of 
dementia including Parkinson’s and Alzheimer’s diseases [219]. Among them, the 
role of TDP-43 in ALS is the most investigated process to this date.
ALS is an adult-onset neurodegenerative disorder characterized by 
progressive loss of motor neurons that leads to fatal paralysis. Although the cause 
of the disease remains elusive, the formation of aggregates in motor neurons is a 
pathological hallmark. Most forms of ALS are sporadic but approximately 10% of 
the patients have an inherited familiar form.
Mutations in several genes have been identified as a risk factor for familiar 
ALS such as ANG, SOD1, FUS/TLS, TDP-43 and other rare mutations. Nearly 4% 
of the familiar ALS present TDP-43 mutations, which are mostly localized in its C- 
terminal domain with the exception of one in the RRM1 domain. Besides one 
truncating mutation, all the detected variations are missense mutations affecting 
highly conserved amino acids. Interestingly, cytoplasmatic aggregates of TDP-43 
were only detected in familiar ALS with TDP-43 and ANG mutations, but not in the 
SOD1 and FUS/TLS mutated familiar forms (reviewed in [219]).
In sporadic ALS, mutations in ANG, SOD1, FUS/TLS and TDP-43 were 
found in less than 1% of the cases. Nevertheless, TDP-43 aggregates have been
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found in the totality of the reported sporadic cases. This indicates that TDP-43 
mutations (and mutations of the other genes as well) can play an important role in 
disease pathogenesis but are not the primary causes trigging the formation of 
TDP-43 inclusions. Consistent with this observation, rare TDP-43 mutations were 
also identified in patients with FLTD (FTLD-TDP-43) [220-224] but not in other 
TDP-43 proteinopathies so far.
Within the aggregates, TDP-43 is hyper-phosphorylated, ubiquitinated and 
abnormally cleaved to generate C-terminal fragments of 20-25 kDa [212, 218]. 
The pathogenic role of these post-translational modification and cleavage has yet 
to be established. Phosphorylation of TDP-43 seems to have no effect on 
aggregation, toxicity or C-terminal cleavage in cellular models [225] but was 
instead found to correlate with insolubility [226]
The 20-25 kDa C-terminal fragments are predominant in cortical region (brain) 
whereas full-length TDP-43 inclusions are prevalent in spinal cord [227-229]. 
However, although the expression in cells of these fragments can recapitulate 
some pathological features, their pathogenic roles remain unknown.
Ubiquitination of TDP-43 indicates that cellular degradation machineries (such as 
autophagy and/or the ubiquitin-proteosome system) are involved in TDP-43 
aggregates removal. Additionally, TDP-43 affects the expression of HDAC6, a 
protein associated with aggregation and autophagic degradation of poly- 
ubiquitinated proteins [230, 231]. Therefore the autophagic system is likely to play 
a crucial role in the pathogenesis of TDP-43 proteinopathies and of other 
neurodegenerative disorders characterized by accumulation of protein aggregates 
(reviewed in [219, 232]).
Although in normal conditions TDP-43 localizes mainly in the nucleus, in 
patients with cytoplasmatic TDP-43 inclusion a partial clearance from the nucleus 
is observed [212, 218]. This altered subcellular localization of the protein and the
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formation of intracellular aggregates may be critical for the disease pathogenesis. 
The formation of TDP-43 inclusions may either have a neuro-protective effect 
through the sequestration of misfolded and truncated species, or a neuro-toxic 
effect (gain of toxic function). The latter is supported by the fact that TDP-43 
overexpression in cellular and animal models leads to increased cytoplasmatic 
TDP-43 localization and TDP-43 aggregates formation, with consequent cell death 
or neurodegeneration. However, it has to be noticed that forced synthesis of high 
levels of TDP-43 does not resemble a physiologically relevant context. In fact, 
although earlier studies detected an increased amount of TDP-43 mRNA levels in 
patients with TDP-43 proteinopathies [233, 234], a more recent study found that 
mRNA levels of TDP-43 were generally normal [223].
Besides the gain of toxic function, sequestration of the protein in cytoplasmatic 
inclusions with consequent clearance from the nuclei may also result in a loss of 
normal functions, since TDP-43 may not be available for interactions with protein 
partners and RNA targets. Additionally, given its role in neuronal recovery, TDP-43 
cytoplasmatic localization in neurons has also been suggested to represent a 
natural response to stress rather than an initiating event in pathogenesis [214].
More hypotheses of how TDP-43 can contribute to neurodegenerative 
disease pathogenesis in terms of loss or gain of function are described later in the 
text in association with TDP-43 identified RNA targets and RNA-binding partners. 
Nevertheless, the exact involvement of TDP-43 misaccumulation in trigging the 
disease remains to be uncovered.
Binding specificity
Early studies showed that TDP-43 predominantly binds single stranded 
RNA UG repeats and single stranded DNA TG repeats, and that this affinity 
increases with the repeat length [178]. In fact, competition assays with synthetic
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oligonucleotides showed that TDP-43 binds single-stranded DNA and RNA with 
TG/UG repeats, but does not bind double-stranded DNA and RNA [173, 178]. 
Nevertheless, in nitrocellulose filter-binding assays TDP-43 was shown to bind 
both single and double-stranded DNA, albeit with higher affinity for single-stranded 
sequences [200]. Also, in hNFL mRNAs, TDP-43 was reported to bind double­
stranded RNA where single UG dinucleotides were brought in close proximity to 
each other by the RNA secondary structure [216, 235].
Consistent with TDP-43 binding specificity for UG repeats is the presence 
of UG motifs in most of the recently identified TDP-43 RNA targets. Also, an 
adenine was found to frequently occur in the binding motif of many TDP-43-RNA 
targets (i.e. (TG)nTA(TG)m; more examples in Table 2) [236].
Nonetheless, the growing number of exceptions in TDP-43 binding 
sequences implies that TG/UG repeats may be the most favored but definitely not 
exclusive TDP-43 binding site (examples of exceptions include binding sites: in 
TDP-43 3’UTR [237], in SMN2 exon 7 [238], in SC35 3’UTR [239], in TAR DNA 
element of HIV-1 in [240], in Nrxn3 and others [86], etc.) (Table 2).
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Table 2. TDP-43 binding sequences. Recent CLIP analysis identified TDP-43 
clusters in RNA sequences containing UG motifs. These observations point at the 
UG-rich elements as TDP-43 preferential binding sequence, as predicted in early 
studies of competition assay with oligonucleotides [178]. Septhon et all. also 
identified a frequently occurring adenine (A) within TDP-43 binding sites [236]. 
Numerous examples of non-UG TDP-43 targets were reported by Polymenidou et 
all. [86] although the exact binding sequence was not indicated. In this table are 
reported three examples of non-UG binding sites in TDP-43 3’UTR [237], in SMN 
exon 7 [238] and in TAR DNA element of HIV-1 [240].
TDP-43 Binding Sequences with UG elements Ref.
(UG)6 [178]
UGUGU [241]
GUGUG [241]
UGUA(UG)4 [236]
(UG)2UA(UG)3 [236]
(UG)4UAUG [236]
(UG)3UA(UG)2 [236]
GUGUA(UG)3U [236]
G(UG)2UA(UG)2U [236]
G(UG)3UAUGU [236]
Non-UG TDP-43 Binding Sequences Ref.
(GA)3(GC)2GUGC(AG)2ACUU(GGU)2GCAUAA 
(A) 5 G AAG G AAG G
C(T)5GCCTGTACTGGG(TC)3TG (DNA sequence)
[237]
[238] 
[240]
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RNA targets overview
In order to establish the physiological role of TDP-43 several studies have 
focused on identifying its targets. Some of them were detected as changes in the 
splicing outcome in response to altered cell conditions such as TDP-43 silencing 
or overexpression, including CFTR, APOAII, SC35 and SMN2 [88, 173, 238, 239]. 
A much higher number of targets (about 400) were predicted from microarray 
analysis upon TDP-43 silencing. Among them CDK6, HDAC6, and Tbc1d1 have 
been further investigated and linked with TDP-43 potential physiological functions 
[199, 242, 243].
Most recently, three independent studies have used CLIP-seq analysis in 
order to comprehensively identify TDP-43 targets in endogenous conditions [86, 
236, 241]. The first study by Sephton et all., has identified 4.352 endogenous 
TDP-43-RNA-targets in rat brain. The reported targets have been classified in 
exonic (22%), intronic (45%) or dual (both exonic and intronic) (33%) targets, 
according to the location of the TDP-43 binding sequence within the genes. TDP- 
43-RNA-targets are enriched in diverse functional classes such as cell- 
communication and signaling pathway, RNA metabolism, cell-structure and 
motility, development, synapses formation and regulation [236]. Strikingly, this 
enrichment is consistent with the dinucleotide TG repeats distribution within 
functional classes previously reported in an independent study [20].
The second study by Polymenidou et all., has identified 6.304 endogenous genes 
targets in mouse brain. In this case, TDP-43 binding sites are mostly intronic 
(93%); among them 82% locate within 500 bases from the nearest exon-intron 
boundary. Additionally, splice-junction microarray analysis detected nearly 1000 
altered splicing events upon in vivo TDP-43 depletion in mouse brain using 
antisense oligonucleotides. Altered splicing, including both exon inclusion and
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exon skipping, was further confirmed for a total of 16 exons using semi- 
quantitative RT-PCR [86].
In the third and last study by Tollervey et all., mRNA targets of TDP-43 were 
compared in healthy human brains versus FTLD human brains leading to the 
identification of 2139 and 2702 targets respectively. The most significant increase 
in TDP-43 binding in FTLD brains was observed in nuclear paraspeckle assembly 
transcript 1 (NEAT1) and metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1). As reported in the other two studies, TDP-43 binding sites were mostly 
localized within intronic sequences (60%). In the same study, a splice-junction 
microarray analysis evaluated splicing changes upon TDP-43 silencing in human 
neuroblasomal cell lines. A total of 229 altered splicing events were detected and 
6 of them have been validated using real time PCR [241].
Noteworthy, a high level of discrepancy was observed among all the 
studies based on microarray analysis [199, 242, 243]. Similarly, the three reported 
CLIP-seq analyses not always reported the same RNA targets. This observation 
might suggest that some of the identified target may be context-specific, cell type- 
specific or also be subjected to high background noise. However, it has to be 
considered that the three studies used cells derived from different animals (rat, 
mouse, human) and that different methodologies where used to deplete TDP-43 
(TDP-43 depletion with antisense oligonucleotides mouse brain; human 
neuroblasomal cell lines silenced with siTDP-43). Possibly this differences account 
for the discrepancy in the results. Indeed a great amount of work will be required 
in the future to explore the functionality of all the identified potential RNA targets 
and to combine the all results in a comprehensive meta-analysis.
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RNA-binding partners
TDP-43 was found to exist predominantly in high molecular mass 
complexes associated with RNA. This TDP-43 interactome, where TDP-43 is likely 
to be present with more than one molecule, has been broadly investigated in 
several independent studies leading to the identification of numerous TDP-43 
interacting proteins [236, 244-246]. Among them are the majority of the known 
hnRNP proteins (AO, A1, A2/B1, C, D, F, H1, H2, H3, I, K, L, M, Q, R, and U), 
splicing factors (i.e. SF3a, SF2/ASF), several RNA-binding proteins (i.e. FUS/TLS, 
CUGBP1, FOX2, ADAR) and components of Drosha microRNA processing 
complexes (i.e. ILF2/NF43, ILF3/NF90, DDX5, DDX17, DDX3X) [247].
In general, TDP-43 interaction with splicing factors and hnRNP proteins is 
consistent with its localization in PFs bodies, nuclear sites of cotranscriptional 
splicing, and further supports a role for TDP-43 in different aspects of RNA 
metabolism. Moreover, the interaction with hnRNP family members points at TDP- 
43 as an integral part of complexes that associate with nascent transcripts and 
influence their fate. The majority of the others TDP-43 interactors remain to be 
fully investigated. Nevertheless, in some cases the interaction of TDP-43 with the 
proteins linked with neurodegenerative disorders has been studied in order to 
uncover a potentially common pathological mechanism.
Interaction with FUS/TLS
One of the most studied is the interaction between TDP-43 and FUS/TLS 
(fused in sarcoma/translocation in liposarcoma). These two proteins were found to 
co-immunoprecipitate in mammalian cells and both TDP-43 G-rich and RRM2 
domains are thought to mediate the interaction [244, 246]. TDP-43 and FUS/TLS 
share several structural and functional features. In fact, like TDP-43, FUS/TLS is 
an RNA binding protein structurally similar to the hnRNP proteins family with
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multifunctional roles in transcription and RNA metabolism. For example, FUS/TLS 
is implicated in transcription regulation (represses Cyclin-D gene expression 
[215]), and interacts with RNAPII and the TFIID complex [248]. Also FUS/TLS 
associates with transcriptional factors, nuclear receptors and Drosha [247] 
implying a potential role in microRNA processing, mRNA transport and local RNA 
translation. TDP-43 and FUS/TLS also share an analogous cellular distribution 
since FUS/TLS is almost ubiquitously expressed and mainly nuclear, with 
cytoplasmatic accumulation detected in different cell type.
Most interestingly, both proteins are linked to ALS. In fact, in addition to 
TDP-43 and FUS/TLS mutations, distinct pathological aggregates of TDP-43 or 
FUS/TLS were found in ALS patients.
Besides ALS, patients with either FTLD or poly-Q diseases also carry FUS/TLS 
mutation. At present 30 dominant mutations in FUS/TLS gene have been found in 
nearly 4% of the familiar ALS cases, with the exception of one mutation showing 
recessive inheritance. Most of them are missense mutations clustered in the G- 
rich domain and in the extreme C-terminal domain of the protein where the NLS is 
likely sited [219, 232, 249, 250]. Despite FUS/TLS mutation, patient’s neurons and 
glial cells (brain and spinal cord) present a normal FUS/TLS nuclear staining. 
However, an abnormal cytoplasmatic and intranuclear accumulation of the protein 
was also observed. Unlike TDP-43 aggregates, no evidences of biochemical 
alterations or truncated forms of the protein were detected in FUS/TLS inclusions. 
Interestingly, FUS/TLS aggregates were found only in neuropathologies where 
specifically FUS/TLS is mutated (ALS-FUS, FTLD-FUS). Conversely, TDP-43 
aggregates were almost ubiquitously present in TDP-43 proteinopathies, mostly in 
the absence of TDP-43 mutations. The occurrence of TDP-43 or FUS/TLS positive 
inclusions is generally mutually exclusive, since TDP-43 cytoplasmatic inclusions 
were not detected in presence of FUS/TLS aggregates. The poly-Q diseases
represent the only exception, where both TDP-43 cytoplasmatic inclusions and 
FUS/TLS intranuclear inclusions were found in Huntington’s disease and SCA 
type 3 (SCA3) [251]. These observations suggest that FUS/TLS mutations drive a 
neurodegenerative process that does not depend on TDP-43 mislocalization [229, 
249, 250].
Although several studies pointed at similar structure, function and 
misaccumulation of these two proteins, very little is known on their functional 
relationship. Only one common RNA target has been identified so far. Specifically, 
TDP-43 and FUS/TLS possibly co-regulate HDAC6 expression since silencing of 
both proteins reduced HDAC6 mRNA levels and the simultaneous knock down 
resulted in a further reduction of gene expression [244].
Interaction with ATXN2
Another interaction with pathological implications is between TDP-43 and 
Ataxin 2 (ATXN2) [252].
In healthy individuals, the ATXN genes generally carry 22/23 trinucleotide CAG 
repeats encoding for a long poly-Q tract. As previously reported, expansion of the 
trinucleotide CAG repeats causes neurodegenerative disorders known as poly-Q 
diseases (page 9). In the ATXN2 gene in particular, expansion of 34 or more 
trinucleotide repeats results in SCA type 2 (SCA2) with 100% penetrance. 
Alternatively, expansions of 27 to 33 repeats are associated with ALS with 5% 
penetrance. Proteins carrying expanded poly-Q like ATXN2 have a strong 
tendency to form large cytoplasmatic aggregates with a potentially toxic effect. 
These aggregates recruit and sequester proteins, which contain poly-Q stretches 
or alternatively Q/N-rich regions [204].
TDP-43 and ATXN2 co-immunoprecipitate in human cell lines and also co- 
localize in poly-Q cytoplasmatic aggregates. Additionally, upregulation of yeast
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and fly orthologues of the human ATXN2 (Pbp1 and Atx2 respectively) were found 
to exacerbate TDP-43 toxicity in terms of lifespan shortening and progressive loss 
of motility [252].
Therefore, TDP-43 interaction with ATXN2 into poly-Q-aggregates might be the 
cause of TDP-43 translocation from the nucleus to the cytoplasm, with consequent 
loss of normal TDP-43 function. In fact, TDP-43 sequestration within poly-Q- 
aggregates was shown to influence the splicing outcome of a reporter minigene 
carrying CFTR exon 9 [204]. Furthermore, the Q/N-rich region identified at the C- 
terminal domain of TDP-43 confers to the protein a strong tendency to aggregate. 
This property identifies a potential self-aggregation mechanism for TDP-43 
inclusion formation, as observed for TIA-1 [253]. Co-localization of TDP-43 with 
poly-Q inclusions in cortical neurons of patients with HD [254] further supports a 
role for TDP-43 in the pathogenesis of poly-Q diseases.
Interaction with MeCP2, nPTB and CELF1:
TDP-43 was also found to interact with two proteins highly enriched in 
neurons such as MeCP2 (methyl-CpG binding protein 2) and PTBP2 
(polypyrimidine tract binding protein 2) [236].
MeCP2 binds methylated DNAs inducing long-range repression of gene 
expression. Moreover, it was found to regulate splicing of CD44 exons 4 and 5 in a 
reporter minigene by interacting with YBX1 (Y box-binding protein 1) [255], a 
protein that was also found to interact with TDP-43 [246]. Interestingly, MeCP2 
function correlates with synapse formation and postnatal development of the 
nervous system. In fact, loss-of-function mutations or abnormal expression of 
MeCP2 cause a spectrum of disorders including Rett syndrome, learning disability 
and autism [256]. Therefore, the interaction between MeCP2 and TDP-43 in a
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non-pathological context may imply a functional relationship between these two 
proteins, which has not been investigated yet.
PTBP2 or nPTB (neuronal PTB) is a member of the hnRNPs family that 
binds to intronic CU repeats, enhancing the assembly of other splicing factors and 
RNA-binding proteins [257]. Besides their co-immunoprecipitation ability, nPTB 
and TDP-43 binding sites are also generally found in close proximity suggesting a 
possible co-regulation of RNA targets [236]. Similarly, a target co-regulation 
function is plausible for the interaction between TDP-43 and CEFL1 (or CUGBP1), 
which share the same UG repeats binding site [182, 246]. Interestingly, CELF 
proteins and PTB were found to co-regulate splicing in different splicing systems 
(i.e. alpha-actinin, beta-thropomyosin [258-260]).
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Overview of TDP-43 nuclear functions
TDP-43 is a multifunctional protein whose precise role has not been fully 
elucidated. Numerous studies have provided insight of its implication in several 
aspects of gene expression regulation including transcription repression, mRNA 
stability, splicing regulation, RNA transport, translation and microRNA biogenesis. 
Multifunctional proteins like TDP-43 could have a role in coupling transcription with 
splicing and other RNA processes. A detailed review of TDP-43 nuclear functions 
is reported in the following pages.
TDP-43 in transcription
The association of TDP-43 with RNAPII [261] and its co-localization with 
nascent transcripts in PFs (nuclear site of transcription and cotranscriptional 
splicing [211, 262]) tend to support a role for this protein in transcription regulation. 
At present, two cases of TDP-43 exerting an inhibitory effect on transcription are 
reported in literature.
HIV-1 LTR transcription inhibition
In the first case, TDP-43 inhibits transcription of the HIV-1 viral genome. 
The HIV-1 gene expression is regulated by several host factors that bind the c/s- 
acting sequences located within its long terminal repeat region (LTR). In particular, 
Tat protein binds a stem-bulge-loop structure called transactivation responsive 
(TAR RNA) element located at 5’ end the HIV-1 mRNAs promoting efficient 
transcription of viral genes (Tat-induced gene expression) [263, 264]. On the other 
hand, TDP-43 was found to bind to a pyrimidine-rich motif in the TAR DNA 
element of the HIV-1 virus (hence the name TAR DNA binding Protein), but not to
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TAR RNA. Moreover, TDP-43 was proved able to repress both basal and Tat- 
induced gene expression from the HIV-1 LTR suggesting that its binding to the 
TAR DNA element might suppress the recruitment of specific transcription factors, 
ultimately leading to transcription inhibition [240].
The general ability of TDP-43 to bind single stranded pyrimidine-rich 
sequence was further investigated in Baralle’s laboratory highlighting a greatly 
higher affinity of TDP-43 for single stranded DNA TG repeats. Moreover, as 
previously shown by Ou et all., TDP-43 did not bind to polypyrimidine single 
stranded RNAs or to equivalent TAR RNA regions [178].
Acrvl transcription inhibition
TDP-43 inhibits transcription of the acrvl gene, which encodes for the 
acrosomal sperm protein-10 (SP-10), regulating its spatiotemporal expression 
during spermatogenesis. In fact, acrvl gene remains silent in the somatic tissues 
and is expressed only in selected stages of spermatogenesis. SP-10 transcription 
repression is regulated by a molecular mechanism typical of "insulators" [265]. In 
this mechanism, chromatin-insulators regulate gene expression by reorganizing 
the DNA in higher-ordered chromatin domains. Protein-insulators bind these 
domains and physically attach the chromatin fiber to a nuclear peripheral substrate 
(possibly the nuclear lamina). As a result, in this highly rearranged structure the 
interaction between enhancer and promoter is blocked and so is transcription. In 
this case, TDP-43 acts as a protein-insulator by binding on the SP-10 chromatin- 
insulator [266]. Within the SP-10 insulator, in fact, TDP-43 binds two TGTGTG 
motifs on the antisense strand, and the disruption of these motifs results in loss of 
TDP-43 binding capability [267, 268].
Recent ChIP analysis together with molecular markers for pausing of transcription
(such as NELF and Ser5s phosphorylation of the RNAPII CTD) revealed that
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RNAPII is paused at the acrvl promoter in correspondence of the TDP-43 binding 
site. This finding suggests that TDP-43 possibly represses transcription by 
pausing RNAPII [267]. The attempt to identify the specific TDP-43 domain 
responsible for transcriptional repression gave discordant results so far. Older 
studies address the C-terminal domain as the key region for repression [266, 269], 
whereas a recent report from the same group indicated that the lone RRM1 
domain is sufficient for transcription blockage [267].
TDP-43 in general gene expression
Consistent with a gene expression regulatory function, depletion of TDP-43 
in cell cultures leads to down- or up-regulation of numerous gene transcripts 
(about 6000). Among them, TDP-43-mediated regulation of gene expression has 
been further investigated in three cases: CDK6, HDAC6 and Tbc1d1 [199, 242, 
243]. However, the exact mechanism through which TDP-43 may control HDAC6 
and Tbc1d1 downregulation, and CDK6 upregulation, has not been clarified yet. 
As both protein and mRNA transcript levels were affected in each case, TDP-43 
might either modulate their transcription rate or their mRNA stability.
CDK6
Protein and mRNA levels of CDK6 (cyclin-dependent kinase 6) were found 
to significantly increase upon TDP-43 removal [199]. These findings suggest that 
TDP-43 naturally represses CDK6 expression, probably through the binding of the 
numerous TG repeats within CDK6 gene sequence. Normally CDK6 regulates cell 
cycle progression by contributing to the phosphorylation and inactivation of the 
retinoblastoma protein (pRb). When TDP-43 is silenced, CDK6 misregulation 
results in hyper-phosphorylation of pRb and pRb2/p130, pRp-pathway disruption 
and subsequent activation of programmed cell death. In fact, genomic instability,
47
activation of apoptosis and inhibition of neurites outgrowth is observed upon TDP- 
43 silencing [199, 270]. Additionally, members of the Rho family, known to affect 
cell morphology and neuronal survival, presented a reduced activity upon TDP-43 
silencing [270]. TDP-43 may therefore have a critical role in cell cycle regulation 
and loss of TDP-43 function may trigger cell apoptosis and neurodegeneration.
HDAC6
Transcript and protein levels of HDAC6 (histone deacetylase 6) decreased 
upon TDP-43 silencing. Accordingly, a concomitant accumulation of acetyl-tubulin, 
the HDAC6 major substrate, was also observed [242]. The exact TDP-43-binding 
site has not been investigated. HDAC6 is implicated in autophagic degradation of 
poly-ubiquitinated protein aggregates, a cellular defense mechanism that 
sequesters toxic and misfolded proteins. A potential role in neurodegeneration 
suppression has also been suggested for HDAC6 [231, 271]. As downregulation of 
HDAC6 upon TDP-43 silencing results in impaired turnover of aggregating 
proteins, the consequent accumulation of toxic proteins possibly contributes to the 
disease onset in TDP-43 proteinopathies [242]. Interestingly, silencing of FUS/TLS 
(TDP-43 interactor) leads to reduced HDAC6 expression as well. Therefore, both 
proteins might be required for HDAC6 expression-regulation in normal conditions 
[244].
Tbc1d1
Whereas in vitro and in cell culture studies uncovered a connection 
between TDP-43 and CDK6 and HDAC6, an in vivo study linked Tbc1d1 with 
Tardbp, the mouse ortholog of the human TDP-43 [243].
Tbc1d1 (tre-2/USP6, BUB2, cdc16 domain family member 1) is an obesity
predisposition gene, which mediates glucose uptake upon skeletal muscle
48
contraction by co-regulating the vesicular traffic of the glucose transporter GLUT4 
(glucose transporter type 4). Skeletal muscle levels of Tbc1d1 protein are strongly 
downregulated in conditional Tardbp-knock down mice. Furthermore, an increased 
fat metabolism and a lean phenotype were also observed in this animal model. 
These observations raise the possibility of TDP-43 involvement in energy 
metabolism and body fat control, consistent with the hyper-metabolic state of 
some ALS patients. Also, TDP-43-dependent altered fat metabolism may 
participate in motor neuron degeneration in ALS [243].
TDP-43 in splicing regulation
TDP-43 involvement in splicing regulation is the best-characterized aspect 
of the protein so far. In different splicing systems TDP-43 either enhances or 
represses exon recognition through the binding of regulatory elements in proximity 
of splice signals. Presently, four cases of TDP-43-mediated regulation of RNA 
processing are reported in literature. In CFTR exon 9 and APOAII exon 3, TDP-43 
binds a polymorphic TG repeats element located at the 3’SS [88, 178]. 
Alternatively in other two cases TDP-43 binds sequences where the TG motifs are 
absent: in the exonic enhancer in survival of motor neurons 2 (SMN2) exon 7 
[238], and in the 3’UTR of the serine/arginine-rich splicing factor 2 (SRSF2 or 
SC35) [239].
CFTR exon 9
Alternative splicing regulation of the CFTR exon 9 has been extensively 
studied in Baralle’s laboratory over the past ten years [173, 174, 178, 202, 203, 
272-276] firstly revealing TDP-43 inhibitory role in exon 9 recognition through the 
binding of a UG polymorphic sequence at the 3’SS (Figure 3A). Interestingly, 
monosymptomatic forms of cystic fibrosis were found to correlate with the non­
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functional CFTR protein resulting from exon 9 skipping in the final CFTR transcript 
[176]. Consistent with TDP-43 inhibitory effect, higher rates of exon 9 skipping 
were observed upon TDP-43 overexpression, whereas increased exon 9 inclusion 
was detected upon TDP-43 silencing [178, 277]. These results were validated both 
in exogenous minigenes and endogenous mRNA from patient’s lymphoblasts 
[272]. Most recently, sequestration of TDP-43 in poly-Q aggregates also results in 
increased CFTR exon 9 inclusion in a minigene system [204].
The interaction of the C-terminal domain of TDP-43 with other hnRNP 
family members was shown to play a synergic role in exon 9 processing both in 
mouse and in minigene systems [196, 202, 203]. In addition to the UG repeats- 
mediated recruitment of TDP-43, further c/s and trans-acting elements located at 
the 5’SS and within the exon were found to influence exon 9 inclusion levels in the 
final CFTR mRNA (Figure 3A). In fact, at the 5’SS, the TIA-1 splicing factor (T-cell- 
restricted intracellular antigen-1) promotes exon inclusion through the binding of a 
pyrimidine-rich enhancer region (PCE); this interaction is thought to stabilize the 
U1 snRNP interaction with exon 9 weak 5’SS [278]. In addition, an intronic splicing 
silencer (ISS) within intron 8-9 recruits SF2/ASF and SRp40 downregulating exon 
9 recognition. Although SR proteins generally promote exon recognition, in this 
splicing system SF2/ASF and SRp40 were found to favour exon 9 skipping [175, 
276]. Finally, composite regulatory elements (so called CERES - composite exonic 
regulatory elements of splicing) located within the exon 9 sequence present 
context-dependent enhancing or silencing properties, which further affect exon 9 
processing [273]. Although numerous modulators of exon 9 processing have been 
identified, TDP-43 plays a dominant inhibitory role that overrides other regulatory 
elements. In fact, TDP-43 silencing resulted in exon 9 inclusion even in presence 
of mutations that disrupt PCE, and CERES elements and in SF2/ASF 
overexpressed conditions [272].
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APOAII exon 3
The APOAII exon 3 is constitutively spliced in the final mRNA and nor 
mutations or diseases have been associated with exon 3 skipping so far. In this 
case, TDP-43 has an evolutionary relevant role in exon 3 splicing regulation. Just 
like previously observed for CFTR exon 9, TDP-43 binds the polymorphic UG 
repeats at the 3’SS of exon 3 exerting an inhibitory effect on exon inclusion 
(Figure 3B) [88]. In addition, in intron 2-3 an ISS composed of mononucleotide G 
repeats recruits hnRNP H1 and further promotes exon 3 skipping. However, 
constitutive exon inclusion is guaranteed by the presence of an ISE at the 5’SS of 
exon 3 that specifically recruits the SR proteins SRp40 and SRp55 [279] and of an 
exonic splicing enhancer (ESE) within exon 3 that binds SF2/ASF and SC35 
(Figure 3B) [279].
Based on the evolutionary conservation of all these elements, it has been 
proposed that these two enhancer sequences evolved in order to offset TDP-43 
and hnRNP H inhibition of exon 3 inclusion. Consistently with this theory, and 
similarly to CFTR exon 9 system, TDP-43 silencing overrides the need of other 
c/s-acting element since constitutive inclusion of exon 3 occurs even with 
disrupted or mutated intronic and exonic enhancers [88].
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Figure 3. TDP-43 involvement in 3’SS definition. C/s-elements and 
trans-acting factors involved in the processing of CFTR exon 9 (A) and 
APOAII exon 3 (B). The trans-acting proteins are illustrated as different 
shapes whereas the c/s-elements are represented as zigzag lines. The red 
colored rectangle represents the UG repeats bound by TDP-43. An 
enhancing effect on exon inclusion is illustrated as an arrow, an inhibitory 
effect with a “— i”.
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SMN2 exon 7
There are two nearly identical copies of survival of motor neuron (SMN) 
genes in the human genome: SMN1 and SMN2. The critical difference between 
them is a C (in SMN1) -> T (in SMN2) change at position 6 of exon 7 (+6C>T). 
This transition results in predominant skipping of exon 7 in the SMN2 transcripts, 
leading in an unstable, rapidly degraded protein. Mutations or deletion of the 
SMN1 gene result in spinal muscular atrophy (SMA) because SMN2 gene fails to 
compensate impaired SMN production [280-282].
Given its implication with SMA, an autosomal recessive disorder with 
degeneration of the alpha-motor neurons, the SMN2 exon 7 alternative splicing 
has been extensively studied over the years leading to the identification of several 
cis- and trans-acting elements involved (Figure 4A). The +6C>T change creates a 
strong exonic splicing silencer (ESS) that recruits hnRNP A1 [283], but also 
disrupts a pre-existing SF2/ASF binding site [284]. At the 5’SS of the exon 7 there 
is another hnRNP A1 binding site [285] and an additional ISS was also found in 
intron 7-8 [286]; both sequences further promote exon 7 skipping. This strong 
inhibition of exon 7 recognition is balanced by the presence of an ESE in the 
central region of SMN2 exon 7. This enhancer recruits several factors such as 
SRp30c, hnRNP G, hTra2-p1 and TDP-43, which act as positive regulators of 
exon 7 inclusion [238, 287-289]. Specifically, the integrity of an AG-rich sequence 
(AAAAAGAAGGAAGG) within the ESE was proved essential for the assembly of a 
mutimeric complex. Overexpression of TDP-43 in the SMN2 exon 7 minigene 
system resulted in an increased exon 7 inclusion, indicating that TDP-43 can 
enhance exon recognition in a TG repeats-independent manner [238]. On the 
other hand, TDP-43 silencing failed to affect SMN2 exon 7 processing.
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SC35 3 ’UTR and auto-regulation
Several proteins involved in RNA processing, including all SR proteins 
family members and some hnRNPs, were shown to negatively auto-regulate their 
own expression to maintain homeostatic levels (i.e. PTB [290]; hnRNP L [291], 
SF2/ASF [292], SR proteins [293-295]). This negative feedback loop mechanism 
generally involves unproductive alternative splicing events such as alternative 
inclusion of poison-cassettes-exons containing a premature termination codon or 
alternative retained introns. When this happens, the resulting mRNAs are targeted 
for degradation through non-sense mediated decay (NMD) or exosome decay.
TDP-43 was shown to be involved in the auto-regulating mechanism of the 
SC35 splicing factor [239]. As observed for other members of the SR proteins 
family, the overexpression of SC35 results in a significant decrease of 
endogenous SC35 mRNA levels, indicating an auto-regulatory capability. 
Specifically, SC35 promotes alternative splicing with both poison-cassette-exon 
and intron retention events, in addition to alternative polyadenylation events in its 
3’UTR. The resulting mRNAs are unstable and get degraded through NMD [296]. 
A key role in the SC35 auto-regulating mechanism is played by a 60-nucleotides 
enhancer region in SC35 exon 5 (terminal untranslated exon at the 3’UTR), which 
recruits SC35 protein leading to the splicing of the upstream intron (intron 4-5) and 
consequent formation of unstable mRNAs (Figure 4B) [239]. Beside SC35, a 
complex pattern of proteins was found to binds to this 60-nucleotides enhancer 
region, including TDP-43. It has therefore been suggested that TDP-43 competes 
with SC35 for this binding site, leading to inhibition of intron 4-5 processing. In 
fact, TDP-43 overexpression resulted in poor exon 5 3’SS recognition and 
consequent inhibition of intron 4-5 processing in a minigene system.
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Figure 4. Examples of TDP-43 involvement in splicing regulation. Cis- 
elements and trans-acting factors involved in the processing of SMN exon 
7 (A) and SC35 exon 5 (B). The trans-acting proteins are illustrated as 
different shapes whereas the cis-elements are represented as zigzag lines. 
An enhancing effect on exon inclusion is illustrated as an arrow, an 
inhibitory effect with a “— i”.
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A recent study in Baralle’s laboratory has shown that TDP-43 as well can 
control its protein level by self-regulating its transcript expression [237]. This auto- 
regulatory activity is exerted through the binding of several low affinity binding 
sites in its 3’UTR, which do not resemble the canonical UG repeats high-affinity 
binding site.
Unlike other auto-regulating proteins described in literature, TDP-43 self-regulation 
does not seem to involve either alternative splicing or alternative polyadenylation 
events, but regulates the translation efficiency of its RNA transcripts by affecting 
the mRNA stability. In this case, the exosome macromolecular complex was found 
to be partially involved in the degradation of the unstable mRNAs, whereas NMD 
played a marginal role. Downregulation of the endogenous TDP-43 expression 
observed upon overexpression of an exogenous TDP-43 is also supported by in 
vivo data in brain lysate from a mouse model [297, 298].
Consistent with these data, a study aimed to identify TDP-43 target 
sequences revealed an enrichment of reads in the 3’UTR of TDP-43 itself [236]. 
Interestingly, the abundance of TDP-43 target sequences at the 3’UTR of other 
genes suggests that TDP-43 may similarly control post-transcriptional regulation of 
numerous other transcripts other than SC35 and its own.
Additional evidences of TDP-43 involvement in splicing regulation
Recently, a splice-junction microarray study from Polymenidou et all. has 
identified 965 altered splicing events, including 203 alternative splicing variations, 
upon TDP-43 depletion using antisense oligonucleotides in adult mouse brain [86]. 
Some of these identified targets have been validated using semi-quantitative RT- 
PCR and real time PCR highlighting alternative inclusion of 9 exons and 
alternative skipping of 7 exons. Among them, exon 18 of the receptor for
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progranulin Sortilinl was found alternatively included upon depletion of TDP-43 
[86].
Similarly, another study by Tollervey et all. identified 158 alternative splicing 
events and 71 constitutive splicing changes in human neuroblastoma cell lines 
depleted of TDP-43 [241]. In this case as well some targets have been validated 
with semi-quantitative RT-PCR and real time PCR. As a result, TDP-43 
knockdown was shown to modulate alternative exon inclusion in four cases: i) in 
ZNF92 exon 2 where a UG repeated sequence is located at the 3’SS of exon 2; ii) 
in REEP6 exon 5, which carries a UG-rich element in the intronic downstream 
sequence; iii) in CACNA1C exon 13 that carries a short UG elements in the 
downstream sequence as well; and iv) in PILRB exon 25 carrying UG repeats in 
the upstream sequence.
On the other hand, depletion of TDP-43 resulted in alternative exon skipping in 
CDK5RAP2 exon 39 and GPBP1L1 exon 4, both carrying UG repeats in the 
downstream region [241].
TDP-43 in microRNA biogenesis
In addition to TDP-43-mediated splicing regulation, a potential role for TDP- 
43 in microRNAs biogenesis has been proposed. This alternative nuclear function 
is supported by TDP-43 association with several components of the Drosha 
microRNA-processing complex such as ILF2/NF43, ILF3/NF90, DDX5, DDX17 
and DDX3X [247, 299], and by TDP-43 localization in nuclear regions linked with 
microRNA processing such as PFs and P-bodies [211]. Most interestingly, specific 
changes in the total microRNA population have been reported in TDP-43 depleted 
cell cultures [300]. Among the differentially expressed microRNAs, TDP-43 was 
shown to directly bind both let-7b microRNA sequence and let-7b hairpin 
precursor in correspondence of a UG-rich motif GGU(UG)3GUU. Downregulation
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of let-7b upon TDP-43 depletion resulted in the upregulation of four different let-7b 
microRNA targets (VAMP3, STX3, DYRK1A and LAMC1) [301]. Another 
microRNA, miR-663, was instead upregulated upon TDP-43 silencing, leading to 
the down regulation of its target EPHX1 (epoxide hydrolase 1, xenobiotic). In this 
case, TDP-43 was shown to bind the pri-miR-663 precursor sequence 
GUC(UG)2U, but not the microRNA sequence itself, which does not present UG 
motifs [300]. In correlation with the growing evidences of microRNAs implication in 
neurodegenerative diseases [302], the up-mentioned microRNAs targets (VAMP3, 
STX3, DYRK1A, LAMC1 and EPHX1) can all be somehow linked with different 
neuropathologies.
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Overview of TDP-43 cytoplasmatic role
Cellular functions of TDP-43 extend beyond its nuclear localization because 
TDP-43 can shuttle to the cytoplasm [206] through the importin-beta 
nucleocytoplasmic transporter [213]. An important but yet to be fully characterized 
TDP-43 cytoplasmatic function has been proposed specifically for neuronal cells. 
Within the cytoplasm of neuronal cells, in fact, TDP-43 was found to reversibly 
associate with several cytoplasmatic RNA granules, such as RNA transport 
granules (Staufen and FMRP positive) and RNA-processing bodies (XRN-1 
positive), pointing at TDP-43 as an active player in RNA transport and translation. 
Moreover, TDP-43 co-localization with stress granules (TIA-1 positive) places this 
protein as a potential participant in cellular response to stress [216, 303]. Finally, 
misregulation of TDP-43 cytoplasmatic functions may contribute to 
neurodegeneration in a still undetermined manner.
TDP-43 in RNA transport granules
Synthesis of specific proteins in spatially restricted areas and in response to 
temporally specific signals is achieved through a precise mRNA localization and 
mRNA translational control. This mechanism has been observed in both somatic 
and neuronal cells. In the latter, neuronal activity represents the specific signal 
capable of triggering the recruitment of translationally dormant mRNAs to the 
dendritic spines and their local translation. For example, dendritic localization of 
BDNF and Trk-B mRNAs increase after neuronal activity [304]. Likewise, synaptic 
stimulation was shown to deliver beta-actin and CaM-KII-alpha mRNAs in 
dendrites and promote in-site synthesis of the corresponding proteins [305-307]. 
These mRNAs are transported to the dendrites within large granules also called
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“localizing complexes”, which include RNA-binding proteins, ribosomal elements 
and translational factors [308]. Interestingly, localizing complexes also include 
microRNAs that inhibit local translation of their associated target mRNAs. In fact, 
in response to neuronal activity microRNA precursors are degraded, microRNA 
are no longer generated and the translational repression is defeated [309, 310]. 
The assembly of the localizing complexes on the mRNAs occurs co- 
transcriptionally and then undergoes dynamic remodeling at different stages [311]. 
The mRNAs targeted for dendrite localization carry a cis-acting dendritic 
localization sequences generally located in their 3’UTRs. Protein factors bind to 
these 3’UTR dendritic localization sequences and subsequently mediate the 
microtubule-based transport. Moreover, given that localizing mRNAs are 
translationally silent during their transport, the protein factors also act as 
translational repressors by targeting different regulators of the translation process 
(reviewed in [312, 313]). Among the multifunctional protein factors are ZBP1 and 
ZBP2 (zipcode-binding protein 1/2), Staufen, CPEB (cytoplasmic polyadenylation 
element-binding protein) and FMRP (fragile X mental-retardation protein).
TDP-43 co-localization with FMRP and Staufen proteins in neurons 
together with its RNA-binding activity and the presence of a strong nuclear export 
signal support a role for TDP-43 in this nuclear to cytosolic shuttling of mRNAs 
and ultimate regulation of their translation. In accordance with this theory, TDP-43 
granules were detected in dendrites of neuronal cells in culture and the number of 
granules increased after depolarization by KCI stimulation. Therefore, TDP-43 
actively translocates to the dendritic spines in response to neuronal activity in 
order to transport specific mRNAs [215]. Within the granules, TDP-43 was found 
to associate at least with two mRNAs: beta-actin and CaM-KII-alpha (calmodulin- 
dependent kinase ll-alpha) [215], whose mRNA levels were previously known to 
increase upon depolarization leading to local synthesis [314]. Furthermore, TDP-
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43 was shown to act as a local translation repressor in cultured neuronal 
dendrites, possibly through its reported interaction with elongating factors and 
ribosomal proteins [215].
Altogether these studies indicate that TDP-43 targets dendritic mRNAs and 
regulates their transport and local translation. At present, a well-characterized 
mRNA cargo carried by TDP-43 is the hNFL mRNA. Specifically found in neurons, 
hNFL (human neurofilaments light chain) are cytoskeletal proteins members of the 
intermediate filaments family. TDP-43 binds the hNFL mRNAs at their 3’UTR, 
likely in correspondence of single UG dinucleotides brought in proximity to each 
other by RNA secondary structure [216, 235] mediating its stability. Other two 
proteins involved in ALS pathogenesis, 14-3-3 protein and the mutated SOD1, 
were shown to co-regulate hNFL mRNAs stability together with TDP-43 [216]. 
Interestingly, NF aggregates were observed in ALS patients and their formation 
may be triggered by a misregulation of their transport by TDP-43.
Besides TDP-43, other members of hnRNP family like hnRNP K, E1 and E2 
bind hNFM (human neurofilaments medium chain) mRNAs through a CA-rich motif 
and mediate mRNA stability transport and ultimate translation [315, 316].
TDP-43 in P-bodies
Within the cytoplasm, TDP-43 was also found to co-localize with P-bodies. 
Therefore, it has been speculated that TDP-43 might transport mRNAs to P- 
bodies as well in order to inhibit their translation upon neuronal activation [215]. 
Degradative granules or P-bodies, in fact, are known to mediate mRNA 
degradation, RNA storage and micro-RNA mediated repression of translation
[317]. However, further studies are needed to fully elucidate this functional aspect 
of TDP-43.
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TDP-43 in stress granules
Stress granules (SGs) are cytoplasmatic dense aggregation of proteins and 
RNAs that appear upon stress signals in order to protect the untranslated mRNAs 
from harmful conditions. The untranslated mRNAs molecules are stored in stalled 
translation pre-initiation complexes and can either be degraded or re-initiate 
translation when SGs gradually dissolve after neuronal recovery (reviewed in
[318]).
TDP-43 was found to reversibly associate with SGs in response to oxidative 
insult [303], heat shock [217] and induced neuronal injury (axotomized motor 
neurons) [213, 214]. In disagreement with earlier studies [303], TDP-43 was 
recently found to co-regulate both assembly and maintenance of stress granules 
in response to oxidative stress [217]. In addition, TDP-43 can differentially regulate 
two SGs nucleating proteins, either at protein and mRNA levels. Specifically, TDP- 
43 upregulates TIA-1 and downregulates G3BP (Ras-GAP SH3 domain binding 
protein), two newly identified targets for TDP-43. However, the specific 
mechanism through which TDP-43 regulates their transcript and protein level has 
not been investigated so far. Interestingly, two ALS-linked mutant TDP-43 were 
found to alter stress granule dynamics. These loss-of-function mutations with 
regards to SGs formation (R361S and G348C) localize in the C-terminal domain of 
TDP-43 indicating a possible involvement of this region in SGs interaction [217, 
319]. Like TDP-43, other members of the hnRNP family such as hnRNP A1, A2 
and Q redistribute to the cytoplasm and localize with SGs under specific stress 
conditions [217, 320].
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Aim of the project
Splicing of both alternative and constitutive exons is co-regulated by the 
presence of short intronic or exonic sequences (c/s- elements) acting as splicing 
enhancers or silencers. Among them, the dinucleotide UG repeats located at the 
3’SS of an exon were found to inhibit splicing of the downstream exon through the 
recruitment of the frans-acting factor TDP-43. A present, this inhibitory effect has 
been validated in two splicing systems: the CFTR exon 9 alternative splicing and 
the APOAII exon 3 constitutive splicing [88, 173].
In addition, it has been observed that, when located in proximity of the 5’SS 
of an exon, the dinucleotide UG repeats can promote the alternative skipping of 
the downstream exons, leading to shorter mRNA products. This effect has been 
highlighted in two splicing systems: the SCL8A1 exon 2 and the CD36 exon 3 
[101,161]
Based on these previous observations, the aim of this project has been to 
investigate whether the UG repeats located at the 5’SS of an exon might influence 
the processing of the upstream exons. Using both artificial and natural systems, 
the impact on splicing of three different variables has been investigated: i) the 
length of the UG repeats; ii) the distance of the UG repeats form the 5’ end of the 
exon; iii) the strength of the 5’SS (in terms of consensus value) of the upstream 
exon; and iv) the presence of UG repeats-binding proteins.
Given its great affinity for the UG repeats elements, the involvement of the splicing 
factor TDP-43 in this regulatory process has also been studied.
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Materials and methods
Constructs preparation
Reporter minigenes used
In this study, the splicing pattern of several exons has been investigated by 
using two reporter minigenes/splicing-constructs (pY7, pTB) inserted in different 
plasmids backbones (pBMN, pBluescript and pcDNA3).
The splicing-construct pY7 contains the alpha-tropomyosin exons 2 and 3 
separated by a 111-nucleotides synthetic intron sequence with a 5’SS partially 
derived from the human beta-globin gene. The SP6 promoter controls the 
expression of this reporter minigene that is inserted into the pBMN vector 
backbone [321] (Figure 5a).
The splicing-construct pTB is composed by the alpha-globin exons 1, 2 and 
3, and fibronectin exon 3 under the control of the SV40 promoter within the 
pBluescript vector backbone [322] (Figure 5b).
In addition, in this work the pY7-based splicing-constructs were inserted 
into the pcDNA3 plasmid, which carries the CMV promoter (pY7-pcDNA3, i.e. 
Figure 6d, e, etc.). This insertion has been made because the SP6 promoter in the 
pY7-pBMN plasmid is not suitable for the in cell culture and the in vitro coupled 
transcription-splicing assays required for this study.
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a pY7 reporter minigene (pBMN backbone)
pY 7
SPl
alpha-tropomyosin 
exon 3 i
alpha-tropomyosin 
exon 2 Ndel
BamHI
b pTB reporter minigene (pBluescript backbone)
pTB
fibronectin 
exon 3-5’
fibronectin 
exon 3-3’
poiy(A)
signalSV40.
alpha-globin alpha-globin 
exon 1 exon 2 1
j alpha-globin 
i exon 3Ndel
BstEII BstEII
Figure 5: Schematic representation of the reporter minigenes used in this 
study, a) py7 reporter minigene; b) pTB reporter minigene. The exons defining the 
minigenes and the cloning restriction sites are indicated.
65
Constructs: TG6 at 8, TG6 at 18, TG12 at 8, TG12 at 18 in the pY7 reporter 
minigene
Four constructs with different number of TG repeats (TG6 and TG12) at two 
different distances (8 and 18 nucleotides) from the 5’SS were constructed by 
modifying the downstream region of the alpha-tropomyosin exons 2 in the pY7 
reporter minigene (Figure 6a, b). The DNA fragments containing the exon 2 
modified 5’SS were generated by PCR reaction using the pY7 minigene reporter 
as template. In example, for the TG6 at 8 nucleotides construct two distinct PCR 
have been performed, one using the oligos TG6 at 8-sense and pY7-Xbal- 
antisense and another one using the oligos pY7-Kpnl-sense and TG6 at 8- 
antisense. Corresponding oligos were used for the other constructs (oligos used 
for PCR reactions: TG6 at 8, TG6 at 18, TG12 at 8, TG12 at 18-sense and 
antisense and the external oligos pY7-Kpnl-sense and pY7-Xbal-antisense; oligo 
sequences are reported in appendix in Table 4).
Afterwards, a mix of the two amplified fragments was used as template in 
another PCR reaction using the external oligos on the alpha-tropomyosin exon 2 
and 3 carrying the Kpnl and Xbal enzymes restriction sites respectively (oligos: 
pY7-Kpnl-sense and pY7-Xbal-antisense). Finally, the obtained DNA inserts and 
the pY7 reporter minigene were digested with the Kpnl and Xbal enzymes (New 
England Biolabs), gel extracted (EuroClone) and ligated with T4 DNA ligase (New 
England Biolabs) according to manufacturer’s instructions.
Constructs BRCA1 5’SS exon 12 wild type and mutant in the pY7 reporter 
minigene
Using the same cloning strategy described above, the 5’SS of alpha- 
tropomyosin exons 2 in the pY7 reporter minigene was substituted with the 5’SS of 
the BRCA1 exon 12 in the two constructs BRCA1 exon 12 wild type (WT) and
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mutant (MUT) (oligos: BRCA1 5’SS WT-sense and antisense; BRCA1 5’SS MUT- 
sense and antisense; Table 4) (Figure 6c). The mutation in the BRCA1 MUT 
construct is a pathogenic mutation found in breast cancer patients, known to alter 
the splicing outcome in the final BRCA1 mRNA in vivo.
Insertion of the pY7 reporter minigenes in the pcDNA3 vector
The six pY7-based splicing-constructs (four TG repeats constructs and two 
BRCA1 WT and MUT constructs) and the unmodified reporter minigene (TGO 
construct) as well, were inserted into the pcDNA3 plasmid, which carries the CMV 
promoter suitable for in vitro coupled transcription-splicing and in cell culture 
experiments. To do so, external oligos on the alpha-tropomyosin exon 2 and 3 
carrying the Kpnl and Xbal enzymes restriction sites respectively were used in 
PCR reactions using each of the seven different constructs as templates (oligos: 
pY7 Kpnl-sense and pY7 Xbal-antisense; Table 4). The DNA inserts generated 
were then cloned into the pcDNA3 plasmid using the Kpnl and Xbal restriction 
sites (Figure 6d, e, f, g).
Additional BRCA1 constructs: BRCA1 5’SS and BRCA1 exon 12
Both BRCA1 5’SS WT and MUT in the pY7 reporter minigene have been
also inserted in the pTB reporter minigene (Figure 6h). To do so, external oligos
on the alpha-tropomyosin exon 2 and 3 carrying the BstEII enzyme restriction site
were used in a PCR reaction using the constructs in figure 6g as templates (WT
and MUT) (oligos: pY7-BstEII-sense and pY7-BstEII-antisense; Table 4).
Afterwards, the DNA inserts generated were cloned into the pTB vector using the
BstEII restriction site.
Using the same cloning strategy, BRCA1 5’SS WT and MUT in the pY7
reporter minigene have been also inserted in the pTB reporter within an additional
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exon cassette (hERG exon 7) using the Bglll restriction site (oligos: pY7-Bglll- 
sense and pY7-Bglll-antisense; Table 4) (Figure 6i).
The BRCA1 constructs carrying the whole length exon 12 were generated 
by PCR amplification of the DNA fragment from genomic DNA (control-WT and 
patient-MUT). Subsequently, the fragments were cloned into both the pTB and 
pY7 reporter minigenes using external oligos carrying the Ndel restriction site 
(Figure 6j, k). The pY7-based BRCA1 exon 12 constructs were also inserted into 
the pcDNA3 vector using Kpnl and Xbal restriction sites (Figure 61).
Constructs: EPHX1, SGK2, NTRK1, RXRG, ETF1 and A TG ETF1 in the pTB 
reporter minigene
Each DNA fragment (containing exon of interest and flanking intronic 
sequences) was amplified from genomic DNA from HeLa cells using oligos 
carrying the Ndel enzyme restriction site at their extremities (Table 4) (EPHX1 
exon 5, SGK2 exon 7 and 8, NTRK1 exon 12, RXRG exon 7, ETF1 exon 7) and 
cloned into the pTB reporter minigene (Figure 6m, n, o, p, q).
The ATG ETF1 construct was generated through modification of the 
downstream sequence of ETF1 exon 7 construct. Using the ETF1 minigene as a 
template, a first set of PCR reactions was performed (oligos: ATG ETF1-sense + 
ETF1 exon 7-antisense and ATG ETF1-antisense + ETF1 exon 7-sense; Table 4). 
The DNA fragments were gel extracted and used as templates for a second PCR 
reaction (oligos: ETF1-sense + ETF1-antisense). The DNA insert obtained was 
then cloned into pTB vector using the Ndel restriction site (Figure 6r).
The generated constructs were sequenced using the CEQ 2000XL 
sequencer (Beckman). Afterwards large scale preparations of plasmidic DNAs 
ware performed using JetStar purification kit (Genomed) according to the 
manufacturer’s instructions.
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Figure 6a-g. Schematic representation of the constructs generated in this 
study. The red rectangles represent the TG repeat elements; the size of the 
rectangles is proportional to the length of the repeat. In figures 6a, b, e and f the 
two red rectangles separated by a T  are representative of the insertion of either 
TG6 or TG12 elements. In figures 6c and g the red rectangles represent the two 
natural GT6 and GT4 at the 5’SS of the BRCA1 exon12, WT and MUT.
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pTB + pY7 reporter minigenes (pBluescript backbone)
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Figure 6h-l. Schematic representation of the constructs generated in this 
study. The red rectangles represent the TG repeat elements; the size of the 
rectangles is proportional to the length of the repeat. In figures 6h-l the red 
rectangles represent the two natural GT6 and GT4 at the 5’SS of the BRCA1 
exon12, WT and MUT.
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pTB reporter minigene (pBluescript backbone)
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Figure 6m-r: Schematic representation of the constructs generated in this 
study. The red rectangles represent the TG repeat elements; the size of the 
rectangles is proportional to the length of the repeat.
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TDP-43 constructs
In cell culture experiments, four different recombinant TDP-43 were used: i) 
TDP-43 wild type (WT); ii) TDP-43 with domain RRM1 and RRM2 mutated, thus 
deprived of its RNA-binding activity (RRM1,2M); iii) TDP-43 lacking the entire C- 
terminal domain (AC); iv) TDP-43 lacking the hnRNP binding site and the Q/N rich 
region (A321-366) (Figure 7). All the TDP-43 constructs were previously 
engineered using the pGEX-3X vector as reported in references: [173, 198, 203, 
206].
TDP-43 constructs:
WT RRM1 RRM2 Glycine-rich domain C
414
RRM1-2MUT
147 149 I229 231 414
A321-366 N
321 366 414
1 260
□  NLS, nuclear localization signal
□  NES, nuclear export signal
□  RRM1 and 2, RNA-recognition motifs 1 and 2 mutated
□  hnRNP A/B binding domain (321-366)
Figure 7. Schematic representation of the TDP-43 constructs used in this 
study. Four recombinant siRNA-resistant and flag-tagged TDP-43 proteins are 
illustrated in this picture. The different domains of the protein are represented with 
different colors. In the RRM1,2 MUT TDP-43 are reported in red color the four 
mutated phenylalanines at the indicated amino acidic positions. In the A321-366 
construct the deletion of the 321-366 part is illustrated in a light green color and 
crossed with an “X”.
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In vitro traditional splicing assay
The pY7 reporter minigenes containing the inserted exons of interest were 
first linearized by digestion BamHI enzyme (Promega) and then phenol/chloroform 
extracted and EtOH precipitated. The resulting DNAs were then transcribed into 
pre-mRNAs using the SP6 RNA polymerase (Promega). The 40pl-volume reaction 
consisted of: 2pg of DNA, 1X transcription buffer (Promega/Stratagene), 7.5mM 
ATP, CTP and UTP, 1.5mM of GTP, 5mM m7G CAP analog and 1U of SP6 RNA 
polymerase (Promega). When producing hot RNAs, 1.5mM of UTP instead of 
7.5mM was used and 1pl alpha-32P-UTP (800 Ci/mmol) (Amersham) was added. 
Transcription was allowed at 37°C for 2 hours; then the samples were treated with 
1U of RNase-free DNasel (Roche) for 15 minutes. Thereafter, the SP6-transcribed 
pre-mRNAs were phenol/chloroform extracted, EtOH precipitated and 
resuspended in RNAse-free water.
Subsequently, splicing reactions were preformed at 30°C for 2 hours in 25 
pi reaction mixtures containing 3.2mM MgCfe, 500pM ATP, 20mM creatine 
phosphate, 2.7% w/v polyvinyl alcohol, 20mM HEPES pH=7.3, 15pl of standard 
HeLa nuclear extract (CilBiotech) and 2pg of SP6-transcribed pre-mRNA.
When necessary, 0.4 pg of GU6 or (GU)2A6(GU)2 RNA oligonucleotides 
(Sigma, Table 4) were pre-incubated at RT for 10 minutes prior addition to the 
splicing reaction.
The processed RNAs were then extracted from the reaction mix using acid 
phenol/chloroform and then EtOH precipitated.
Hot RNAs were directly re-suspended in RNA loading buffer, denatured at 
96°C for 3 min and separated in denaturing polyacrylamide-urea gels with proper 
concentrations. The gels were then dried and the RNA fragments visualized by 
phosphor imager (Molecular Dynamics) or detected by autoradiography.
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Cold RNAs were retro-transcribed and analyzed by RT-PCR as described 
later in the text (see “cDNA synthesis and analysis” at page 75).
In vitro coupled RNAP II transcription and splicing
The DNA fragments were PCR-amplified from the pY7-based minigenes 
inserted in pcDNA3 (oligos used for PCR reactions: CMV-sense and BGH- 
antisense; Table 4). Afterwards, the resulting DNA fragments were 
phenol/chloroform extracted and EtOH precipitated.
In vitro transcription-splicing reactions were performed as described in [261] 
at 30°C in 25pl reaction mixtures containing 0.5mM ATP, 3.2mM MgCI2, 20mM 
creatine phosphate, 1pl alpha-32P-UTP (800 Ci/mmol), 15pl standard bulk nuclear 
extract and 0.6pg of DNA. Alpha-amanitin (10ng/25pl reaction) was used to block 
transcription. At each time point, an aliquot of the reaction was removed from the 
coupled RNAPII transcription-splicing reaction, de-proteinized, phenol/chloroform 
extracted, EtOH precipitated and analyzed on a denaturing polyacrylamide-urea 
gels as mentioned above.
In vitro splicing assay in cell culture
The pTB and pY7-pcDNA3 reporter minigenes carrying the exons of interest 
were transfected in HeLa cells in a liposome-mediated manner. Specifically, a total 
of 3X105 HeLa cells were seeded in 35mm Petri dishes and grown in DMEM- 
GlutaMAX-l media (GIBCO) supplemented with 10% fetal bovine serum 
(EuroClone). After 24 hours, the 80% confluent plates were transfected with 1pg of 
plasmidic DNA using the effectene transfection reagent (Qiagen) according to the 
manufacturer’s protocols.
Finally, total RNAs were collected after 48 hours using the TRIzol reagent
(Invitrogen) according to manufacturer’s instructions, treated with 1U of RNase-
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free DNase I (Roche) at 37°C for 15 minutes, phenol/chioroform extracted and 
EtOH precipitated. The RNA quantity was detected using the Nanodrop 
spectrophotometer instrument (Thermo Scientific) and equal amounts were used 
for cDNAs synthesis (see “cDNA synthesis and analysis” later in the text).
When needed, depletion of TDP-43 was performed by RNA interference. In 
this case, 8X104 HeLa cells were seeded in 35mm Petri and grown for 24 hours. 
For each 35mm Petri dish, 1.2 nmol of siTDP-43 (Dharmacon) or of the controls 
(non-targeting siRNA and si-Luciferase; Dharmacon) were transfected using the 
oligofectamine reagent (Invitrogen) according to the manufacturer’s protocol in 
Opti-MEM GlutaMAX-l media (GIBCO). After 24 hours siRNAs transfections were 
repeated to ensure proper TDP-43 depletion, given the abundance of this protein 
in the cells. Six hours after the second siRNAs transfection cells were washed with 
PBS1X (137mM NaCI, 2.7mM KCI, 10mM Na2HP04, 1.8mM KH2P04, pH 7.4) 
and 1 pg of the plasmidic DNAs (minigenes) was transfected using the effectene 
transfection reagent as described above.
When the overexpression of recombinant TDP-43 was required, 1pg of the 
plasmidic DNAs carrying the different siRNA-resistant and flag-tagged TDP-43 
sequences (Figure 7) was simply added to the transfection mixture used for the 
minigene construct.
Cells were finally harvested after 48 hours and total RNA was extracted as 
mentioned above. When siRNA treatment and recombinant TDP-43 
overexpression were performed, total proteins were also extracted using the 
TRIzol reagent according to manufacturer’s instructions.
cDNA synthesis and analysis
Both the RNAs extracted from the cells and the RNAs from the in vitro
traditional splicing assay were retro-transcribed into cDNAs and subsequently
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PCR-amplified. The 12pl-volume reaction mixtures composed of 200ng of random 
primers (Pharmacia), 1mM dNTPs mix (Promega) and 2pg of RNA were 
denaturated at 94°C for 3 minutes and then chilled on ice. Afterwards specific 
solutions (Invitrogen) were added to the reaction mix: 10mM DTT, 1X first strand 
buffer (10mM Tris-HCI ph8.4, 50mM KCL, 2.5mM MgCI2), 2U of MML-V reverse 
transcriptase enzyme (moloney murine leukemia virus). The final mixture was then 
incubated at 37°C for 1 hour and 2pl of the retro-transcribed cDNAs were used as 
PCR template (oligos used for PCR reactions: pY7 exon 2-sense and pY7 exon 3- 
antisense for the pY7-based constructs; alpha 2,3-sense and bra-antisense for the 
pTB-based constructs; Table 4). All RNAs were tested for DNA contamination by 
retro-transcription PCR (RT-PCR) lacking the reverse transcriptase enzyme.
Finally the PCR products representing the splicing products were separated 
on 2% agarose gels and ethidium bromide-stained. Quantification of band 
intensities in the acquired pictures was performed using the lmageJ64 software 
(available at http://rsb.info.nih.gov/ij).
Western blots and antibodies
Upon quantification with Bradford assay, 30pg of proteins from each
sample were mixed with 10X protein loading buffer (20% w/v SDS, 1M DTT,
0.63M Tris-HCI pH 7, 0.2% w/v bromophenol blue, 20% v/v glycerol, 10mM EDTA
pH 7). Conventional gels SDS-PAGE were performed using the required
percentage of polyacrylamide (37,5:1 acrylamide:bis-acrylamide; ProtoGel
National Diagnostics), run at 40mA in 1X SDS-PAGE running buffer (50mM Tris,
0.38M glycine, 0.1% w/v SDS). SDS-PAGE gels were then blotted on standard
nitrocellulose membrane and incubated in blocking solution (PBS1X, 0.2% Tween,
2% milk) over night. Primary antibodies were incubated with the membrane in the
same buffer for 2 hours. Afterwards, the membrane was then washed three times
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in washing solution (PBS1X, 2%Tween), incubated with the proper HRP- 
secondary antibodies (anti-mouse/rabbit, Dako) for 1 hour, washed twice and 
stained with ECL reagent (Thermo Scientific). Finally, an autoradiography was 
taken on Kodak Biomax XAR films.
Endogenous TDP-43 was detected with anti-TDP43 polyclonal antibodies 
[178] (1:2000); recombinant TDP-43 with anti-FLAG M2 monoclonal antibody 
(1:2000) (Sigma F1804); and the loading control with anti-tubulin monoclonal 
antibody (1:5000) (Sigma T5168).
Spliceosomal assembly analysis
The SP6-transcribed pre-mRNAs were used in a traditional splicing reaction 
with the same conditions described above (see “In vitro traditional splicing assay” 
page 73). Prior addition to the reaction mix, nuclear extracts were incubated at RT 
for 10 minutes with the GU6 or (GU)2A6(GU)2 RNA oligonucleotides (Table 4). 
Aliquots were collected at 5 and 30 minutes time points and reaction was stopped 
by addition of 2.5pl of 5X spliceosome gel loading buffer (1X TBE, 30% v/v 
glycerol, 0.5g/l Heparin, 0.1% w/v bromophenol blue). The splicing complexes 
were separated through electrophoresis using a 4% polyacrylamide native gel run 
at 300V for 3 hours. Finally, gels were dried and visualized by phosphor imager 
(Molecular Dynamics).
In silico analysis and predictions
The bioinformatic analysis of the dinucleotide TG repeats located at the 
5’SSs was performed by downloading the “exon/intron boundaries sequences” file 
from the “alternative splicing database” (ASD) combined with the “alternate 
transcript database” (ATD), which contains alternatively transcribed/spliced exons 
in nine different organisms collected from literature (available at
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http://www.ebi.ac.uk/asd/) [323, 324]. Firstly, the TG repeats with a repeat unit 
number equal or greater than six were simply highlighted in the Microsoft Word 
downloaded file. Secondly, the exons carrying the TG repeats sequences at the 
5’SS were selected and identified one by one based on the reported accession 
code using the “nucleotide database” in the NCBI website (available at 
http://www.ncbi.nlm.nih.gov/nuccore).
The 5’SS consensus values (CVs) were calculated according to the “splice 
site prediction by neural network” website.
(available at http://www.fruitfly.org/seq_tools/splice.html).
The comparative genomic alignments for the ETF1 and RXRG exons 7 and 
the identification of the different alternative spliced transcripts for all the genes 
listed in Table 3 were detected using the “Ensembl” website.
(available at http://www.ensembl.org/Homo_sapiens/lnfo/lndex).
In silico analysis of the ESE and ISE sequences were performed using the 
“human splicing finder” website.
(available at http://www.umd.be/HSF/4DACTI0N/input_SSF).
Restriction reports indicating all the enzyme restriction sites present in a 
sequence were predicted using “the sequence manipulator site” website.
(available at http://www.bioinformatics.org/sms/).
CLIP analysis
The CLIP analysis (Cross Linking and ImmunoPrecipitation) is a procedure 
used for the identification of protein-binding sites on RNA, in the context of an 
intact cell. This methodology is often mentioned in the thesis introduction and 
discussion as an alternative approach pursued from other laboratories to provide 
genome-wide insight of the TDP-43 potential binding sites and RNA targets.
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Furthermore, in the process of selecting potential TDP-43 targets, we also used 
CLIP data from Prof. J. Ule’s laboratory (personal communication) that reported 
specific TDP-43 binding sites within the RNAs sequences of ETF1, EPHX1, 
NTRK1, RXRG and SGK2. Briefly, in a CLIP analysis cells are dissociated and 
UV-treated on ice leading to the formation of a covalent bond between protein and 
RNAs. After cell lyses and partial RNA digestion, the protein of interest is 
immunoprecipitated together with the bound RNA fragments. Prior to SDS-PAGE 
and transfer to nitrocellulose membrane, RNAs are ligated to the 3' end with an 
RNA linker and radioactively labeled at the 5’ end. Afterwards, the membrane is 
exposed to X-ray film, and the region of the membrane corresponding to protein- 
RNA complexes is excised, proteins are digested and a 5' end RNA linker is 
ligated to RNAs. The CLIP tags are then amplified by RT-PCR, using DNA 
primers with sequence complimentary to the RNA linkers, and finally 
sequenced.
Statistical Analysis
A statistical analysis was performed on the investigated groups of data using 
the Student's t-test (also known as two-sample t-test), the most common statistical 
data analysis procedure for hypothesis testing. Specifically, the tested hypothesis 
was the “null hypothesis” (the hypothesis of “no difference” between two measured 
phenomena/groups of data) versus and the “alternative hypothesis” (the 
hypothesis of significant difference between two measured phenomena). For 
example, in this work for each minigene the alternative hypothesis tested has 
been whether there was a significant (not due to chance) difference in exon 
inclusion between groups A and B if group A was treated with a no-target siRNA 
and group B with a TDP-43 siRNA, or alternatively if group A was treated with a
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wild type recombinant TDP-43 and group B with a mutated form of TDP-43.
The p value (probability value) represents the estimated probability of 
rejecting the null hypothesis and accepting alternative hypothesis. Therefore, if the 
p value is lower than the chosen significance level, the null hypothesis is rejected 
and the analyzed data are considered “statistically significant”. Although the 
choice of significance level is arbitrary, in this case the conventional 5%, 1% and 
0.1% levels were used (p<0.05 *; p<0.01 **; p<0.001 ***).
In order to perform this test, all the experiments were repeated at least 
three times since the Student's t-test investigates the null hypothesis of no 
difference between the means of two normally distributed groups of data.
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Results
Influence of UG repeat length and distance from the 5’SS 
on exon processing
UG repeats lengths
In order to investigate whether the length of a UG element located near the 
5’SS of an exon can affect the exon processing, four constructs with different UG 
repeat lengths were engineered using the pY7 reporter minigene (Figure 8a). This 
minigene [321] has been previously used in Baralle’s laboratory to prove that UG 
repeats at the 3’SS inhibit processing of the downstream exon. Furthermore, in 
this case the inhibition was proved to be TDP-43-mediated and to correlate with 
the UG repeat length [277]
For this study, the downstream region of the pY7 alpha-tropomyosin exon 2 
was modified by adding either TG6 or TG12 repeats at 18 nucleotides from the 5’ 
end of the exon (Figure 8a). This distance from the 5’SS was chosen because 
close enough to the 5’SS to affect the splicing outcome, but also far enough to not 
directly interfere with UlsnRNP recruitment. The unmodified minigene, reported 
here as TGO, does not carry TG repeats at the 5’SS and represented the negative 
control for these experiments. The TGO, TG6 and TG12 at 18 nucleotides 
constructs were then used for in vitro traditional splicing assay. The RNA was 
transcribed using the SP6 enzyme and then allowed to splice for 60 and 120 
minutes using commercial nuclear extract. The splicing intermediates and 
products (pre-mRNAs and mRNAs) were retro-transcribed, PCR amplified and 
separated in 2% agarose gels.
As shown in Figure 8B, no significant differences in splicing efficiency were
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detected at 60 or 120 minutes between the TGO control and the two constructs 
carrying 6 or 12 TG repeats at 18 nucleotides from the 5’ end of the exon (Figure 
8B). Earlier time points of 30-60 and 45-90 minutes were also tested but reported 
no differences in splicing patterns (data not shown).
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Figure 8. Insertion of TG6 and 12 at 18 nucleotides from the 5’ end of exon 
2 does not affect exon 2 processing, a) Schematic representation of the 
minigenes used, b) Splicing assay of pY7 constructs carrying TG repeats at 18 
nucleotides from the 5’ end of the exon 2 and the TGO control. For each 
construct (TGO, TG6 and TG12), is reported the splicing pattern, the 
quantification of the bands and the sequences showing the authentic location of 
the TG elements (N=3).
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UG repeats distance from the 5’SS
Based on the extremely similar splicing pattern observed in the two 
constructs carrying 6 and 12 TG repeats it was hypothesized that the UG repeats 
might influence splicing in correlation with their proximity to the 5’SS. Therefore 
using the same procedure, the TG6 and TG12 repeats were inserted at 8 
nucleotides from the 5’SS (Figure 9a) and the resulting constructs were again 
used for in vitro splicing assay (Figure 9b). A distance of +8 nucleotides does not 
perturb the 5’SS consensus sequence (from -3 to +6), but given the great 
proximity to the 5’SS can potentially interfere by sterical hindrance with UlsnRNP 
recruitment. However, the splicing pattern observed with these constructs 
resembled the one observed with the constructs carrying TG repeats at greater 
distance form the 5’SS.
Similarly, no significant differences were detected between the constructs carrying 
different TG repeats length at different distances from the 5’SS using radio-labeled 
RNA as well (data not shown).
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Figure 9. Insertion of TG6 and 12 at 8 nucleotides from the 5’ end of exon 2 
does not affect exon 2 processing, a) Schematic representation of the 
minigenes used, b) Splicing assay of pY7 constructs carrying TG repeats at 8 
nucleotides from the 5’ end of the exon 2 and the TGO control. For each 
construct (TGO, TG6 and TG12), is reported the splicing pattern, the 
quantification of the bands and the sequences showing the authentic location of 
the TG elements (N=3).
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RNAPII coupled transcription-splicing assay with TGO, TG6 and TG12 at 8 
and 18 nucleotides form the 5’SS
In order to test whether differences in splicing regulation might be visible in 
conditions that closely resemble the splicing dynamics in the cells, the RNAPII 
coupled transcription-splicing system was used [261]. In the coupled system the 
DNA (not pre-transcribed RNA) is added to nuclear extract in optimized splicing 
conditions and in presence of alpha-32P-UTP. The DNA is then transcribed by the 
RNAPII, which is endogenously present in the nuclear extract, and spliced into 
mRNA. In this co-transcriptional splicing system the nascent RNA synthesized by 
RNAPII is more efficiently spliced with respect to the one transcribed by phage 
RNA polymerases. The enhanced efficiency is likely due to the fact that the 
nascent RNA is immediately and quantitatively directed into the spliceosome 
assembly pathway instead of being assembled into non-specific hnRNP 
complexes, which are inhibitory for spliceosome assembly [261].
To perform these coupled transcription-splicing assay the four pY7-based 
constructs with TG repeats and the TGO control described in Figures 8a and 9a 
were inserted into the pcDNA3 vector because the presence of a strong promoter 
such as CMV is required for this method (Figure 10a).
Subsequently, equal amounts of the PCR-amplified CMV-pY7 fragments 
were incubated with nuclear extract for 15 minutes to generate nascent pre- 
mRNA, followed by addition of alpha-amanitin to block further transcription and to 
let splicing occur. Different time points were collected in order to track the splicing 
process (25-35 and 30-45 minutes). After 30 minutes the spliced mRNA was 
detected and by 45 minutes splicing was nearly complete. However, there were no 
detectable differences in the splicing pattern between the TGO control and the four 
constructs carrying TG repeats (Figure 10b).
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of exon 2 does not affect exon 2 processing, a) Schematic representation of 
the minigenes used, b) RNAPII coupled transcription-splicing assay of pY7 
constructs carrying TG repeats at 18 and at 8 nucleotides from the 5’ end of the 
exon and the TGO control (N=2).
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Therefore, the presented in vitro results suggest that the simple insertion of 
UG repeats at the 5’SS of the alpha-tropomyosin exon 2, which carries a very 
strong/splicing optimized 5’SS, has no significant effect on the splicing outcome of 
the upstream exon.
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Correlation between UG repeats effect and 5’ss strength
UG repeats and 5’SS strength: selection of the BRCA1 exon 12 splicing 
system
The pY7 reporter minigene used for the in vitro experiments represented an 
optimized artificial system carrying an extremely well defined 5’SS consensus 
sequence. In fact, bioinformatic prediction of the intrinsic strength of its 5’SS 
reported an optimal consensus value (CV=1=100%). Therefore, this well defined 
5’SS might not require the presence of additional cis-acting elements such as the 
UG repeats to be efficiently recognized by the splicing machinery.
Based on this observation, a natural substrate was used in order to check 
whether, in a more natural context, the presence of UG repeats in proximity of a 
5’SS consensus sequence can influence the splicing outcome. The first system to 
be studied has been the BRCA1 exon 12, which carries two GT repeat elements in 
its downstream region: a GT6 at 9 nucleotides from the 5’SS followed by a GT4 at 
22 nucleotides. In normal conditions exon 12 is constitutively included in the 
BRCA1 mRNA. Interestingly, in the BRCA1 system a natural and documented 
mutation was found to weaken the strength of the exon 12 5’SS in terms of 
consensus value.
Generally, mutations in BRCA1 gene correlate with a strong increase of 
breast and ovarian cancer risk. The majority of the mutations described in 
literature are non-sense and frame-shift mutations whereas only 4% of the 
identified genomic variations are splice site variants. Among these variants, the 
BRCA1 G->A mutation at position -1 of exon 12 (-1G>A; c.4304G>A BIC 
nomenclature; or c.4185G>A systematic nomenclature) identified by Gayther in 
1999 was chosen [325]. The G nucleotide at position 4304, the last nucleotide of
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exon 12, is conserved in 86% of splice sites in mammals. Previous published data 
had reported that the abolishment of this highly conserved 5’SS consensus 
sequence in patient’s lymphoblasts leads to the partial skipping of the upstream 
exon where the mutation is located [326]. This -1G>A mutation has been detected 
in Czechs, German and American populations and is currently considered a 
pathogenic mutation, predisposing carriers to breast and ovarian cancer [327, 
328]. In these patients, the expected (but yet to be proven) effect of the mutation 
at the protein level is the production of a shorter product, due to the introduction of 
a stop codon at position 1373 (p.Ser1363fsX10) [327].
BRCA1 exon 12 in vitro traditional splicing assay
For this study, both wild type (WT) and -1G>A mutated (MUT) BRCA1 exon 
12 5’SS were used to produce constructs suitable for in vitro splicing assay. The 
pY7 exon 2 5’SS consensus sequence, which consist of 9 partially conserved 
nucleotides at the exon/intron boundary, was substituted with the one of the 
BRCA1 exon 12. To better mimic the natural BRCA1 context, some additional 
exonic and intronic regions were also changed for a total of 69 nucleotides (18 
exonic nucleotides, 51 intronic nucleotides) (Figure 11).
The TGO negative control, the WT and MUT BRCA1 5’SS constructs were 
then tested using in vitro splicing assays as previously described. Nearly identical 
splicing efficiency was observed for the BRCA1 WT construct and the TGO control, 
which carries the splicing-optimized 5’SS consensus sequence (CV=1=100%) and 
no TG repeat elements (Figure 12a). Consistent with this observation, the 
bioinformatic prediction of the BRCA1 WT consensus sequence revealed a sub- 
optimal strength (CV=0.95=95%). As shown in Figure 12a, the pre-mRNA was 
more than 80% processed after 60 minutes and almost completely processed after 
120 minutes, both in the TGO control and in the BRCA1 WT construct. Therefore,
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the presence of the TG repeats in the BRCA1 WT construct did not affect the 
splicing efficiency, in respect to the TGO control (Figure 12a). This result suggest 
that the BRCA1 WT 5’SS consensus sequence is naturally very well defined and 
ensures the constitutive inclusion of exon 12 in normal conditions.
On the other hand, in the BRCA1 MUT construct the pre-mRNA was 
processed in a slower manner compared to the BRCA1 WT and the TGO control 
constructs. In the BRCA1 WT after 60 minutes 84% of the pre-mRNA was 
processed, whereas only 57% of it was processed in the BRCA1 MUT and this 
difference was statistically significant (p=0.0151). Similarly, after 120 minutes 96% 
of the pre-mRNA was processed in the BRCA1 WT and 78% in the BRCA1 MUT 
constructs (p=0.0147) (Figure 12a). Additionally, earlier time points during splicing 
(20, 30 and 40 minutes) were checked and differences in splicing efficiency could 
be detected already at 20 minutes (Figure 12b). Therefore, these observations 
indicate that the -1G>A mutation weakened the 5’SS strength (predicted 
CV=0.38=38%) causing a delay in intron processing.
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Figure 11. BRCA1 5’SS minigene constructs (WT and MUT). The sequence 
of the BRCA1 5’SS inserted into the pY7 reporter minigene is illustrated. The 
mutation G>A in position -1 and the TG repeat elements is also indicated. The 
GT repeats can be easily spotted within the sequence.
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Figure 12. The mutation -1G>A weakens the BRCA1 5’SS and affects exon 
processing, a) Splicing assay of the two BRCA1 constructs (WT and MUT) and 
the pY7 control. Changing the optimized pY7 exon 2 5’SS consensus sequence 
with the BRCA1 WT once did not affect the correct processing of the exon. The 
insertion of the BRCA1 MUT weak 5’SS instead results in exon processing 
inhibition (N=3). b) Differences among the two constructs WT and MUT are also 
visible at earlier time points (N=1). The asterisks indicate statistical significance 
(p<0.05 *).
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BRCA1 exon 12 in vitro coupled RNAPII transcription-splicing assay
In order to perform in vitro coupled transcription-splicing assay the pY7- 
based systems were inserted in the pcDNA3 vector (Figure 13a) and subsequently 
assessed for splicing as previously summarized (Figure 13b). After 15 minutes, 
both BRCA1 WT and MUT DNAs were equally transcribed by RNAPII into pre- 
mRNAs suggesting that the mutation does not affect proper transcription. 
Subsequently, splicing was allowed for 30 and 45 minutes. In the BRCA1 WT 
construct, splicing of the intron occurred efficiently and the pre-mRNA was almost 
completely spliced into mRNA after 45 minutes (Figure 13b). In the BRCA1 MUT 
construct splicing also occurred but in a slower manner further indicating that the 
presence of the mutation causes a delay in intron processing by affecting the 
splicing machinery (Figure 13b).
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Figure 13. BRCA1 5’SS MUT presents delay in exon processing, a) Splicing 
representation of the minigenes used, b) Coupled splicing-transcription assay of 
the two BRCA1 constructs. Again a delay in exon processing is observed in the 
BRCA1 MUT construct with respect to the WT one (N=3).
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Full length BRCA1 exon 12 in vitro splicing assay and in vitro coupled 
transcription-splicing assay
As previously mentioned, in patients carrying the -1G>A mutation partial 
skipping of the exon 12 was observed [326]. Based on this evidence, it was 
hypothesized that the delay in intron processing observed in the BRCA1 MUT 
constructs could be representative of the in vivo exon 12 skipping situation. To 
confirm this hypothesis, two pY7 constructs carrying the full length BRCA1 exon 
12 (WT and MUT) were engineered in a three exons-two introns system (Figure 
14a). Subsequently, these constructs were used for both traditional in vitro splicing 
and coupled transcription-splicing assays.
In the traditional in vitro splicing assay, by 60 minutes exon 12 was mostly 
included into the resulting mRNA in the BRCA1 WT construct, as expected. Also a 
certain amount of exon skipping was observed. On the other hand, exon 12 was 
completely skipped in the BRCA1 MUT construct (Figure 14b).
In the in vitro coupled transcription-splicing assay, both DNAs were equally 
transcribed into pre-mRNAs. In the BRCA1 WT construct both exon 12 inclusion 
and skipping were detected, whereas in the BRCA1 MUT construct exon 12 was 
completely skipped (Figure 14c).
Both in vitro approaches therefore indicate that the delay in intron processing 
previously observed in the two exons-one intron systems can be traduced into 
exon 12 skipping when using the whole BRCA1 exon 12 sequence in a three 
exons-two intron system. Moreover, this splicing pattern successfully mimics the 
aberrant splicing observed in vivo in patients carrying the -1G>A mutation.
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Figure 14. The mutation -1G>A leads to exon 12 skipping in constructs 
carrying the full length exon 12. a) Schematic representation of the minigene 
used (three exons-two introns). b) Splicing assay reveals exon 12 skipping in 
presence of the mutation (BRCA1 exon 12 MUT). A mild skipping is also 
observed in this case with the WT construct (N=2). c) Coupled transcription- 
splicing assay also reports complete exon 12 skipping in the MUT construct. 
Additional splicing intermediates are also visible on the gel (N=4).
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The results obtained with the BRCA1 exon 12 constructs confirm that the 
presence of the -1G>A mutation at the 5’SS of an exon is the direct cause of 
aberrant splicing. Moreover; consistent with the previous reported data on TG6 
and TG12 repeats at 8/19 nucleotides, the similar splicing pattern observed for the 
TGO control and the BTCA1 WT construct carrying the UG repeats at the 5’SS, 
indicate that UG repeats located downstream of an extremely well defined 5’SS 
are likely not required for splicing regulation.
Nonetheless, the BRCA1 minigene constructs successfully mimicking the in 
vivo situation represent a suitable system for further studies on the effects of the 
UG repeats and of the UG repeats-binding proteins on splicing regulation, in 
correlation with the 5’SS consensus strength.
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Effect of UG repeats-binding proteins on BRCA1 exon 12
processing
UG repeats-binding proteins affect splicing of BRCA1 exon 12
Once confirmed that both systems (with the full length exon 12 and with the 
5’SS consensus sequence of exon 12, Figures 12, 13 and 14) were accurately 
representing the in vivo context, I investigated the effect of trans-acting factors 
binding to the auxiliary UG repeat elements on 5’SS definition.
For further in vitro studies, the two exons-one intron pY7 system carrying the 
BRCA1 5’SS consensus sequence was selected since the shorter length of the 
constructs better suits the in vitro experiments with nuclear extract.
The previously presented results indicate that the introduction of UG repeats 
in proximity of a strong and well defined 5’SS consensus sequence does not 
significantly affect splicing (see the artificial systems TG6 and TG12 versus the 
TGO control and the BRCA1 WT versus the TGO control, Figures 8-13). On the 
other hand, the -1G>A mutation was shown to be responsible for the aberrant 
splicing outcome observed in the BRCA1 MUT construct. Therefore, it was next 
investigated whether the presence of UG repeats at the 5’SS of exon might 
influence the splicing outcome in correlation with the 5’SS strength. In particular 
the UG repeats were considered as a binding site for trans-acting proteins.
To test whether trans-acting factors binding the UG repeats play a role in the 
pre-mRNA processing events in correlation with the 5’SS strength, the nuclear 
extract used for splicing assay was pre-incubated with GU6 RNA oligonucleotides. 
The rationale of this competition assay is that the UG repeats-binding proteins 
present in the nuclear extract would bind to the GU6 oligonucleotides and 
therefore become partially unavailable for binding to the UG sequences in the
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BRCA1-pY7 splicing constructs. A GU2A6GU2 oligonucleotide was used as a 
negative control.
After pre-incubation the nuclear extract was used in a traditional in vitro 
splicing assay. When compared to the results obtained with the GU2A6GU2 
control oligo, the splicing pattern of the BRCA1 WT construct was affected by the 
presence of the oligonucleotides GU6 in the nuclear extract (Figure 15a). In fact, 
by 30 minutes 31% of the pre-mRNA was processed in the control sample but only 
14% of it was processed in presence of GU6 oligonucleotides (p=0.04). Similarly, 
the processing of the intron decreased from 78% to 57% after 50 minutes (Figure 
15a). This observation indicate that in this particular context the removal of UG 
repeats-binding proteins can exert an inhibitory effect on exon processing, even in 
presence of a strong 5’SS. Therefore, the presence of UG repeats at the 5’SS 
may favour the exon processing through the recruitment of trans-actmg factors.
Most strikingly, the removal of UG repeats-binding proteins strongly 
affected splicing in presence of the weak consensus sequence of the BRCA1 MUT 
construct. In this system, a marked reduction of the pre-mRNA processing rate 
was observed. In particular, compared to the results obtained with the control 
oligo, pre-mRNA processing dropped from 7% to 0.2% in presence of the GU6 
oligonucleotides (p=0.0029) after 30 minutes and from 44% to 9% after 50 minutes 
(p=0.0028) (Figure 15b). These observations highlight the importance in 5’SS 
definition of the UG repeats acting as trans-acting factors recruiters in presence of 
a weak consensus sequences. In fact, when the 5’SS is poorly defined or 
weakened by a mutation, auxiliary elements such as the UG repeats can become 
important elements for the upstream exon 5’SS definition.
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UG repeats-binding proteins affect spliceosomal assembly
Based on the observation that the UG repeats can help the splicing 
machinery through the recruitment of UG repeats-binding proteins, I next analyzed 
the spliceosome assembly on both BRCA1 WT and MUT constructs, both in 
absence and in presence of UG repeats-binding proteins (Figure 16).
Spliceosomal constituents are recruited stepwise to the pre-mRNA 
substrate and remodeled multiple times in order to properly insure the final 
production of the spliced mRNA [329, 330]. Briefly, when the pre-mRNA is initially 
added to HeLa cells nuclear extract the H complex assembles on ice or at 30°C 
[331]. This H complex consists almost exclusively of hnRNP proteins and is 
considered an unspecific non-functional intermediate in the spliceosome assembly 
pathway. The earliest detectable functional intermediate in spliceosome assembly 
is the E complex, where the 5’ and 3’SSs are recognized by U1 snRNP and the 
heterodimeric complex U2AF35/65 respectively, thus committing the pre-mRNA to 
the splicing pathway. Mutations of either the 5’ or the 3’SSs are reported not to 
abolish E complex assembly [332, 333].
The E complex is rapidly converted to the A complex, characterized by the ATP-
dependent recruitment of U2 snRNP to the branch point sequence. Subsequent to
A complex formation, the U4/U6 and U5 snRNPs are recruited as a preassembled
complex U4/U6.U5 tri-snRNP forming the B complex. A distinct role for the 5’SS in
the B complex formation was highlighted in early studies where mutations of the
5’SSs resulted in accumulation of the A complex and slower formation of the B
complex [334, 335]. Afterward, the spliceosome undergoes catalytic activation
through major conformational and compositional rearrangements [336, 337]. The
activated B complex (reported as B* complex) promotes the first catalytic step of
splicing and finally the C complex leads to the formation of spliced mRNA in an
ATP-mediated manner. The spliceosome complex then dissociates and the
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different components are recycled for additional rounds of splicing.
In order to perform a spliceosome assembly assay, the BRCA1 WT and 
MUT constructs were firstly transcribed with SP6 polymerase in presence of 
UTP32. Secondly, a splicing reaction was carried out using bulk nuclear extract 
pre-incubated with either GU6 oligonucleotides or control GU2A6GU2 
oligonucleotides. Three time points (0, 5 and 30 minutes) of each reaction were 
analyzed on a native gel in order to detect the complexes (Figure 16). In the 
BRCA1 WT construct, at 0 minutes the H complex was equally detected in the 
control and in the GU6 oligonucleotides-treated samples. After 5 minutes of 
incubation, complex A was equally detected as well. At 30 minutes the B complex 
was slightly visible both in the control and in the GU6 oligonucleotides-treated 
samples. The A complex was still vaguely present after 30 minutes in presence of 
GU6 oligonucleotides but it was not longer visible in the control.
In the BRCA1 MUT construct the H complex at 0 minutes and the A complex at 5 
minutes were equally assembled. Most interestingly, at 30 minutes in the control 
sample the A complex was converted in B complex and only loosely detectable, 
but in presence of the GU6 oligonucleotides a marked accumulation of the A 
complex was observed (Figure 16). Interestingly, no significant difference were 
observed between the BRCA1 WT and MUT constructs in the negative control 
samples, indicating that the lone presence of the mutation did not affect the initial 
spliceosome assembly.
Significantly, the observation that the A complex strongly accumulates in 
presence of GU6 oligonucleotides, but not in presence of the control, only in the 
BRCA1 MUT construct carrying the weak 5’SS suggests that UG repeats-binding 
proteins may favour the transition between the A complex and late complexes.
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The effect of UG repeats-binding proteins removal on both splicing and 
spliceosome assembly strongly suggests a role for the UG repeats-binding 
proteins in enhancing the processing of the upstream exon. In addition, the effect 
of the UG repeat-binding protein was solidly related to the 5’SS strength indicating 
that auxiliary elements such as the UG repeats help 5’SS definition in poorly 
defined exons.
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Effect of TDP-43 levels on BRCA1 exon 12 splicing regulation
Selection of the most suitable BRCA1 splicing system
As reported in the introduction, proteins binding to the UG/TG repeats 
identified so far include TDP-43, CELF1, CELF2, PTB, SRp55 and FUBP3. All 
these proteins have various effects (i.e. act as splicing silencer or enhancers) and 
might compete with each other for their preferential biding site to ultimately affect 
the splicing outcome. Among these UG repeats-binding proteins this study 
focused on TDP-43, to better define its potential involvement in 5’SS definition and 
splicing regulation.
The previously reported in vitro results using competitor GU6 RNA 
oligonucleotides presented the limitation of potentially affecting all the variety of 
UG/TG repeats-binding proteins present in the extract and not only TDP-43. 
Therefore, in order to selectively observe TDP-43 effects on splicing regulation of 
the BRCA1 constructs, in vitro experiments in siRNA treated cell cultures were 
performed. In Baralle’s laboratory a common procedure based on transfection of 
pTB-based minigenes in HeLa cells upon TDP-43 depletion/overexpression has 
been successfully used over the years to study TDP-43-mediated splicing 
regulation in different systems of interest [88, 203, 272]. Therefore, this same 
procedure was applied to the study of TDP-43 involvement in BRCA1 exon 12 
processing.
As for the in vitro with nuclear extract systems, it was first established the 
most suitable system capable of mimicking the in vivo context to use for 
experiments in cell cultures. To do so, different splicing systems for the BRCA1 
exon 12, based on pY7, pcDNA3 and pTB vectors were tested. Subsequently, all 
the constructs were transiently transfected in HeLa cells. After 24 hours, total RNA
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was harvested, retro-transcribed and PCR-amplified; finally the splicing products 
were separated on 2% agarose gels. In some cases, TDP-43 was silenced 
through RNA interfering technique previous construct transfection in order to 
detect the potential TDP-43 involvement in exon processing. A control-siRNA was 
always used as a negative control.
The BRCA1 WT and MUT pY7-based splicing systems inserted in the 
pcDNA3 vector under the control of the CMV promoter (constructs formerly used 
for coupled transcription-splicing system) were transfected in HeLa cells in 
presence of the control siRNA (siLuciferase) or the siTDP-43 (Figure 17a). In this 
splicing system both BRCA1 WT and MUT constructs were efficiently processed in 
control siLuciferase-treated cells. Also in this particular context, the mutation in the 
BRCA MUT construct did not seem to affect the splicing outcome as previously 
observed in control condition. In the TDP-43-silenced cells a reduced amount of 
PCR product was observed for the BRCA1 MUT construct. Since the performed 
RT-PCR does not represent a quantitative technique, real time PCR experiments 
were also performed but did not report significant differences among the different 
samples.
No differences in the splicing pattern of the BRCA1 WT and MUT were 
observed by inserting the two pY7-based splicing systems into the pTB vector 
(Figure 17b) and also by inserting it into an exonic cassette within the pTB vector 
(Figure 17c).
These results indicated that the pY7-based splicing-optimized systems
might not be suitable for cell culture experiments. In fact, no cases of pY7-based
systems have ever been reported in literature as a successful tool in cell cultures
experiments. Nevertheless, the use of different vectors has already been reported
to affect the splicing outcome of the studied systems, and also to produce
conflicting results (i.e. [182] and [183]). In fact, the structure of different minigene
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systems might affect in unpredictable ways the splicing outcome. These 
observations highlight the importance of evaluating the splicing outcome of the 
system of interest in more than one reporter minigene in order to select the one 
that better mimics the in vivo context.
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Figure 17. Splicing analysis of BRCA1 5’SS WT and MUT in different 
reporter minigene systems, a) A schematic representation of the pY7 
minigenes inserted into the pcDNA3 vector, the splicing pattern and the western 
blots detecting TDP-43 silencing, b) A schematic representation of the BRCA1 
5’SS WT and MUT inserted into the pTB vector and the reported splicing patter 
in HeLa cells, c) A schematic representation of the BRCA1 5’SS WT and MUT 
inserted into an exonic cassette within the pTB vector and the splicing assay. 
The tested constructs do not represent a suitable tool for further studies (N=1).
109
Therefore in further studies, the two exons-one intron pY7 system was 
abandoned in favour of an extended genomic context of the BRCA1 exon 12 in a 
three exons-two intron system. These BRCA1 exon 12 cassettes (WT and MUT) 
with the flanking alpha-tropomyosin exon 2 and 3 were inserted in the pcDNA3 
(pY7-based construct used for the coupled transcription-splicing system as well). 
Additionally, the same BRCA1 cassettes were inserted in the pTB vectors, which 
carries the alpha-globin/fibronectin flanking exons (Figure 18a, 18b).
In the pcDNA3 context the BRCA1 exon 12 WT was, as expected, equally 
processed both in the control and in the siTDP-43 treated samples, thus further 
confirming the previous results. The BRCA1 exon 12 MUT was not recognized by 
the spliceosomal complex and therefore skipped in the final mRNA both in the 
control and in the TDP-43 silenced experimental contexts. These observations 
indicate that the mutation itself directly causes exon 12 skipping and additionally 
that the silencing of TDP-43 does not enhance or inhibit exon 12 recognition in this 
context (Figure 18a).
In the pTB context the BRCA1 exon 12 WT was again properly recognized 
and correctly processed. On the other hand, the BRCA1 MUT presented both 
regular exon 12 inclusion (57%) and exon 12 skipping (Figure 18b), consistent 
with previous observations (De Conti, personal communication). Additionally, a 
cryptic 5’SS located 58 nucleotides downstream to the authentic one in intron 12- 
13 was also recognized (CV=0.27=27%). This cryptic 5’SS corresponds to 
nucleotide 37848 (GenBank accession number L78833).
Silencing of TDP-43 did not affect the BRCA1 WT construct but resulted in the 
complete abolishment of exon 12 recognition, leading to exon 12 skipping in the 
BRCA1 MUT construct (Figure 18b).
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Among the ten minigene systems tested in cell cultures (Figures 17a-c, 
18a-b), the splicing pattern obtained with the full length exon 12 inserted in the 
pTB vector was the one better mimicking the in vivo pattern detected in patients 
(Figure 18b). In fact, in patient’s lymphoblasts both exon 12 inclusion and skipping 
were observed [326]. Based on the great similarity with the in vivo condition the 
pTB-based splicing system was selected for further studies.
Noteworthy, Claes et all. detected an in-frame insertion of 66 bp from intron 
13-14 both in the control and in the patient (Figure 18c). This DNA cassette, 
previously referred to as pseudoexon 13a [338, 339], corresponds to nucleotides 
49332-49397 (GenBank accession number L78833) and does not correspond to 
the cryptic splice donor site observed in Figure 18b in the BRCA1 MUT lanes. 
Analysis of the literature did not reveal any reported cases of 37848 cryptic 
recognition in vivo. Based on the null biological relevance of this cryptic site and 
on the fact that its recognition did not occur in any of the other minigenes tested in 
cells culture nor in vitro, the corresponding splicing product was not considered in 
further studies under the assumption that the 37848 cryptic activation was likely 
driven by the pTB vector structure itself.
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Figure 18. Splicing analysis of BRCA1 exon 12 WT and MUT in different 
reporter minigene systems, a) A schematic representation of the minigenes 
used in the pcDNA3 vector, the splicing pattern and the western blots detecting 
TDP-43 silencing (N=2). b) A schematic representation of the BRCA1 exon 12 
WT and MUT inserted into the pTB vector and the reported splicing patter in 
HeLa cells, c) In vivo assay using patient’s fibroblasts reveals partial BRCA1 
exon 12 skipping in presence of the -1G>A mutation (L: ladder, C: controls, P: 
patients) (N=3).
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Effects of TDP-43 on BRCA1 MUT exon 12 processing
In the selected pTB-based BRCA1 exon 12 MUT construct, TDP-43 
silencing abolished exon 12 recognition, indicating that in this splicing system the 
protein exerts an enhancing effect on exon 12 recognition.
To further examine TDP-43 involvement in BRCA1 exon 12 definition and to 
better define which TDP-43 domain is directly involved in splicing regulation, flag- 
tagged and siRNA-resistant TDP-43 constructs were overexpressed in cell culture 
experiments. Four different recombinant TDP-43 were used: i) TDP-43 wild type 
(WT); ii) TDP-43 with domain RRM1 and RRM2 mutated, thus deprived of its 
RNA-binding activity (RRM1.2M); iii) TDP-43 lacking the entire C-terminal domain 
(AC); iv) TDP-43 lacking the hnRNP binding site and the Q/N rich region (A321- 
366).
Firstly TDP-43 was silenced and secondly the recombinant siRNA resistant TDP- 
43 constructs transfected together with the BRCA1 minigenes. After 24 hours total 
RNA was collected, retro-transcribed and PCR-amplified. Splicing products were 
finally separated on 2% agarose gels (Figure 19b).
Overexpression of WT TDP-43 failed to completely restore exon 12 
inclusion but a partial rescue (25%) was observed further indicating that TDP-43 
helps the recognition of exon 12 (Figure 19b). As expected, overexpression of 
RRM1.2M TDP-43 failed to recover exon 12 recognition from the TDP-43-silenced 
condition, indicating that the integrity of the RNA-binding domain is an absolute 
requirement for TDP-43-mediated splicing regulation. On the other hand, 
overexpression of both AC TDP-43 and A321-366 TDP-43 partially restored exon 
12 inclusion. In particular, overexpression of A321-366 TDP-43 was found to 
better rescue exon 12 inclusion (17%) with respect to the AC TDP-43 (9%). 
Therefore, the TDP-43-mediated enhancement of exon 12 inclusion might not be
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driven just by the 321-366 specific region but by a wider region in the C-terminal 
domain.
The western blots reported in Figure 19c show that all the four flag-tagged 
siRNA-resistant proteins were expressed in similar quantities in the transfected 
cells and that TDP-43 was efficiently knocked down. Also, the loading control 
protein (tubulin) was present at similar levels in control and 
silenced/overexpressed cells.
As an additional control, the same pattern of experiments was performed 
using the BRCA1 WT construct. Indeed, neither silencing nor overexpression of 
the four different recombinant TDP-43 proteins were able to affect exon 12 regular 
processing (Figure 20b and 20C for the western blot controls) in line with the 
previously reported results.
In summary, the experiments in cell culture indicate that UG repeats 
located in the downstream region of the BRCA1 MUT exon 12 can help the 5’SS 
definition of the poorly defined exon 12 through the recruitment of TDP-43, which 
acts as a splicing enhancer. In particular, TDP-43 RRM1 and RRM2 domains are 
required for the protein to modulate splicing. Moreover, not only the 321-366 
region involved in the interaction with others hnRNP family members, but the 
entire TDP-43 C-terminal domain plays a role in exon 12 splicing regulation.
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Figure 19. TDP-43 favors BRCA1 exon 12 MUT inclusion in the final mRNA 
product, a) A schematic representation of the BRCA1 exon 12 MUT construct 
in the pTB reporter minigene used for splicing assay in HeLa cells, b) Splicing 
assay in cell cultures reveals that TDP-43 favors exon 12 MUT inclusion. 
Overexpression of the protein restores, but not completely, exon 12 inclusion, c) 
Western blots detecting the TDP-43 silencing and flagged-tagged recombinant 
TDP-43 proteins overexpression (N=6). The reported results showed statistical 
significance (p<0.001 ***).
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Figure 20. TDP-43 does not affect BRCA1 exon 12 WT inclusion, a) A
schematic representation of the BRCA1 exon 12 WT construct in the pTB 
reporter minigene used for splicing assay in HeLa cells, b) Splicing assay in cell 
cultures reveals that TDP-43 does not affect exon 12 processing in presence of 
the strong 5’SS. c) Western blots detecting the TDP-43 silencing and flagged- 
tagged recombinant TDP-43 proteins overexpression (N=3).
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Identification of new TDP-43 potential RNA targets
Identification of exons carrying UG repeats in proximity of their 5’SS 
through bioinformatic analysis
Our previous results have shown that the BRCA1 WT exon 12 has 
remained unaffected by both TDP-43 silencing and overexpression. On the other 
hand TDP-43, thought the binding of UG repeats located near the 5’SS, enhanced 
the recognition of the upstream exon 12 in the BRCA1 MUT pathological context. 
To identify new potential TDP-43 regulated exons carrying UG elements in their 
5’SS proximal intronic sequence, I performed a genome-wide bioinformatic 
analysis. Specifically, using a database of human genes that undergo alternative 
splicing of their pre-mRNAs (AltSplice database [323, 324]), 130 exons were 
identified carrying at least six UG/TG repeats either at the 3’ or 5’SS. Among 
them, the 45 exons carrying UG/TG repeats at their 5’SS are reported in Table 3.
In Table 3, for each exon involved (third column), the number of UG/TG 
repeats in its downstream sequence is reported (forth column). Noteworthy, in this 
study a downstream sequence of 70 nucleotides has been considered. Therefore, 
the reported number of UG/TG repeats in Table 3 refers to this interval, although 
in different cases the UG/TG elements extended beyond it. In addition, given that 
the 5’SS consensus sequence consist of 9 nucleotides spanning from position -3 
to +6, the location definition (fifth column) indicates whether the UG/TG repeats 
are located within the consensus (within +1 and +6) or in the downstream 
sequence (for distances longer than +6). Finally, the 5’SS strength in terms of 
consensus value (CV) was calculated using a bioinformatic tool (seventh column). 
Clearly, the BRCA1 exon 12 previously analyzed in this dissertation was also 
reported in the bioinformatics analysis.
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Among the new potential TDP-43 targets identified with the bioinformatic 
analysis, I selected five representative exons, which were also reported as TDP- 
43 clusters on CLIP analysis (Ule, personal communication) and affected by TDP- 
43 silencing in a previous microarray analysis form Baralle’s laboratory [199]. The 
selected exons (in bold in Table 3) represent a variable pool in terms of CVs 
(ranging from CV=0=0% to CV=0.97=97%), location (ranging from +4 to +34) and 
number of UG repeats. This significant variability allowed investigation of the 
potential effect of TDP-43 in different genomic contexts.
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Table 3. Exons carrying UG/TG repeats at their 5’SS. The gene symbols (first 
column) and gene names (second column) are reported for each involved exon 
(third column). In the forth column the number (n) of UG/TG repeats is listed; the 
indicates that the repeat elements are interrupted by non-repeated sequences. 
The fifth column reports the number of the intronic nucleotides from the 5’ exon 
end. Given that the 5’SS consensus sequence is defined by 9 nucleotides, the 
location definition (sixth column) identifies whether the TG elements are in the 
consensus sequence (from +1 to +6) or in the proximal downstream region (from 
+7 to +70). Finally, the last column reports the consensus value for each 5’SS 
(seventh column).
Gene
Symbol
Gene
Name
Exon
Involved (TG)n Location
Location
Definition CV
ACSS2
Acyl-CoA synthetase 
short-chain family 
member 2
exon 8 21 +5 5'SS 0.4
AMHR2 Anti-Mullerian hormone receptor, type II exon 6 7_3 +21
down
stream 1
ATF6B Activating transcription factor 6 beta exon 5 2_6 +46
down
stream 0.95
BRCA1 Breast cancer 1, early onset exon 12 6_4 +10
down
stream 0.95
CDC25A Cell division cycle 25 homolog A (S. pombe) exon 7 8_2 +6
down
stream 0.88
COL4A5 Collagen, type IV, alpha 5 exon 15 14_7 +44
down
stream 0.99
COL4A6 Collagen, type IV, alpha 6 exon 22 3_13 +35
down
stream 1
CST3 Cystatin C exon 2 2_11 +3 5'SS 0.99
CST5 Cystatin D exon 2 2_2_3_6 +3 5'SS 1
CTH
Cystathionase
(cystathionine
gamma-lyase)
exon 11 14 +14 downstream 0.96
DDR1
Discoidin domain 
receptor tyrosine 
kinase 1
exon 8 9 +51 downstream 0
DMC1
DMC1 dosage 
suppressor of mck1 
homolog
exon 13 25 +18 downstream 0.94
EPHX1
Epoxide hydrolase 1,
microsomal
(xenobiotic)
exon 5 19 +21 downstream 0.97
ETF1
Eukaryotic 
translation 
termination factor 1
exon 7 2_14 +27 downstream 0.23
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Gene
Symbol
Gene
Name
Exon
Involved (TG)n Location
Location
Definition CV
GAGE8 Cancer/testis antigen 4.7 exon 3 3_5_6 +31
down
stream 0.99
HLA-DRB1
HLA-DRB3
HMG14
Major
histocompatibility 
complex, class II, DR
betaj_____ ___ ___ _
Major histocompatibility 
complex, class II, DR 
beta 3
High-mobility group 
nucleosome binding 
domain 1
exon 2
exon 2 
exon 5
2_9
2_6
14
+32
+32
+8
down
stream
down
stream
down
stream
0.99
0.99
0.51
HMGN1
IGFBP7
High-mobility group 
nucleosome binding 
domain 1 
Insulin-like growth 
factor binding 
protein 7
exon 5 
exon 2
19
15
+8
+29
down
stream
down
stream
0.51
0.9
JAG1 Jagged 1 exon 26 2_14 +5 5’SS 0.99
KLF8 Kruppel-like factor 8 exon 4 2_11 +30
down
stream 0.98
MAP3K19
Mitogen-activated 
protein kinase kinase 
kinase 19
exon 3 9_2 +3 5'SS 0.59
MICALL1 MICAL+like 1 exon 2 2_11_12 +35
down
stream 0.99
MSH6 MutS homolog 6 (E. coli) exon 2 5_11 +19
downs
stream 0.99
MYH7 Myosin, heavy chain 7, cardiac muscle, beta exon 32 6 +1 5'SS 0.89
MYL2
Myosin, light chain 2, 
regulatory, cardiac, 
slow
exon 4 8_3_2 +9 downstream 1
N4BP2L2 NEDD4 binding protein 2-like 2 exon 3 9 +7
down
stream 0.86
NTRK1
Neurotrophic 
tyrosine kinase, 
receptor, type 1
exon 12 16 +34 downstream 0
ORC5L Origin recognition complex, subunit 5 exon 6 11_2 +32
down
stream 0.81
PLP2 Proteolipid protein 2 exon 4 7_14 +5 5'SS 1
PPIA
Peptidylprolyl 
isomerase A 
(cyclophilin A)
exon 2 2_7 +38 downstream 0.86
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Gene
Symbol
Gene
Name
Exon
Involved (TG)n Location
Location
Definition CV
PTPRU
Protein tyrosine 
phosphatase, receptor 
type, U
exon 24 2_7_5 +16 downstream 0
RBCK1
RanBP-type and 
C3HC4-type zinc finger 
containing 1
exon 5 
(AS) 8 +53
down
stream 0.45
RGL2
Ral guanine nucleotide 
dissociation 
stimulator+like 2
exon 11 6 +8 downstream 0.78
RXRG Retinoid X receptor, gamma exon 7 3_14 +25
down
stream 0.15
SCAP2 Src kinase associated phosphoprotein 2 exon 9 8_6 +39
down
stream 0.76
SFTPC Surfactant protein C exon 4 6_18 +1 5'SS 0.95
SGK2 Serum/glucocorticoid regulated kinase 2 exon 8 18_2 +4 5'SS 0.67
SIGLEC1
Sialic acid binding 
Ig-like lectin 1, 
sialoadhesin
exon 12 20 +5 5’SS 0.98
ST5 Suppression of tumorigenicity 5 exon 13 9 +51
down
stream 0.99
SYF2
SYF2 homolog, RNA 
splicing factor 
(S. cerevisiae)
exon 5 2_8 +26 downstream 0.99
T3 delta CD3d molecule, delta exon 3 (AS) 2_18 +26
down
stream 0.5
TBX19 T-box 19 exon 3 20 +7 downstream 0.98
TG Thyroglobulin exon 10 13_3 +27
down
stream 0.54
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TDP-43 in splicing regulation of five new potential targets
Five potential target exons analyzed in minigene systems
The five selected exons (EPHX1 exon 5, ETF1 exon 7, NTRK1 exon 12, 
RXRG exon 7 and SGK2 exon 8) together with 300 nucleotides-flanking intronic 
sequences were firstly amplified from the genomic DNA (from HeLa cells) and 
secondly inserted in the pTB vector. The pTB vector was selected for studies in 
cell culture. Each of the five minigene systems was transiently transfected in 
control cells and in TDP-43 silenced cells. Additionally, overexpression the four 
different recombinant forms TDP-43 was performed (WT; RRM1,2M; AC; and 
A321-366 TDP-43).
In this set of experiments the main goal was to determine whether in these 
five new splicing systems, the UG repeats act an enhancers favoring exon 
inclusion in a TDP-43-mediated manner as observed in the BRCA1 MUT system, 
or conversely act as silencers promoting exon skipping through the recruitment of 
TDP-43, as reported in literature for the CFTR exon 9 and APOAII exon 3 
systems. In addition, the involvement of the different TDP-43 domains in splicing 
regulation was also investigated.
TDP-43 overexpression induces RXRG exon 7 skipping
The RXRG (retinoid X receptor gamma) is a member of the nuclear retinoid 
X receptor family (RXR) together with RXRA (alpha) and RXRB (beta). The three 
members function as ligand-activated transcription factors and contain three 
conserved domains: i) a DNA-binding domain; ii) a ligand-binding domain; and iii) 
a transcription-activator domain. The RXRs can form either homodimers or 
heterodimers with many other nuclear receptors [340]. In particular, heterodimers
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of RXR and retinoic acid receptors (RAR) bind to the ligand retinoic acid (RA), a 
metabolic product of vitamin A known to modulate gene expression of more than 
500 RA-responsive genes. Upon activation by the RA ligand, the heterodimeric 
pair RXR:RAR binds to DNA sequences and induces or represses gene 
expression [341]. Concerning RXRG, three different isoforms of the protein 
corresponding to alternative splicing events have been observed 
(ENST00000465764); exon 7 is normally included in the final transcript (Figure 
21a). As reported in Table 3, the downstream sequence of RXRG exon 7 presents 
a UG repeat element composed of a UG3 at position +25 followed by a UG14 at 
+36. This UG element is mostly conserved among primates, but poorly conserved 
among amniotes vertebrates (Figure 21b). Although the bioinformatic examination 
reported a very weak 5’SS (CV=0.15=15%), exon 7 is normally included in the 
final RXRG mRNA probably because of significant ESE and ISE sequences 
located in the nearby sequences that compensate for the weak 5’SS consensus 
sequence (Figure 29 in appendix).
In order to determine the biological impact of the UG repeats and TDP-43 in 
this splicing system a minigene system carrying both RXRG exon 7 and 300 
nucleotides of the intronic flanking region was engineered (Figure 22a) and then 
transfected in control, TDP-43-silenced and recombinant TDP-43-overexpressed 
cells (Figure 22b).
In the control sample RXRG exon 7 was fully included, resembling the wild type 
conditions. Silencing of TDP-43 did not seem to affect the processing of the exon 
that was included in the final mRNA as in the control. Based on these 
observations it can be exclude that TDP-43 exerts an enhancing effect on exon 7 
inclusion since no exon 7 skipping was observed upon TDP-43 silencing. On the 
other hand, given the already complete inclusion of exon 7 in the control sample it 
was not possible to detect an increase in exon 7 inclusion upon TDP-43 silencing.
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For this reason, it cannot to be excluded that TDP-43 might exert an inhibitory 
effect on the exon 7 recognition.
Most interestingly, however, overexpression of WT TDP-43 resulted in exon 7 
skipping (27%). Moreover, mild exon 7 skipping was also observed by 
overexpressing the AC and A321-366 TDP-43, 2% and 7% respectively. These 
results suggest that in overexpression conditions TDP-43 can act (directly or 
indirectly) as a splicing silencer or alternatively that overexpressed TDP-43 can 
competes for the binding site with other UG repeats-binding proteins possibly 
involved in promoting exon 7 inclusion.
Moreover, the overexpression of RRM1,2M TDP-43 mimicked TDP-43-silencend 
conditions, suggesting that, as for the BRCA1 MUT, the RNA-binding function of 
TDP-43 is fundamental to affect TDP-43-mediated exon 7 processing (Figure 
22b).
124
3  RXRG reported transcripts
W
5 6 exon 7 is constitutively included
RXRG genomic aligments
RXRG
Human (Homo_sapiens) 
Chimpanzee (Pan troglodytes): 
Gorilla (Gorilla gorilla): 
Orangutan (Pongo pygmaeus): 
Macaque (Macaca mulatta): 
Marmoset (Callithrix jacchus):
GTATTTGTGTGTATTATGTGTGTGTGTGTGT-------- GTGTGTGTGTGTGTATACA
GTATTTGTGTGTATTATGTGTGTGTGT-----------------GTGTGTGTGTATACA
GTATTTGTGTGTATTGTGTGTGTGTGTGTGTGTGTGT— GTGTGTGTGTGTGTATACA
G TATTTGTGTGTATTATGTGTGTGTG------------------- TGTGTGTGTATACA
G TATTTGTGTGTATTATGTGTGTGTGTGTGT------ ACACGTGTGTGTGTGTGTACA
GTATTTGTGTGTATTATGTATGTG------------------------- TATGTATACA
Chicken (Gallus gallus): GC-TTATCA-----------------------------------------------------
Turkey (Meleagris gallopavo): GG-TT-GTCA----------------------------------------------------
Zebra Finch (Taeniopygia guttata): GG-TT-GCCA---------------------------------------------------
Mouse (Mus musculus): GGATTTACACACAGTG-----------------------------------TGCATATGCA
Rat (Rattus norvegicus): GGATTTACACCCACTG-----------------------------------TGCACATGCA
Rabbit (Oryctolagus cuniculus): GTATCCTCTCTG------------------------------------- TGTGTATATACA
Horse (Equus caballus): GTGCTTGTGTGTG-----------------------------------GTATGTGTATACA
Dog (Canis familiaris): GTGCTCGTGTGTGTGTGT---------------- ---------- GTGTGTGTGTCTACA
Pig (SU3 scrofa) : G TGTTCGTGTGT-----------------------------------TGTGTGTGTGTGTG
Cow (Bos taurus): G CA TGTG------------------------------------TGTGTGTGTGTGTG
Figure 21. RXRG exon 7 constitutive splicing and UG element 
conservation among mammals, a) RXRG exon 7 is constitutively included in 
the resulting mRNAs. b) The UG element at the 5’SS is mostly conserved 
among primates, but poorly conserved among amniotes vertebrates.
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8  RXRG exon 7 minigene
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©
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siNoTarget +
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Flagged TDP-43
Figure 22. TDP-43 overexpression inhibits RXRG exon 7 inclusion, a) A
schematic representation of the RXRG exon 7 construct in the pTB reporter 
minigene used for splicing assay in HeLa cells, b) Splicing assay in cell cultures 
reveals that, whereas TDP-43 silencing does not seem to affect exon inclusion, 
TDP-43 overexpression enhances exon 7 skipping (N=2). c) Western blots 
detecting the TDP-43 silencing and flagged-tagged recombinant TDP-43 
proteins overexpression. The reported results showed statistical significance
(p<0.01 **).
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TDP-43 levels do not affect EPHX1 exon 5 processing
The EPHX1 (microsomal epoxide hydrolase 1) is a detoxifying enzyme that 
regulates ossidative stress. Interestingly, this enzyme can be linked to 
neuropathologies since significantly elevated levels of EPHX1 were found in 
hippocampal regions of patients suffering from Alzheimer’s disease [342]. The 
bioinformatic analysis revealed a GU17 element in the downstream region of exon 
5 (+20), which presents a very well defined consensus sequence (CV=0.97=97%). 
Although EPHX1 levels were previously found to be downregulated upon TDP-43 
silencing in a study from Baralle’s laboratory [300], no alteration of the splicing 
pattern was observed in our minigene construct where exon 5 was always 
regularly included in all the different experimental condition tested (Figure 23a). 
Buratti et all. suggested that EPHX1 downregulation might be due to the specific 
upregulation of miR-663 expression upon TDP-43 removal [300]. Alternatively, 
TDP-43 might regulate EPHX1 at a transcriptional level or changes in EPHX1 
levels might be ultimately caused by secondary modifications in the oxidative 
pathways occurring upon TDP-43 silencing.
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TDP-43 levels do not affect NTRK1 exon 12 processing
As previously mentioned in Table 1, the NTRK1 gene encodes for the 
neurotrophic tyrosine kinase receptor type 1, also known as TRK1 or Trk-A 
(transforming tyrosine kinase protein 1/A). This kinase induces cell differentiation 
and might also play a role in specifying sensory neuron subtypes. Mutations in this 
gene have been associated with congenital insensitivity to pain with anhidrosis 
(CIPA), self-mutilating behavior, mental retardation and cancer [146, 147]. The 
bioinformatic analysis showed a GU16 element in the downstream region of exon 
12 (+34). This UG repeat element has been reported as a polymorphic region, 
although the polymorphism was not found to correlate with incidence of CIPA 
disease (Table 1). The NTRK1 protein is almost ubiquitously expressed and 
different protein isoforms have been described. The NTRK1 exon 12 is reported 
as constitutively included in the final mRNA (Ensembl ENST00000534682) 
(CV=0=0%). In the NTRK1 exon 12 minigene system the exon 12 always resulted 
skipped and the splicing outcome was not affected by either TDP-43 silencing or 
overexpression (Figure 23b).
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TDP-43 levels do not affect SGK2 exons 7, 8 processing
The SGK2 gene encodes for the serum-glucocorticoid regulated kinase 2, a 
modulator of the epithelial channels ENaC activity in human kidneys (ENaC gene 
has been previously reported in Table 1) [343, 344]. The SGK2 transcripts 
undergo alternative splicing leading to nine different protein isoforms (Ensembl 
ENSG00000101049). The bioinformatic analysis reported a long 
UGG(UG)18UA(UG)2 element at the 5’SS of SGK2 exon 8 (CV=0.67=67%). 
Given the particularly short exon 8 (37 nucleotides), in engineering the minigene 
construct to study the potential role of TDP-43 in splicing regulation I included also 
the upstream exon 7 (Figure 15A). In normal conditions, both exon 7 and 8 are 
generally included constitutively in SGK2 mRNA. In this study, SGK2 exon 8 was 
always included in the final mRNA and its processing was not affected by either 
TDP-43 silencing or overexpression (Figure 23c).
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EPHX1 exon 5
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/
+
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Figure 23. TDP-43 levels do not affect exon processing in EPHX1 exon 5, 
NTRK1 exon 12 and SGK2 exons 7, 8. a) A schematic representation of the 
EPHX1 exon 5 construct in the pTB reporter minigene used for splicing assay in 
HeLa cells and the splicing patter unaffected by TDP-43 levels (N=2). b) A 
schematic representation of the NTRK1 exon 12 construct in the pTB reporter 
minigene used for splicing assay in HeLa cells and the splicing patter unaffected 
by TDP-43 levels (N=2). c) A schematic representation of the SGK2 exons 7, 8 
construct in the pTB reporter minigene used for splicing assay in HeLa cells and 
the splicing patter unaffected by TDP-43 levels (N=2).
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TDP-43 overexpression induces ETF1 exon 7 skipping
The ETF1 gene encodes for the eukaryotic translation termination factor 1, 
also called eukaryotic release factor 1 (eRF1). In eukaryotes ETF1 mediates 
translation termination in concert with eRF3/ETF3, as for the yeast homologues 
SUP45 and SUP35 [345]. In particular, ETF1 recognizes all the three termination 
codons (UAA, UGA, UAG) in the mRNAs inducing the hydrolysis of the peptidil- 
tRNA ester bond and finally leading to translation termination [346, 347].
The bioinformatic analysis of the 70 nucleotides downstream region of an 
exon revealed the presence of a UG repeat element in the downstream sequence 
of ETF1 exon 7. However, additional analysis of the sequence revealed that the 
UG element extends beyond the 70 nucleotides reaching position +88. The UG 
rich element is composed by a UG2 at +27 followed by an imperfect 
G(UG)14UA(UG)6UAUG repeated element at +41. The element is poorly 
conserved among primates and amniotes vertebrates (Figure 24b) and various 
ESE and ISE sequences compensate for the weak 5’SS consensus sequence 
(CV=0.23=23%) (Figure 30 in appendix).
Based on the complex patter of alternative splicing involving ETF1 exon 7 (intron 
7-8 retention and cryptic donor site within exon 7 upstream to the authentic one) 
(Ensembl ENSG00000120705; ETF1-008 ENST00000512198; ETF1-004
ENST00000506345) (Figure 24a), when engineering the ETF1 construct exon 8 
was also included (Figure 25a).
Upon transfection in HeLa cells, in control conditions ETF1 exon 7 was
mostly included and 33% skipped, whereas TDP-43 silencing enhanced exon 7
inclusion reporting only 5% of exon skipping (Figure 25b). This observation
suggests that TDP-43 exerts an inhibitory effect on exon 7 processing. In
accordance with this observation, overexpression of WT TDP-43 resulted in 73%
of exon 7 skipping. Additionally, with RRM1,2M TDP-43 overexpression the
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recover of exon 7 skipping did not occur, confirming once again that TDP-43 RNA- 
binding function is essential to mediate splicing modulation. Finally, skipping of 
ETF1 exon 7 was also observed when either AC or A321-366 TDP-43 were 
overexpressed, 60% and 47% respectively. The milder effect of A321-366 TDP-43 
overexpression on exon 7 skipping in respect to AC TDP-43 suggests that the 
entire C-terminal regions might be required for TDP-43-mediated splicing 
regulation (Figure 25b).
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ETF1 reported transcripts
5 6 8 9 10 I 11
5 6
5 6
alternative 5 ’SS in exon 7
intron 7-8 retention + alternative 5 ’SS in exon 8
ETF1 genomic aligments
ETFl
Human (Homo_sapiens)
Chimpanzee (Pan troglodytes): 
Gorilla (Gorilla gorilla): 
Orangutan (Pongo pygmaeus): 
Macaque (Macaca mulatta):
Marmoset (Callithrix jacchus):
Chicken (Gallus gallus):
Turkey (Meleagris gallopavo): 
Zebra Finch (Taeniopygia guttata)! 
Mouse (Mus musculus):
Rat (Rattus norvegicus):
Rabbit (Oryctolagus cuniculus): 
Horse (Equus caballus):
Dog (Canis familiaris):
Pig (Sus scrofa):
Cow (Bos taurus):
GTGAAATGTTTTCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTATGTAC 
GTGAAATGTTTTCGTGTGTGTGTGTGTGTGTGTGTGTGTGTG— TGTGTGTGTGTGTGTGTAC
G TGAAATGTTTTTGTGTGTGTGTA------------------------ TATGTATGTATGTAC
G TGAAATGTTTTCGTGTGTGTGTGT---------------------- GTATGTATGTATGTAC
G TGAAATGTTTTCGTGTGTGTGT---------------------------- GTACGTATATAC
GTGAAATGTTTTGTTTT TG-------GAGGGGGTGTGTGTATGCATATGTATGTATGTAC
-TTTG-
-TATG-------
-TTTGTGTGTGT-
-TTTATCTGTAT-
-TTTGTATGTAT-
-TTTGTATGTGT-
-ATA— TGTATGTAC 
-ATT— TGTGTGTAC 
-A TGTCTGTAT
Figure 24. ETF1 exon 7 alternative processing and UG element 
conservation among mammals, a) ETF1 exon 7 can either be included or an 
alternative 5’SS within its sequence can be recognized. The resulting product in 
this case is reported to be degraded by NMD. Alternatively a third processed 
transcript with intron 7-8 retention and alternative 5’SS in exon 8 has been 
detected, but no corresponding protein product has been detected so far. b) The 
UG element at the 5’SS of exon 7 is poorly conserved among primates and 
amniotes vertebrates.
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Figure 25. TDP-43 overexpression inhibits ETF1 exon 7 inclusion, a) A
schematic representation of the ETF1 exon 7 construct in the pTB reporter 
minigene used for splicing assay in HeLa cells, b) Splicing assay in cell cultures 
reveals that TDP-43 silencing enhance exon 7 inclusion whereas TDP-43 
overexpression inhibits it (N=3). c) Western blots detecting the TDP-43 silencing 
and flagged-tagged recombinant TDP-43 proteins overexpression. The asterisks 
represent the p values (p<0.05 *; p<0.01 **; p<0.001 ***) indicating the statistical 
significance of the results.
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UG repeats enhance ETF1 exon 7 inclusion
Once proved that TDP-43 can affect the correct processing of ETF1 exon 7 
through the binding of the UG repeats in the downstream region, the UG element 
was completely removed to observe the effect of UG repeats absence on exon 7 
processing (Figure 26a). The ATG ETF1 construct was then transiently 
transfected in HeLa cells after TDP-43 silencing and overexpression.
The removal of the c/s-regulatory element in the ATG ETF1 construct resulted in 
major exon skipping (70%), whereas in presence of the UG repeats exon 7 was 
mostly included (67%) (Figures 25b and 26b). These observations highlight the 
importance of the UG repeats as a splicing enhancer element ensuring the 
inclusion of the upstream exon 7. Upon either silencing or overexpression of TDP- 
43, exon 7 was still mostly skipped. In fact, in absence of the UG element TDP-43 
cannot bind and therefore regulate the processing of the exon. As expected, 
overexpression of RRM1,2M, AC and A321-366 TDP-43 proteins did not affect 
exon processing, given the absence of TDP-43 binding site (Figure 26b).
Interestingly, both saturation of the UG element with TDP-43 (in WT TDP-43 
overexpression conditions, third lane on the gel) and removal of the UG element 
(in the ATG ETF1 construct in general) equally result in predominant exon 7 
skipping (Figures 25b and 26b). These observations indicate that the long UG 
element itself represents an ESE promoting exon 7 inclusion likely through the 
recruitment of additional UG repeats-binding proteins, whereas TDP-43 act as an 
inhibitor of exon 7 inclusion. Consistent with this hypothesis, overexpression of 
TDP-43 possibly saturates the UG repeats element preventing the binding of other 
regulatory proteins with opposite (enhancing) effect ultimately resulting in exon 7 
skipping. In line with this, TDP-43 silencing increased exon 7 inclusion (Figure 
25b).
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3  ATG ETF1 exons 7, 8 minigene
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Figure 26. The UG repeated element enhances ETF1 exon 7 inclusion, a) A
schematic representation of the ETF1 construct where the TG repeats have 
been deleted, b) Splicing assay in cell cultures reveals that TDP-43 does not 
affect exon 7 processing in absence of its UG repeats binding site (N=2).
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In summary, TDP-43 does affect splicing of SGK2 exon 7-8, EPHX1 exon 5 
and NTRK1 exon 12. However, in RXRG exon 7 and ETF1 exon 7 TDP-43 
silences exon inclusion when overexpressed, therefore acting as a splicing 
inhibitor. In addition, the absence of UG repeats in the ATG ETF1 construct 
revealed that the UG element itself strongly promotes ETF1 exon 7 inclusion, 
further indicating the enhancer role of the UG repeats at the 5’SS in line with our 
previous results.
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Potential TDP-43 involvement in endogenous 5’SS definition
In order to further establish whether the presence of 5’SS-located UG 
repeats can endogenously affect exon processing in a TDP-43-mediated manner, 
I started to analyze the endogenous splicing patter of the exons reported in Table 
3. Upon silencing of TDP-43 in HeLa cells, total RNA was extracted and semi- 
quantitative RT-PCR was performed in order to detect the splicing products. 
However, endogenous RNA analysis of 20 out of 45 exons did not show any 
splicing misregulation with this method (Figure 27a). Given the reported effect of 
TDP-43 overexpression in a SMN exon 7 minigene system [238], analysis of the 
endogenous SMN exon 7 splicing patter was also performed, although no UG 
elements are present in the analyzed sequence. Also in this case no significant 
differences were observed upon TDP-43 depletion on SMN exon 7 endogenous 
processing.
Similarly, investigation of the endogenous effects of TDP-43 silencing on the 
five exons previously studied in the minigene systems did not report variations in 
the exons processing with this method (Figure 27b). Additionally, based on the 
results obtained with the ETF1 and ATG-ETF1 minigene constructs, the potential 
effect of both TDP-43 silencing and overexpression in the processing of 
endogenous ETF1 exon 7 were considered. To identify any possible splicing 
variation a wide genomic context was analyzed using a different set of 
oligonucleotides on ETF1 exons 5, 6, 7, 8 and 9 (Figure 28a). However, this 
approach did not reveal any variations in endogenous ETF1 exon 7 processing as 
well (Figure 28b).
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Endogenous RNA splicing assay
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Figure 27a. TDP-43 silencing does not affect endogenous exon processing 
in the exons analyzed so far. For each studied exons a schematic 
representation of the analyzed sequence and the endogenous splicing assay 
are reported. The exons of interest are illustrated in purple color. 
Oligonucleotides on the flanking exons (pink color) have been used in PCR 
reactions to analyze the splicing patter of the central exon. For each exon the 
PCR reaction was performed twice using two endogenous RNA samples (N=2).
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Figure 27a-c. TDP-43 silencing does not affect endogenous exon 
processing in the exons analyzed so far. For each studied exons a schematic 
representation of the analyzed sequence and the endogenous splicing assay 
are reported. For each exon the PCR reaction was performed twice using two 
endogenous RNA samples (Trial 1 and 2) (N=2). In some cases the PCR 
reaction did not report any product (although different oligonucleotides have 
been used) possibly because the corresponding mRNA is not expressed in 
HeLa. b) Western blots detecting the TDP-43 silencing in each trial are also 
reported, c) Endogenous analysis of the exons studied in minigene systems.
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Figure 28. TDP-43 silencing and overexpression do not affect endogenous 
ETF1 exon 7 processing, a) A schematic representation of the wider genomic 
context of ETF1 considered. The small and different colored arrows represent 
the oligonucleotides used in PCR reactions, b) Endogenous RNA analysis did 
not show variations in ETF1 exon 7 processing in presence of TDP-43 silenced 
or overexpressed conditions (L: ladder) (N=2).
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Discussion and Future Directions
Dinucleotide UG repeats located in proximity of splice site signals can act 
as additional c/s-regulatory elements influencing exon processing in different 
splicing systems [88, 101, 161, 178, 279]. In particular, when located in proximity 
of the 5’SS of an exon the UG elements promote a particular event that consists in 
the exclusion of downstream exons, ultimately leading to shorter mRNA products 
[101, 161]. These UG repeats-mediated events result in tissue specific expression 
of the SCL8A1 gene [161] and promote an advantageous phenotype conferring 
resistance to malaria in the CD36 receptor [101]. This study further investigated 
the role of the 5’SS-located UG repeats by exploring their potential impact on 
splicing of the upstream exons. In particular, the synergic effect of the UG repeats- 
binding factor TDP-43 has been investigated. As shown in the results section, this 
has been mostly performed in vitro using several artificial and natural experimental 
systems using a variety of minigene-based techniques. Furthermore, analysis of 
the potential synergic effect of UG repeats and TDP-43 on the endogenous RNA 
processing has also begun to be explored.
In vitro minigene-based RNA analysis
UG repeats and 5’SS definition
In the first part of this study, results obtained with an artificial system based 
on the pY7 reporter minigene suggested that the lone insertion of UG elements at 
the 5’SS does not significantly affect splicing of the upstream exon, regardless of 
different UG repeats length (6 and 12) and distances from the 5’SS (8 and 18 
nucleotides) (Figure 8-10). In contrast to these results, it should be noted that this 
same reporter minigene was successfully used in the past to demonstrate that
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longer UG repeats at the 3’SS inhibit splicing [277]. However, this initial 
experimental approach presented the limitation of analyzing the potential effect of 
UG repeats in a splicing-optimized system carrying a strong 5’SS consensus 
sequence.
Therefore, different natural systems carrying innate UG repeats in their 5’SS 
proximal intronic region were subsequently used as a more suitable substrate. In 
parallel, when evaluating the involvement of the UG repeats in splicing regulation, 
their ability to recruit UG repeats-binding proteins was also considered.
The first splicing systems to be analyzed was the BRCA1 exon 12 5’SS, 
which carries a GT6 at 9 nucleotides followed by a GT4 at 22 nucleotides from the 
5’SS. This system presents the advantage of a natural and documented mutation 
that weakens the strength (in terms of consensus value) of the BRCA1 exon 12 
5’SS, leading to exon 12 skipping in vivo in breast cancer patients [326].
The analysis of the mutated 5’SS of the BRCA1 exon 12 both in a two exons-one 
intron system (Figures 11-13) and the full length exon 12 in a three exons-two 
introns system (Figure 14) successfully mimicked the in vivo situation, confirming 
that the mutation is the direct cause of aberrant splicing events. Therefore, a 
competition assay was subsequently performed in order to investigate the 
involvement of UG repeats as trans-acting factors recruiter in BRCA1 exon 12 WT 
and MUT processing.
Splicing analysis of the BRCA1 exon 12 5’SS WT in the presence of GU6 RNA
competing oligos revealed that the UG elements at the 5’SS of exon 12 can
enhance exon processing through the recruitment of UG repeats-binding proteins
(Figure 15a). Interestingly, this enhancement was strongly marked in the BRCA1
exon 12 5’SS MUT carrying the weakened 5’SS (Figure 15b). Generally, additional
regulatory elements are required for proper exon processing in the presence of
weak canonical splicing signals (5’SS and 3’SS) [348, 349]. Consistent with this
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knowledge, our results indicated that UG repeats and UG repeats-binding proteins 
are indeed required for proper 5’SS definition of the poorly defined exon 12. 
Further analysis showed that in this system the UG repeats-binding proteins also 
favour the transition between the A complex and late complexes, possibly by 
recruiting additional spliceosomal components, as shown by the analysis of the 
spliceosomal complex assembly (Figure 16).
It can be noted that the 5’SS strength-dependent synergic role played by 
the UG repeats and UG repeats-binding proteins in 5’SS definition observed in the 
BRCA1 exon 12 5’SS MUT system resembles the genomic context-dependent 
effect observed in the APOAII splicing system by Mercado et all.. In fact, 
polymorphic UG repeats at the 3’SS were found to induce APOAII exon 3 skipping 
only upon disruption of additional regulatory sequences with inclusion-enhancing 
properties [88]. Similarly, in the BRCA1 exon 12 model the UG repeats at the 5’SS 
play a key role in 5’SS definition, through the recruitment of UG repeats-binding 
proteins, but only when the strong WT 5’SS is weakened by the mutation.
In addition to these considerations on the effects of UG repeats on 5'SS 
recognition it should be noted that, from a simple diagnostic point of view, these 
conclusions represent the first mechanistic evaluation of a putative splicing- 
affecting pathological mutation, providing insight of a direct correlation between 
the genetic variation and the splicing defect.
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TDP-43 enhances mutated BRCA1 exon 12 inclusion
Among the numerous UG repeats-binding proteins reported in literature 
(PTB, FUBP3, CELF1, CELF2, SRp55, etc.), we have focused predominantly on 
TDP-43, a protein with great affinity for this sequence [198]. TDP-43 is 
ubiquitously expressed in human tissues and has been described to be involved in 
neuropathologies such as ALS and FTLD. In this study we investigated TDP-43 
involvement in the regulation of different splicing systems.
TDP-43 is bona fide a heterogeneous nuclear ribonucleoprotein acting as a 
splicing regulator (either inhibitor or activator) [86, 88, 178, 238, 239, 241], as well 
as influencing other post-transcriptional steps in gene expression [199, 240, 242, 
243, 268, 270, 300]. Since our studies on the BRCA1 exon 12 system indicated 
that UG repeats-binding proteins in general help the processing of the exon, the 
role played by TDP-43 in this splicing system was investigated. Experiments in 
HeLa cells showed that either TDP-43 silencing or overexpression failed to affect 
the splicing of the well defined BRCA1 exon 12 5’SS WT. However, TDP-43 
silencing completely inhibited proper exon 12 recognition in presence of the weak 
mutated 5’SS in BRCA1 exon 12 MUT, whereas overexpression of the protein 
partially restored exon 12 inclusion (Figure 18). These results indicated that the 
UG repeats at the 5’SS of BRCA1 exon 12 MUT can lead to TDP-43-mediated 
enhancement of exon 12 inclusion. Hence, our investigation allowed the 
identification of novel system in which the protein displays a 5’SS strength- 
dependent splicing enhancing functionality.
Interestingly, quite a few other cases of TDP-43-mediated splicing activation 
are found in the literature. The first case was reported by Bose et all. in 2008 and 
concerned the SMN2 exon 7 system, where a mutation in position +6 of exon 7 
leads to major exon skipping. In this study, whereas silencing of TDP-43 did not 
affect exon 7 processing at all, overexpression of TDP-43 successfully restored
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exon 7 inclusion, although no UG elements were present in this system [238]. 
Most recently, Tollervey et all. reported that TDP-43 silencing enhances 
alternative skipping of CDK5RAP2 exon 39 and GPBP1L1 exon 4, which carry UG 
repeats in their “deep” intronic sequences, implying TDP-43 correlation with 
alternative exon inclusion enhancement in normal condition [241]. Similarly, seven 
exons were found mostly skipped following TDP-43 depletion in mouse brain: 
POLDIP3 exon 3, TSN exon 5, RBM33 exon 6, DCLK1 exon 16, DST exon 96 and 
PPP3ACA exon 13. However, since in these cases no significant TDP-43 binding 
sites were found within 2kb of the splice sites of most of the altered splicing 
targets the authors suggested an indirect effect of TDP-43, possibly through the 
alteration of other splicing factors [86].
Considerations on TDP-43 binding sites and splicing modulation activity
In the second part of this study, a genome-wide bioinformatic analysis 
brought to the identification of 45 exons carrying long UG repeats elements in their 
5’SSs or proximal intronic sequences (within 70 nucleotides form the 5’SS). Given 
the presence of UG repeats, these exons may represent potential targets of the 
UG repeats-binding protein TDP-43. Consistent with this simple assumption is the 
presence of UG motifs in most of the recently identified TDP-43 RNA targets [236, 
241].
Among the 45 identified exons, we selected for further studies five exons with
reported TDP-43 clusters on CLIP analysis (Prof. Jernej Ule, personal
communication) and whose transcripts levels were affected by TDP-43 silencing in
our microarray analysis [199]. Splicing assay analysis in HeLa cells revealed that
three out of five examined exons (NTRK1 exon 12, EPHX1 exon 5 and SGK2
exon 7, 8) were not affected by either silencing or overexpression of TDP-43.
These observations suggested that either other RNA-binding proteins successfully
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compensate TDP-43 altered levels or, alternatively, that these exons are not 
bound by TDP-43 although the presence of its preferential binding site (Figure 23). 
Consistent with the latter, recently published CLIP data claimed that 96% of RNAs 
containing UG-clusters are actually unaffected by TDP-43 depletion in vivo in 
mouse [86], indicating that not all the UG motifs necessarily represent a TDP-43 
binding site.
On the other hand, in ETF1 exon 7 and RXRG exon 7 systems, 
overexpression of TDP-43 resulted in skipping of the corresponding exons, 
identifying a previously unknown dependency on TDP-43 of these two splicing 
events in vitro (Figures 22 and 25). Additionally, in the ETF1 exon 7, silencing of 
TDP-43 produced the expected opposite effect of enhancing exon 7 inclusion 
(Figure 26). The inhibitory role played by TDP-43 was first described in early 
studies in Baralle’s laboratory showing that UG repeats at the 3’SS of the CFTR 
exon 9 and APOAII exon 3 inhibit exon inclusion [88, 173]. More recently, UG 
repeats in the upstream proximal intronic sequence of ZNF92 exon 2 and PILRB 
exon 39 and in the downstream proximal intronic sequence of REEP6 exon 5 and 
CACNA1C exon 13 were also found to promote skipping of the corresponding 
proximal exons through the recruitment of TDP-43 [241]. In addition, nine exons 
were found to be mostly included upon TDP-43 silencing in mouse (SORT1 exon 
18, KCND3 exon 5, MPZL1 exon 5, DDEF2 exon 25, PDP1 exon 1, SEMA3F exon 
5, ATP2B2 exons 6, 7, 8, EIF4H exon 5, DNAJC5 exon 4a) [86].
In conclusion, in line with the previously described cases of TDP-43- 
mediated silencing of exon inclusion, the results obtained in the ETF1 exon 7 and 
RXRG exon 7 reported two additional systems depending on TDP-43 levels.
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TDP-43 overexpression silences ETF1 exon 7 inclusion
The downstream sequence of the human ETF1 exon 7 present a long, 
poorly conserved throughout evolution and nearly perfect UG element (Figure 24). 
By investigating the role of TDP-43 in exon 7 regulation through the binding of 
these TG repeats we found that silencing of TDP-43 enhances ETF1 exon 7 
inclusion, whereas its overexpression results in exon 7 skipping (Figure 25). In 
addition, the removal of the UG repeats in the ATG ETF1 construct mostly resulted 
in exon 7 skipping, implying that the UG repeats per se enhance exon inclusion, 
possibly by recruiting additional splicing factors (Figure 26). In this case, TDP-43 
might exert its inhibitory activity by competing for the binding site with other UG 
repeats-binding proteins with splicing-enhancing properties. Moreover, the fact 
that either TDP-43 silencing or overexpression did not affect exon 7 splicing in the 
absence of UG repeats (ATG ETF1 construct) supports the direct involvement of 
TDP-43 in splicing regulation through these identified UG repeats, rather than 
through an indirect effect caused by its eventual modulation of other splicing 
factors (Figure 26).
In fact, the potential indirect effect of this protein on general splicing 
regulation is supported by the fact that TDP-43 binding sites were identified on 
pre-mRNAs of different RNA-binding proteins directly involved in the splicing 
process (FUS/TLS, TAF15, Noval and 2, Mbnl, nPTB, etc.). In these instances, 
either the mRNA levels of these proteins were altered or alternatively spliced upon 
TDP-43 silencing (i.e. FUS/TLS mRNA reduced levels; nPTB exon 10 skipping; 
TIA1 exon 5 inclusion) [86]. Based on these observations, and in light of the 
enormous amount of genes (over 6000) found affected by TDP-43 levels, a likely 
indirect effect of TDP-43 has to be considered when analyzing a splicing systems 
affected by either TDP-43 silencing or overexpression.
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In conclusion, from a functional point of view it can be reasoned that by 
affecting the ETF1 mRNA transcripts, a key factor in translation termination, TDP- 
43 might indirectly affect translation of several proteins, regulating their levels 
post-transcriptionally. The next stage of this work will be to validate this hypothesis 
in vivo in order to obtain a clear evaluation of the real functional consequences of 
exon 7 regulation by TDP-43.
TDP-43 overexpression silences RXRG exon 7 inclusion
The RXRG exon 7 downstream sequence presents a long imperfect UG 
element, mostly conserved among primates, but poorly conserved among 
amniotes vertebrates (Figure 21). Upon overexpression of TDP-43, exon 7 is 
nearly 30% skipped (Figure 22). Since in normal minigene conditions exon 7 is 
completely included in the final mRNA, no enhancing effect on exon inclusion 
expected upon TDP-43 silencing could be detected with this approach. As 
reported for the ETF1 exon 7, TDP-43 might generally interfere with the enhancing 
effect of the UG repeats at the 5’SS, ultimately silencing RXRG exon 7 inclusion. 
Also in this case, both direct and indirect effects of TDP-43 will have to be 
considered in further studies in order to better define TDP-43 involvement in this 
splicing event and its consequences.
The recent discovery of its key function in accelerating spontaneous
remyelinization in multiple sclerosis lesions has brought great scientific interest to
the RXRG gene, which might represent a pharmacological target for regenerative
therapy in the central nervous system [350]. Interestingly, Latasa et all. recently
reported that retinoic acid (RA) strongly inhibits RXRG expression [351].
Interestingly, and as already presented in the introduction, the majority of the RA-
downregulated genes present TG repeats in their regulatory sequences. These
TG repeats are required for RA-induced repression of gene expression in
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Xenopus laevis embryos through the recruitment of PTB, another TG repeats- 
binding protein [171, 172]. Based on these published data and on our results on 
RXRG exon 7, it would therefore be interesting to investigate whether TDP-43- 
mediated exon 7 skipping might interfere with the capability of this RA receptor to 
bind its ligand and to trigger RA-induced gene modulation. In fact, RXRG exon 7, 
together with exons 6, 8, 9 and 10 is expected to code for the protein ligand- 
binding domain (information not based on experimental findings, but transferred by 
similarity to other protein family members). Furthermore, TDP-43 indirect role on 
RXRG mRNA processing through its direct modulation of the splicing factor nPTB 
(neuronal PTB) might be a possible explanation that needs further investigation 
[86].
Also in this case, further work will be aimed to test the effects of TDP-43 on 
RXRG exon 7 at the endogenous level in different experimental conditions to 
accurately determine its functional consequences in vivo.
Better understanding of TDP-43 functionality
Interestingly, a growing number of RNA-binding proteins were found to
exert a position-dependent regulation of splicing events, such as Fox-1 [352], PTB
[353], Nova, Mbnll, Sxl, hnRNP C, L and H [354]. Generally, when the
corresponding binding sites are located in the upstream proximal intronic regions
or in the 5’ and 3’SSs, the RNA-binding proteins silence exon inclusion;
alternatively they enhance exon inclusion when binding at the downstream region
of an exon [354]. In line with these observations, a recent study from Tollervey et
all. proposed a position-dependent regulation of splicing for TDP-43 as well.
Although several exceptions were reported in this same study, the authors
identified a tendency for TDP-43 to silence exon inclusion when binding UG
repeats located within the exons, -1 to -150 nucleotides upstream or +150 to +500
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nucleotides downstream (deep intronic sequences), but to enhance exon inclusion 
when binding +1 to +150 nucleotides downstream of alternative exons [241].
Our in vitro results, however, contrast with these conclusions because TDP- 
43 binding to UG repeats within +70 nucleotides resulted in silencing of exon 
inclusion both in ETF1 exon 7 and RXRG exon 7 systems (UG repeats at +36 and 
+42 respectively). Alternatively, our findings highlight a possible correlation 
between the effects on splicing of TDP-43 and the splice site features, in particular 
the 5’SS strength, rather than a correlation with the position of the binding site. 
This observation is supported by the fact that both TDP-43-repressed exons 
(ETF1 exon 7 and RXRG exon 7) and TDP-43-activated exon (BRCA1 MUT) 
present weak 5’SS, whereas unaffected exons present strong 5’SS values 
(BRCA1 WT, SKG2, EPHX1). Therefore, based on these data it can be reasoned 
that TDP-43 levels are an important factor defining weak 5’SSs.
Finally, our analysis of the different TDP-43 domains involvement in splicing 
regulation indicated that in all cases (BRCA1 MUT, RXRG and ETF1) the integrity 
of the RNA-binding domains is absolutely required for TDP-43 to affect splicing 
(Figure 12, 14, 18), further confirming pre-existing data [203]. Mutation of these 
domains results in the abolishment of TDP-43 splicing functionality. In addition, 
overexpression of the proteins lacking the entire C-terminal domain or the 321-366 
domain always mimicked the overexpression of the WT protein, although with 
weaker penetrance, indicating that the C-terminal domain of the protein is 
important but not strictly necessary for the protein to exert its splicing regulatory 
functions.
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Endogenous RNA analysis
Following the results of these in vitro studies the logical follow up of this 
work has been to evaluate the effects of TDP-43 depletion in the endogenous 
context. Disappointingly, a preliminary analysis of the endogenous RNAs in TDP- 
43 silenced conditions did not reveal any splicing variation for all the tested genes 
with putative UG-regulatory motifs near their 5'SSs (Figure 27). Of course this was 
particularly disappointing for the RXRG and ETF1 genes, where the analysis of 
the endogenous RNA did not report the expected results, although a neat effect of 
TDP-43 levels on exon processing was observed in minigene analysis.
However, there are several possibilities that could account for this apparent 
discrepancy. In fact, the splicing pattern observed in the two minigene systems 
could be representative of a tissue-specific event, yet to be characterized. For 
example, RXRG is highly expressed in brain and skeletal muscle, whereas we 
analyzed its endogenous splicing patter in cervix-derived cells (HeLa). Therefore, 
in order to test this possibility it will be important to evaluate in the future the 
endogenous RXRG expression in these tissues following TDP-43 depletion. In 
addition, the developmental stage could be an important factor determining the 
effects of TDP-43 in the inclusion of these exons, and this possibility can be 
investigated using suitable cellular and animal models. Finally, the combination of 
quality and quantity of splicing factors present in natural versus transfected cell 
environment could also negatively influence the role of TDP-43 in a particular 
endogenous situation making it less determinant.
Nevertheless, it is important to note that a comparison between minigenes
and endogenous situations always requires some careful considerations. Not
necessarily, in fact, an apparent lack of consistency between these two systems
should be taken as a demonstration that minigene results do not reflect the
endogenous situation. Regarding this issue, Baralle's laboratory has clearly shown
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in the past that apparent discrepancies can sometimes be solved by a careful 
consideration of the various factors that are known to affect the splicing process. 
For example, it has been shown that in the NF1 (neurofibromatosis 1) gene the 
genomic context plays a very important role in explaining apparent discrepancies 
between minigenes and endogenous situations [355]. In particular, it was 
observed that the minigene system did not successfully mimic the endogenous 
splicing pattern unless an extended genomic context was added. Because our 
situation is different (an effect on splicing was observed only in the minigene 
context but not at the endogenous level), it was impossible to try and solve these 
discrepancies by performing a similar analysis on the ETF1 and RXGR systems. 
Nonetheless, what has been seen with the minigene systems is a potential effect 
of TDP-43 on exon recognition of these two genes. Whether this potential 
influence may be confined to particular cell types/developmental 
stages/combination of splicing factors, as discussed above, is something that will 
require further studies (that are currently in progress).
In conclusion, this study has provided positive proof of concept that UG 
repeats located in the downstream region of poorly defined exons may help 5’SS 
definition, acting as auxiliary c/s-regulatory elements in vitro. In addition, this study 
has improved our understanding of TDP-43 involvement in splicing regulation with 
the identification and characterization of three potential and previously unknown 
RNA targets. Also, in line with the most recent findings [86, 241], this study has 
shown that, in vitro, TDP-43 can either function as a splicing inhibitor or activator.
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Appendices
Table 4. Oligonucleotides List. List of the primers used for PCR reactions. The 
DNA oligonucleotides were purchased form IDT (integrated DNA Technologies); 
the RNA oligonucleotides from Sigma-Aldrich.
OLIGONUCLEOTIDES FOR REVERSE TRANSCRIPTION
ALPHA 2-3 CAA CTT CAA GCT CCT AAG CCA CTG C
BRA TAG GAT CCG GTC ACC AGG AAG TTG GTT AAA TCA
PY7 EXON 2 FW GAA TAC AAG CTT GTC GAG GAG GAC A
PY7 EXON 3 REV AGA CCG GAA TTC GGA TCC TCT AGA G
OLIGONUCLEOTIDES
ACSS2 FW
ACSS2 REV
BRCA1 FW
BRCA1 REV
CDC25A EXON 6 FW 
CDC25A EXON 8 REV
COL4A6 EX24 FW
COL4A6 EX2627 REV
EPHX1FW
EPHX1 REV
ETF1 EXON 8 end REV
ETF1 EXON 5
ETF1 EXON 6 FW
ETF1 EXON 6 REV
ETF1 EXON 7REV
ETF1 EXON 8 short REV
ETF1 EXON 9 REV
HMGN1 EXON 4 FW
HMGN1 EXON 6-281 
REV
MAP3K19 FW 
MAP3K19 REV 
MYH7FW  
MYH7 REV 
N4BPL2L EXON 4 FW 
N4BPL2L FW 
N4BPL2L REV 
N4BPL2L4 EXON 6 REV 
NTRK ENDOG FW 
NTRK ENDOG REV 
NTRK1 bis FW 
NTRK1 bis REV
FOR ENDOGENOUS RNAs AMPLIFICATION
GGG TTT CCC AGT AAG ATG C
CAA AAC ACT GGT GGC ACC A
CTG CTT GTG AAT TTT CTG
CTT TTT CTTG ATG TGC TT
GAA GCC TTT GAG TTT AAG 
CTC ACA AGG TTT GTA GTT
AAT CAC CCT GCC CTG TAT TA
TTC CCG TGC ACA CCC TTG AGT CCT GG
GGC TGG ACA TCC ACT TCA T
CTA CGG TGT CAG GCT TGG T
CTT CTG TGC CTT GGC AAT GAA GA
GCT CTT ACA GCA CTA CTT TCA GAT G
GTA GAG GAG GTC AGT CAG CCT TG
CTG ATC AAA CAT ATC AGA TTG ACT T
TTA ATT TCT TCT CTT GAA TGA ATT TCA CGT TGG AG
ACA CGG GCA AGT ACT GTT TTG GCG TTG AAG ATA
CTC TTT GTC TGT GAA ATG AGA TTT A
AAA CCT CCT GCA AAA GTG G
TAT CCC ACA CTA TTT TCT G
TTT TGC TAC TTG AGA AGA T
CTT TTC CTT TGT TCT CAA C
ATC CTG GCC GAG TGG AAG
CTT CAA CAA GCT CTG GAG
AGA AAG AGT TTT GAA GAA A
GTT TGA TAG AAA GCT GAA AAG
TCT GTT GAG TTT TTT TAT TAT TC
AGT TCA AGG AAT TTT CAT T
AAC ACC TTT TGG GGT CTC GGT GGC TGT
CGC CTC CTT CAG TGC CTT GAC AGC CAC
GTC TCG GTG GCT GTG GGC C
CTT GAC AGC CAC CAG CAT C
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ORC5L FW GCT GAC AGA AAT GTG ACT G
ORC5L REV CTT CTC CTT TAA CCA CGG G
PPIA FW CGT TTT GCA GAC GCC ACC
PPIA REV CAC TCA GTC TTG GCA GTG
PTPRU FW CGC GGG CAC CGG CCG CAC A
PTPRU REV GTC AGT CAG GGC TGC ATT A
RBCK1 FW AGG AAA TGG CCC TGA GCC
RBCK1 REV CAT GTC CTT GAG AGA CGC
RGLEXON 10 FW GAG GTG AAG CTG CAG GTC
RGLEXON 12 REV CTT CCT CCG CTT GTC AAA
RGL LONGER FW TCT GTC CAC TGC GAG ATG ACC
RXRG ENDOG EX56 FW TAT GGA GAA CTC GAC AAA TGA CCC TGT T
RXRG ENDOG EX89 ACA GGC CCT TGG CAT CTG GGT TAA AGA G
SCAP2 FW TTT ACA GCA GCT TCT CCC A
SCAP2REV CTG AGG TGT GAT GGA CAC T
SGK2 EXON 7 FW CTC TTC TTC CAC CTG CAG
SGK2 EXON 9 REV GCT GCA GGT GGA AGA AGA GA
SGK2 EXON 6 FW CAG AGC CAC ATC ATG GCA GAG CGC A
SGK2 EXON 9/10 REV TCA GGT GCC AAG TAC TCA GGG GTA CCA
SMN EXON 6 FW CCA GGT CTA AAA TTC AAT G
SMN EXON 8 REV TTA ATT TAA GGA ATG TGA GC
T3D FW TGA GCC CCT TCA AGA TAC
T3D REV CTG ATA GAC CTG GTC ATT
TG EXON 11 REV TAG ACT GAG CCG CCA GGC G
TG EXON 9 FW CTG AAG GCC AAT CTT GTG C
OLIGONUCLEOTIDES FOR MINIGENES CONSTRUCTS
BRCA 5'SS pY7 FW CAA GTC AGG TAA AAA GCG TGT GTG TGT GTG CAC ATG
CGT GTG TGT GGT GTC CTT TGC ATT CAA AGC CGC GC 
BRCA 5'SS pY7 REV ATA TGC GCG GGT TGA ATG CAA AGG ACA CCA CAC ACA
CGC ATG TGC ACA CAC ACA CAC GCT TTT TAC CTG A 
BRCA 5'SS MUT pY7 FW CAA GTC AAG TAA AAA GCG TGT GTG TGT GTG CAC ATG
CGT GTG TGT GGT GTC CTT TGC ATT CAA AGC CGC GC 
ATA TGC GCG GGT TGA ATG CAA AGG ACA CCA CAC ACA 
CGC ATG TGC ACA CAC ACA CAC GCT TTT TAC TTG A 
GGA ATT CCA TAT GGA ATT CCC AGT AGT ATT TGG GGA TCC 
ACA
GGA ATT CCA TAT GGA ATT CCC TTT AGT GAT CTC GGA CAA 
GTC
GGA ATT CCA TAT GGA ATT CCC TTC TGG GGA GTT CTG CTC 
A
GGA ATT CCA TAT GGA ATT CCC CCT CGC CAA GGG TGG GC
BRCA 5'SS MUT pY7 
REV
COL4A6 FW clone 
COL4A6 REV clone
EPHX1 EXON 5 REV 
clone
EPHX1 FW EXON 5 
clone
ETF FILL IN FW
ETF FILL IN REV
ETF FILL IN TG NON 
REP FW
ETF FILL IN TG NON 
REP REV 
ATG ETF1 FW
TTA TTC TGT GAA ATG TTT TCC CAA ACA ACC AAA CAA CCA 
AAC
ATA CAT ACA ATC ACG TAC ATT TGG TTG TTT GGT TGT TTG 
GTT
TTA TTC TGT GAA ATG TTT TCG GTT TGT TGG TTT GTT GGT 
TTG
ATA CAT ACA ATC ACG TAC ATA ACC AAC AAA CCA ACA AAC 
CAA
GTG AAA TGT TTT CAT GTA CGT GAT TGT ATG TAT GAG AC
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ATG ETF1 REV ACA ATC ACG TAC ATG AAA ACA TTT CAC AGA ATA AGT AG
ETF1 EXON 7 FW clone 
ETF1 EXON 7 REV clone
NTRK clone-nde FW
NTRK clone-nde REV
NTRK EXON 11 FW 
clone
NTRK EXON 11 REV 
clone
RXGR clone-nde FW 
RXRG clone-nde REV
RXRG EXON 7 FW clone
RXRG EXON 7 REV 
clone
SGK2 FW clone 
SGK2 REV clone
TG 12-18NT FW
TG 12-18NT REV
TG 12-8NT FW
TG 12-8NT REV 
TG 6-18 FW 
TG 6-18 REV 
TG 6-8 FW 
TG 6-8 REV
pY7 Kpn 
pY7 Xba
GGA ATT CCA TAT GGA ATT CCC CTA CTA CCT TAT TTG GCA
GGA ATT CCA TAT GGA ATT CCC GAT GTT CAA GAT ATA GTC 
CTG GT
GGA ATT CCA TAT GGA ATT CCC GAG GCG GCA GCT GCT AAT 
TG
GGA ATT CCA TAT GGA ATT CCC TAA AAT TCA ACC TGC ACC 
CCT T
AAT TCG GGG TAC CCC GGA GGC GGC AGC TGC TAA TTG G 
AAT TCG GGG TAC CCC GGC ATG GGG GCT AAA ATT CAA CC
GGA ATT CCA TAT GGA ATT CCC TAA ATG TTC AAC CCA CA
GGA ATT CCA TAT GGA ATT CCC GAG AAT AGG TTC TCC CAA 
CT
AAT TCG GGG TAC CCC GTA AAT GTT CAA CCC ACA 
AAT TCG GGG TAC CCC GGA GAA TAG GTT CTC CCA ACT G
GGA ATT CCA TAT GGA ATT CCC TGC TGA CTC TTT GGA CA
GGA ATT CCA TAT GGA ATT CCC TAT GCT CAA ATG CCT CCT 
CT
CAA GGT ATG TAT CAA GCT TAC ATG TGT GTG TGT GTG 
TGT GTG TGT GAG ACA GCT TTA AGG AGA CCA ATA GAA 
CCC GCG C
ATA TGC GCG GGT TCT ATT GTT CTC CTT AAA GCT GTC TCA 
CAC ACA CAC ACA CAC ACA CAC ATG TAA GCT TGA TAC ATA 
C
CAA GGT ATG TAT TGT GTG TGT GTG TGT GTG TGT GTG 
CAA GCT TAC AAG ACA GCT TTA AGG AGA CCA ATA GAA 
CCC GCG C
ATA TGC GCG GGT TCT ATT GTT CTC CTT AAA GCT GTC TTG
TAA GCT TGC ACA CAC ACA CAA TAC ATAC
CAA GGT ATG TAT CAA GCT TAC ATG TGT GTG TGT GAG
ACA GCT TTA AGG AGA CCA ATA GAA CCC GCG C
ATA TGC GCG GGT TCT ATT GTT CTC CTT AAA GCT GTC TCA
CAC ACA CAC ATG TAA GCT TGA TAC ATA C
CAA GGT ATG TAT TGT GTG TGT GTG CAA GCT TAC AAG
ACA GCT TTA AGG AGA CCA ATA GAA CCC GCG C
ATA TGC GCG GGT TCT ATT GTT CTC CTT AAA GCT GTC TTG
TAA GCT TGC ACA CAC ACA CAC ACA CAC ACA CAA TAC
ATAC
TAG AGG ATC TGG CTA GTA GCG ATG ACC CTG C 
TTC GGA TCC TCT AGA G TAG AGG ATC TGG CTA G
OLIGONUCLEOTIDES FOR COUPLED SPLICING-TRANSCRIPTION
CMV FW TGG AGG TCG CTG AGT AGT GC
BGH REV TAG AAG GCA CAG TCG AGG
RNA OLIGONUCLEOTIDES
(GU)6 GUG UGU GUG UGU
(GU)2A6(GU)2 GUG UAA AAA AGU GU
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taaatgttcaacccacatttgttgactgattaaaaaaaaaaagaatccttgtctt 
caagctgtcattctgggttgcatctgagagagagtggggggatgtgcagagccat 
aagtcaggagaccccagtcttatcctttgtttcttcgctaatgaactgtgtcatc 
ttgaactaattcttaacctccctagattgtcaattctgcttgtgttatgtgggat 
aatagtacatgccttgggtgattataagtaaagaaagaatgtgttctgttttccc 
tc aagacc tcctccttatccttgcagGGTGGAATGAATTGCTGATTGCCTCTTTC 
TCCCACCGCTCAGTTTCCGTGCAGGATGGCATCCTTCTGGCCACGGGTTTACATG 
TCCACCGGAGCAGTGCCCACAGTGCTGGGGTCGGCTCCATCTTTGACAGgtgtCt 
ctctcctgcttccagtatttgtgtgtattatgtgtgtgtgtgtgtgtgtgtgtgt 
gtgtataGacatgtgtacatacatgaattctcacgtgggcatgaacctctgggta 
gtgGtgggatggaggatgggcagcccaaacagttagctacacatgaccatgcaga 
gaccactaggcacatgaaactataaacctggggaatgagggagagattaaaagaa 
agattgagatcacaataagatggagccactcagaggccagcacagttgccaggca 
gttgggagaacctattctc
□  TDP-43 □  SC35
□  SRp40 ■  SRp55
□  SF2/ASF
Figure 29. ESE and ISE sequences ensuring RXRG exon 7 constitutive 
inclusion. The cis-elements within the sequence representing trans-acting 
proteins-binding sites are represented with different colored lines on the top of 
the sequences.
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ctactaccttatttggcaggagccagtggtcccccctttcctGcacaataactta
tttttgtttgeacttaatgagttgtcctatagtaggtctaataaaatgtgtgata
taattggcagtgctgttcactttaagagcagcttttgattaaattgggctccttc
cccatatttagacttcagtgatcataatgctgagctttgcataccattaagagtt
agtgggtttgagtaaaggtgttttaataatattttaaataagtaccagtaagtac
taataatattttttttgtgtgttagAGGTTACAATCAAAAGTTTTAAAATTAGTT
GATATATCCTATGGTGGTGAAAATGGATTCAACCAAGCTATTGAGTTATCTACTG
AAGTCCTCTCCAACGTGAAATTCATTCAAGAGAAGAAATTAATAGgtatcggtga
aatgcaactacttattctgtgaaatgttttcgtgtgtgtgtgtgtgtgtgtgtgt
gtgtgtatgtgtgtgtgtgtatgtacgtgattgtatgtatgagacaaggtaccaa
aaatgtaaaaaggaatatttagtatttttattaactcttttgcctcagtaaaagc
attattttttatGttGtttagtcattaggtcgaataggtgtgtttgtatctacta
gggaaactttaatatatatGGtgttgactgatGCCtaatcgtagGACGATACTTT
GATGAAATCAGCCAGGACACGGGCAAGTACTGTTTTGGCGTTGAAGATACACTAA
AGGCTTTGGAAATGGGAGCTGTAGAAATTCTAATAGTCTATGAAAATCTGGATAT
AATGAGATATGTTCTTCATTGCCAAGGCACAGAAGgtatgagaattagaaaataa
ggttgGtatttgttactgagccaggaagcctggggtggagatttgggagggatgg
ctgatttcaggagcaatGagaaggtagatctaccGattgttCGCcagtccttcag
tctgtagcacattcctgcatagatttttctgcttgaactgtttaacgtctgctta
agattgttacatGtgctgaggaccaggactatatcttgaacatc
□  TDP-43 □  SC35
□  SRp40 ■  SRpSS
□  SF2/ASF
Figure 30. ESE and ISE sequences ensuring ETF1 exon 7 and 8 inclusion.
The c/s-elements within the sequence representing frans-acting proteins-binding 
sites are represented with different colored lines on the top of the sequences.
